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Abstract
Immunoproteomics approach applied on affective disorder and schizophrenia 
patient CSF samples yielded a number of candidate autoantigens. An overall 
analysis of those candidates revealed that impairment of myelination might have 
a role in etiology of such psychiatric disorders.
Validations were based on phage ELISA that is applied on the most prominent 
autoantigen candidate obtained from phage display selection. In parallel, a 
conventional ELISA by recombinant peptide rather then purified phage, helped 
reproduce the results that imply a tendency of autoimmune reactivity in patient 
CSF samples compared to controls. Comparison of these results with the closest 
family members of the candidate protein mapping to the same N-terminal 
sequence revealed that, the sequence obtained by phage display is more 
antigenic than its homologues.
Genomic expression profile of selected candidate and three other functionally 
related schizophrenia susceptibility genes were studied on mRNA in brain and 
spinal cord of mice, from postnatal day one until postnatal day forty-two. We 
could observe patterns of expression that may suggest a possible interplay of 
candidate proteins in the relevant neuronal maintenance mechanism.
Our approach using cDNA phage display used in the identification of 
autoantigens in inflammatory and autoimmune diseases of the CNS is quite 
feasible despite several drawbacks like high false-positive number.
Finally, our results may raise interest on myelination related proteins that may 
have roles in schizoaffective symptoms. However, strictly more effort has to be 
implemented to confirm and get more insight on our findings, for example 
developing mouse models and studying a broader range of serum and CSF 
samples.
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Summary
Major Depression and Bipolar Disease (BPD) are chronic affective disorders. 
Severe depression and BPD may exhibit psychotic symptoms like schizophrenia 
(SZ), implying the overall diffusion of psychiatric conditions. Genetic susceptibility 
risks and course of these disorders, as well as pathological mechanisms, are 
under extensive investigation, but are still elusive.
Today affective disorders and schizophrenic symptoms are usually controlled by 
lifetime commitment to certain mood stabilizers. Consequently, patients feel even 
more dejected due to the multiple side effects of the long-lasting treatment course 
of psychotropic medications or other neuroleptic treatments. Up to date, there are 
no reliable diagnostic biomarkers available for an effective diagnosis. Such a 
biomarker would ideally be able to differentiate the type and severity of an 
affective disorder or schizophrenia case with respect to other mood disorders and, 
thereby, offer a personalized therapeutic approach.
The fundamental hypothesis behind this work is based on the growing evidence 
showing elevated autoimmune responses associated with schizophrenic or bipolar 
disorder symptoms. The dissertation presented here is aimed at identification of 
biomarkers in the cerebrospinal fluid (CSF) of affective disorder and SZ patients, 
using an immunoproteomics approach with the major focus on phage display (PD) 
technology. PD is a molecular interaction study by which recombinant proteins 
are expressed on the surface of bacteriophages. PD technology is unique owing to 
two major factors: Firstly, the encoded nucleotide sequence of expressed proteins 
is easily accessible by a simple sequencing of phage DNA. Secondly, phages are
xiv
able to replicate in the bacterial host system, thereby vastly amplifying the 
captured interaction.
The thesis has evolved in three phases. The first is an empirical phase in which 
PD technology was modified in order to use CSF for autoantigen screening, and to 
set threshold criteria for discriminating real interactions from false-positives. This 
includes control experiments for a normal brain cDNA PD library, optimizations to 
upgrade the sensitivity of detection to minute IgG levels of CSF, and finally pilot 
selections on other diseases to spell out the background clones while getting 
familiar with the limitations of the technique.
The second phase mainly covered the selection of brain autoantigens by 
employing the modified biopanning protocol and characterization of these clones. 
Results referring to one particular candidate clone were highly motivating. Thus, a 
limited functional study on mice at different postnatal ages was included within the 
framework of the study.
The third phase mostly overlapped with the biopanning process and addressed 
the possibility of detecting candidate autoantigens directly from patient CSF 
without amplification of the signal through panning steps. In accordance, various 
ELISA protocols and a protein array were assessed and modified.
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Chapter 1
Affective disorders, Schizophrenia and Autoimmunity
1.1 Introduction
Affective disorders are psychiatric disorders including bipolar, unipolar and 
schizoaffective disorders. Affective disorders have a remarkable social and 
economical impact reflected in the magnitude of research going on in order to 
understand the etiology and, thus, to improve diagnostic and medical approaches. 
Unfortunately, the causality and molecular mechanisms of bipolar disease and SZ 
remain obscure.
Bipolar and SZ affect the central nervous system (CNS) of individuals who 
experience first symptoms during early adulthood. These may involve delusions, 
irrational thinking and even hallucinations together with affective symptoms in a 
spectrum from mania to depression. Patients may exhibit complex and sometimes 
overlapping symptoms. Even though relapsing remitting cycles of symptoms are 
characteristic features of affective disorders, some patients suffer from a 
continuous disturbance.
Current diagnosis for affective disorders is assessed mainly by the Diagnostic and 
Statistical Manual of Mental Disease IV (DSM-IV) criteria via psychiatric 
counseling. Additionally, the patient’s response to antidepressants is measured, 
although the mechanism as to how these drugs exert their action on affective 
disorders is still unknown.
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1.2 Affective disorders
1.2.1 Unipolar (Major) depression (MDD)
Unipolar depression or major depression disorder (MDD) is clinically characterized 
by episodes of depression without a manic, mixed, or hypomanic phase according 
to the DSM-IV-TR criteria. The lifetime prevalence of unipolar MDD is around 
10%. Women are twice more subject to MDD than men (Tsuang et al. 1994; 
Weissman et al 1996). Studies on twins and adoptions revealed that the 
heritability of MDD is 40-50% (McGuffin et al.; 1991, 2003; Sullivan et al., 2000; 
Torgersen 1986). A depressive patient may experience MDD with one single 
episode or it can be chronic with several relapses. MDD symptoms include a 
long-lasting feeling of sadness, insomnia or hypersomnia, loss or increase in 
appetite. Hallucinations, bizarre thoughts, desocialization, psychomotor retardation 
or agitation fall under severe symptoms. Having a wide spectrum of symptoms 
that resemble anxiety, schizoaffective, bipolar, and personality disorders or 
substance abuse render diagnosis of MDD rather complicated (Stein et al., 1995, 
Farabaugh, Mischoulon, Fava, Guyker, Alpert, 2004). Genetic epidemiology 
based on susceptibility genes is given below (Table 1.1).
Table1.1. Susceptibility genes for MDD
Candidate susceptibility 
gene for MDD Name Reference
Apolipoprotein E APOE Fan et al., 2006, Butters et al., 2003, Forsell et al., 1997
G-protein beta 3 GNB3 Bondy et al.,2002, Kunugi et al., 2002, Lee et al., 2004
Solute carrier protein family 6 
member 3 (DAT) SLC6A3 Frisch et al., 1999
Solute carrier protein family 6 
member 4 (SERT) SLC6A4
Furlong et al., 1998, Bellivier et al., 
1998
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1.2.2 Bipolar disease (BPD)
In the late 19th century, Emil Kraepelin defined BPD as a manic-depressive illness 
distinguishing it symptomatically from SZ. BPD is a mental condition with 
disturbances in mood shifting dramatically from depressive episodes to mania or 
hypomania, occasionally with a mixed state. A hallmark of BPD is the fact that 
symptoms usually merge during early adulthood with a devastating impact on the 
most productive period of life. Relapsing remitting cycles are characteristics of 
BPD with a great tendency to suicidal ideation during depressive episodes.
Bipolar disorders are categorized into 4 entities: bipolar I, bipolar II, cyclothymic 
disorder (bipolar I and bipolar II together in a rapid cycling nature), and bipolar 
disorder not otherwise specified, as described in DSM-IV (Bowden, 2002).
Co-morbidity of BPD with other disorders like attention-deficit/hyperactivity, 
substance abuse or mania is rather prominent. In addition, patients may present 
different symptoms according to subtype of the disorder, complicating and 
affecting the accuracy of diagnosis (Evans, 2000). Anxiety, for instance, is a highly 
frequent co-morbidity occurring in several studies (Henry C et al., 2003, Tamam L 
et al., 2002, Simon NM et al., 2003).
There are differences in presentation and the course of BPD between women and 
men, (Arnold, 2003, Christensen et al., 2003) although gender-dependent 
secondary factors tend to influence the response to medication and diagnosis 
more (Burt and Rasgon, 2004). However, a study by Hendrick et al., reports no 
gender difference in the 63 female and 68 male subjects studied, but nevertheless 
noted a higher risk of co-morbidity associated with women (Hendrick et al., 2000).
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Kennedy et al. reported that male BPD subjects tend to have an earlier onset of 
mania and bipolar disorder than female (Kennedy et al., 2005).
Treatments with mood stabilizers like lithium, sodium valporate, or antipsychotic 
drugs (neuropileptics) like olanzapine are used to support therapy counseling. In 
the case of BPD, medication dependency is a lifelong commitment, which brings 
about multiple side effects over the years.
Epidemiology of BPD is unclear, yet a number of indications reveal a genetic 
predisposition. Twin, family, and adoption studies demonstrate the concordance 
ratio among monozygotic (MZ) twins to be 65%, compared to dizygotic twins with 
14%. Thus the heritability of BPD is deduced to be up to 80% (Kendler et al., 
1993). BPD and SZ both have 13q32 (Berrettini et al., 1994, Detera-Wadleigh et 
al., 1999) and 22q11 (Kelsoe et al., 2001) chromosomal regions as confirmed 
susceptibility loci. Together with evidences from genome-wide significant linkage 
studies (Lander, 1995), genetic epidemiology of BPD has overlapping findings that 
confirm a complex mode of transition involving may genes that predispose 
individuals to psychosis (Gottesman et al., 1967, McGue et al., 1989).
Table1.2. Recently characterized susceptibility genes for BP
Candidate susceptibility 
gene for BP Name Reference
G protein receptor kinase 3 GRK3 Barrett et al., 2003, Alexander et al., 2000
phosphatidylinositol-4-phosphate 
5-kinase, type II, alpha PIP5K2A Stopkova et al., 2003
transient receptor potential- 
related channels TRPC7
Nagamine et al., 1998, 
Yoon et al., 2001
putative cation-channel gene MLC1 Verma et al., 2005
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1.2.3 Schizoaffective disorders (SZAD)
Schizoaffective psychosis was coined by Jacob Kasanin in 1933. It is described as 
a more episodic psychotic illness compared to SZ or BPD, having both mood 
disorder and SZ-related symptoms of which affective symptoms are stronger than 
schizophrenic ones (Goodwin, 1990). ICD-10 Classification of Mental and 
Behavioral Disorders describes the schizoaffective disorder as an episodic 
disorder which presents both affective and schizophrenic symptoms prominently 
within the same episode of illness, usually simultaneously, but at least within a few 
days of each other. SZAD are given a separate category for diagnosis, because 
they are too common to be ignored. Subtypes of SZAD are, firstly, the bipolar type 
when manic and mixed states are involved, and secondly, the depressive type 
when depression is more pronounced. In general, a schizoaffective patient has a 
better prognosis than a schizophrenic, but worse than a bipolar patient. Usually 
anti-psychotic drugs and mood stabilizers are offered for treatment. Prevalence is 
not reported and there is no gender difference in the bipolar type of SZAD though 
women are more affected by the depressive subtype.
1.3 Schizophrenia (SZ)
SZ is a severe yet highly prevalent neuropsychiatric illness affecting 1% of the 
population worldwide. Patients suffer from a great decline in quality of life, along 
with high risk of suicidal attempts.
The symptoms usually initiate in early adulthood, between the ages of 25 to 30, 
mainly composed of delusions, hallucinations, depression and neurocognitive 
dysfunction. Today, the treatments are more experimental than rational with low 
efficiency and a great deal of side effects.
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There are controversial reports concerning role of gender in SZ. Women have a 
later age of onset that may partially be due to the female sex hormone oestradiol 
acting as a protective factor (Riecher-Rossler A, 2000). On the other hand, it was 
claimed in a review by Goldstein that women with SZ experience affective 
disturbances more than men, and that the overall etiology is bound up with 
neuroendocrine and sex effects (Goldstein, 2006).
Genetics and developmental predisposition are risk factors supported by a lot of 
evidence (Mueser and McGurk, 2004). Genetic epidemiology studies on SZ 
revealed several susceptibility genes (Table 1.3) and chromosomal abnormalities. 
Many studies indicate a higher risk of developing SZ in genetically related people. 
Environmental factors influence the overall picture. This is demonstrated in twin 
studies with monozygotic twins revealing a concordance of only 50% and 
heritability estimates around 85% (Tsuang, 2000).
Table1.3. Recently characterized susceptibility genes for SZ
Candidate susceptibility 
gene for SZ Name Reference
Dystrobrevin binding protein 1 DTNBP1 Straub et al., 2002
Neuregulin 1 NRG1 Stefansson et al., 2002, Corvin et al., 2004
D-Amino-acid oxidase and 
D-amino-acid oxidase activator
DAO,
DAOA Chumakov et al., 2002
Discoidin domain receptor DDR1 Roig B et al., 2007
Regulator of G-protein 
signaling 4 RGS4 Chowdari, 2002
Disrupted-in-schizophrenia DISC Blackwood et al., 2001, Millar et al., 2000, Miyoshi et al., 2003
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Recent findings convey several changes in the neurotransmitter system in the 
CNS of subjects with SZ, including the GABAergic (Dean et al., 2000, Ohnuma et 
al., 1999), serotonergic (Dean et al., 1999), glutamatergic, dopaminergic (Tallerico 
et al., 2001), and cholinergic (Tandon, 1999, Taylor et al., 1998) systems revealed 
by postmortem studies.
Growing evidence suggests abnormalities in white matter integrity in SZ. The most 
recent report on a study conducted in adolescents, involving patients with a history 
of visual hallucinations, provided strong evidence of lower white matter integrity 
using high resolution imaging techniques (Ashtari et al., 2007). SZ has a wide 
range of proposed etiologies; therefore, some examples based on the selected 
literature are given in appendix A1.
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1.4 Immune and autoimmune activity within the CNS
1.4.1 CNS immunity
The CNS is an immunologically specialized site as there is no lymphatic drainage. 
Moreover it is protected from the entry of large macromolecules like circulating 
proteins and cells by the blood brain barrier (BBB). For instance, circulating 
leukocytes cannot enter the CNS through the tight junctions of the BBB. In 
addition, cerebral capillary endothelial cells are not reactive to endocytosis and the 
expression of adhesive molecules (Ransohoff, Kivisakk and Kidd, 2003). When a 
systematic immune response is induced, endothelial cells of the CNS upregulate 
the expression of cell adhesion molecules allowing activated T cells to cross the 
BBB (Figure 1.1). When an antigen is present and associated with MHC 
molecules, activated T-cells stay in the CNS. After antigen is eliminated, activated 
cells either leave the CNS or they die in-situ (Griffin, 2003).
Glial cells have important roles in maintaining CNS during and after an 
inflammation. There are three major glial cell types: Firstly, the oligodendrocytes 
that are responsible for the generation and maintenance of the myelin sheet that 
surrounds the axon of neurons. In case of an inflammation, they are indispensable 
for the repair mechanism. Secondly, the astrocytes that support neurons by 
producing neurotrophic factors, maintain the BBB and dispose of toxic substances. 
Finally, the microglial cells take over the job of macrophages. Microglial cells are 
bone marrow derived and become active when an injury occurs or, in the case of 
inflammation, by expressing MHC class I and class II molecules.
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Figure 1.1 Mechanism that drives immune cells into CNS. Schematic overview of the initiation 
of CNS infiltration: A tight BBB (Blood brain barrier) is the key mechanism for immunologically 
privileged environment, simply blocking the entry of immunoglobulins and resting immune cells. In 
presence of an antigen that has a potential to activate astrocytes and/or microglia, these cells 
secrete pro-inflammatory cytokines and chemokines that prime immune cells in the periphery and 
endothelial cells of the BBB. Increased chemokine gradient attracts immune cells, while cytokines 
modulate expression of cell adhesion molecules on lining endothelial cells and initiate a migratory 
phenotype on attracted immune cells. Following the initial infiltration, contact of CD4+ T-cells with 
antigen presenting cells (APC) that result in formation of the right MHC-Antigen-TCR complex 
starts a cascade resulting in activation and proliferation of antigen specific T-cells in the CNS 
(modified from a review by Kielian T., Journal of Neuroinflammation 2004, 1:16).
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1.4 2 Cerebrospinal fluid (CSF)
Cerebrospinal fluid (CSF) is produced from arterial blood of the lateral and fourth 
ventricles by a combined process of diffusion and active transfer. CSF circulates 
the brain and spinal cord, working as a buffer, nourishing and removing wastes 
and, at the same time, acting like a cushion protecting the CNS (Figure 1.2A).
In adults, the CSF volume is approximately 150 ml and it is produced at a rate of 
0.2 - 0.7 ml per minute, 600-700 ml per day. CSF from the lumbar region contains 
15 to 45 mg/dl proteins and 50-80 mg/dl glucose (2/3 of serum value). Protein 
concentration in cisternal and ventricular CSF is lower. Normal CSF contains less 
than 5 mononuclear cells per microliter and the white blood cell to red blood cell 
ratio is 1:700.
X.
CSF is collected by lumbar puncture, during which a needle is cautiously inserted 
into the spinal canal between lumbar vertebrae L3/L4 or L4/L5 (Figure 1.2B). The 
maximum CSF that can be taken at a time is approximately 20 ml, whereby, for 
basic investigations, 4-8 ml CSF is sufficient. CSF used for analysis should look 
clear as a slightly red color indicates blood contamination that may cause 
considerable deviation of the IgG/albumin index and contaminate the CSF with 
serum proteins.
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Figure 1.2 CSF and lumbar puncture. A. Cerebral spinal fluid (CSF) circulates from the ventricles 
through the subarachnoid space, protecting and nourishing the brain and spinal cord. B. CSF is 
collected by lumbar puncture (spinal tap). During the procedure, a needle is usually inserted 
between the vertebrae L3/L4 or L4/L5, the third and fourth lumbar vertebrae (figures modified from 
University of Wisconsin Hospitals and Clinics Authority and U.S. National Library of Medicine; 
(lumbar puncture as updated version by Bentley-Hibbert S., M.D., Ph.D., Department of Radiology, 
Weill Cornell Medical Center, New York, NY).
Central nervous 
system (CNS)
Cerebrospinal fluid (CSF)
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1.5 Immunological aspects in AFD and SZ:
1.5.1 From inflammation to autoimmunity
Inflammation is a consequence of the generalized innate immune response. 
Without inflammation, survival of the organism would be compromised. Due to 
this, it is a very effective yet non-specific defense mechanism, where many 
antigens are targeted. As explained earlier, CNS inflammation differs vastly from 
the periphery. However, CNS can get sensitized to inflammatory signals from the 
surrounding and initiate local responses. Microglia activation is an obvious sign of 
CNS inflammation that involves the release of pro-inflammatory cytokines such as 
interleukin-lp (IL-1 |B), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), 
chemokines (IL-8, MIP-1a, MIP-1(3, MCP-1) and anti-inflammatory mediators, such 
as IL-1 receptor antagonist (IL-1 ra) and TGF-p. Eventually, the pathogen is 
eliminated and activated immune cells, namely leukocytes, either leave the tissue 
or undergo apoptosis followed by the repair of the damaged tissues. Although this 
process is rigorously regulated, abnormalities related to inflammatory factors have 
roles in the etiology of various disorders including chronic inflammation, allergy 
and autoimmune disorders.
Autoimmunity is the aberrant immune response that occurs when immunological 
tolerance to “se lf has failed. Learning to distinguish tissues and cells that belong 
to self from “non-self (e.g. pathogens) occurs during maturation (ontogeny) of T- 
cells in the thymus. Immature T-cells that are not able to pass this vital 
assessment are eliminated. Nevertheless, there are always a number of immune 
cells that escape this filter. T-cells attacking self-antigens, so-called autoimmune 
T-cells, are constitutively suppressed by CD4+, CD25+, FoxP3+ regulatory T-cells 
if they escape thymic deletion. In other words, everybody has autoimmune T-cells 
that remain idle below the threshold of a pathological attack of autoimmunity. 
Indeed, such low-level autoimmunity is essential during development.
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In addition, it is advantageous to the organism as it helps the immune system to 
function properly and to recognize neoplastic cells in cancer. Accordingly, 
autoreactive T-cells are particularly important in the CNS for neural maintenance 
and repair (Kipnis and Schwartz, 2005).
Autoimmunity is a concept far from being totally understood. One consensus is the 
fact that an autoimmune disease like lupus, multiple sclerosis, and rheumatoid 
arthritis affects women far more often than men. This phenomenon was explained 
by studies showing estrogens promoting, and androgens abrogating, the B-cell- 
mediated autoimmune diseases (Ahmed et al., 1999; Rider et al., 2001). However, 
this fact brings about a striking paradox as estrogen has a neuroprotective role 
demonstrated via in vivo and in vitro models (Behl et al., 2002, Sheldahl et al., 
2007, Pozzi et al., 2006). Furthermore, a recent study indicates the 
neuroprotective effects of 17-beta estradiol E2 that promotes axon and myelin 
survival (Offner and Polanczyk, 2006). Furthermore, it has been demonstrated that 
autoimmune diseases have a geographical factor with a higher prevalence 
observed in the northern hemisphere and western community in contrast to a 
much lower frequency in countries with multiple infectious epidemics.
Autoimmune diseases are either systemic or localized. For instance, rheumatoid 
arthritis (RA) is systemic where joints are the targets; multiple sclerosis (MS) is 
local to the CNS; Hashimoto's thyroiditis affects the thyroid gland; in Type I 
diabetes (T1D, IDDM) insulin-producing beta cells in the pancreas are targeted. 
Autoimmune diseases are usually treated with immunosuppressive or anti­
inflammatory agents, or replenishment of the eliminated metabolic components, 
for example, the insulin hormone in the case of T1D.
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1.5.2 Evidence that supports inflammation and autoimmune hypothesis of 
AFD and SZ
A great number of studies have elucidated the role of inflammation and 
autoimmunity in several CNS-related diseases and psychiatric disorders, reporting 
various autoantibodies against CNS proteins in the sera, CSF and brain tissues 
from BP and SZ patients (Henneberg et al., 1993, 1994; Muller et al., 1992; 
Legros et al., 1985).
Regarding affective disorders, an increased IgG titer during the depressed state 
have been described in many studies similar to the findings supporting the 
inflammatory hypothesis for SZ with increased concentrations of immunoglobulin 
and proinflammatory cytokines in serum and CSF. For instance, interleukin-6 (IL- 
6), IL-6 receptor (IL-6R), IL-1R antagonist (IL-1RA) and IL-2R plasma levels, 
interleukinl and interleukin 3 activity (Maes et al., 1995) are higher in SZ patients 
compared to controls. A function of IL6 is activating B-cells to produce antibodies, 
thus high levels of IL-6 may be part of an ongoing humoral response (Jones, 
Mowry, Pender and Greer, 2005). In this regard, elevated IL-6, interleukin-6 
receptor (IL-6R), IL18, IL12 have been shown in schizoaffective patients with a 
bad prognosis, resistance to treatment and intensified symptoms with a longer 
duration of illness (Muller et al., 2000; Nunes, 2005; Lin et al., 1998; Altamura et 
al., 2003). In contrast, Clara cell 16KD protein (CC16), which is an endogenous 
protein with an anti-inflammatory and immunosuppressive effect, has lower serum 
concentrations in SZ patients (Altamura et al., 1999).
McAllister et al. have provided evidence of elevated levels of CD5+ B cells in 
approximately 30% of SZ patients. This was opposed by Ganguli et al., who 
confirmed other immune alterations but not an elevation of the CD5+ B
lymphocyte population for the characterization of a subset of patients with SZ 
(McAllister et al., 1989; Ganguli et al., 1993).
Epitope similarities to viral agents increase the risk of developing the disease 
when accompanied by an immune dysfunction. (Yolken and Torrey, 1995; Torrey 
et al., 1997; Tatsumi et al., 2002).
Evidence supporting the inflammatory hypothesis postulates that etiopathogenesis 
of some cases of SZ is based on altered levels of antibodies to cytomegalovirus, 
Toxoplasma gondii, and human herpesvirus type 6, provided that the patients with 
recent onset of SZ were untreated (Leweke et al., 2004; Yolken et al., 2001; 
Pelonero et al., 1990; Dickerson et al., 2003). It is shown that anti-psychotic 
treatment changes characteristics of inflammatory responses (Maes et al., 2000).
Interestingly, SZ has been associated with a reduced occurrence of other 
autoimmune diseases and malignancies. SZ patients and their first-degree 
relatives usually possess a lower risk of having another autoimmune disease 
(Eaton et al., 2006).
Similarly, Yovel et al. reported high natural killer cell activity in the serum of SZ 
patients, which may explain the low incidence of lung cancer and other 
malignancies in those patients, despite their higher rate of smoking (Yovel at al., 
2000).
Other evidence reveals an impaired blood-brain barrier, besides immune 
dysfunction, in affective disorder patients, increasing their susceptibility for an 
autoimmune reaction. In addition, two independent studies have reported age and
gender to be relevant factors for autoantibody association with affective disorders 
(Hornig et al., 1999, 1996; Schwarz et al., 1998).
Excessive IgG transmissions from blood into the CSF, increased synthesis of IgG 
within the CSF, together with elevated monocytes and T lymphocytes, have been 
observed in some of the affective disorder patients (Breunis et al., 2003; Maes et 
al., 1993; Hornig et al., 1999). This activity results in aberrant antibody 
surveillance in the CNS. Such an unusual exposure to increased immune 
response may potentially result in mal-recognition of certain endogenous proteins 
within the CNS that resemble exogenous antigens. Similarly, self-peptides or 
cellular components that are normally out of scope of immune surveillance may 
become targets of humoral and cellular response. For instance, nuclear and 
phospholipid antigens (De Vries et al., 1994; Legros et al., 1985), myelin basic 
protein and nerve growth factor (Klyushnik et al.) are well-studied cases.
Detection of autoantibodies against the heat shock protein Hsp60 have gathered 
considerable interest as heat shock proteins are known targets in autoimmune 
diseases (Wang et al., 2003; Rothermundt et al., 2001; Schwarz et al., 1998; 
Kilidireas et al., 1992). However, one study reported that sera from MDD and SZ 
patients, and all normal controls, reacted similarly with Hsp60, and claimed that 
heat shock proteins are antigens of many pathogens and, thus, cannot be 
regarded as autoimmune specific indicators. Alternatively, their study yielded an 
80-85 kDa antigen that was highly reactive with the IgG of 30% of SZ patient 
samples (Mazeh et al., 1998).
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Direct evidence in favor of an autoimmune basis for AFD/SZ etiology would have 
been the presence of lesions in affected regions of the brain, or transmissibility of 
T cells or antibody to a healthy individual to create similar symptoms. There are no 
lesions detected in AFD/SZ patients. However, the transfer of purified IgG from 
patients to rats subsequently caused structural changes in the brain that are 
similar to SZ, while an identical experiment on monkeys created EEG 
disturbances (reviewed by Jones, Mowry, Pender and Geer, 2005).
On the other hand, a very important support for autoimmune basis for SZ was put 
forward by a study involving systemic lupus erythematosus (SLE), a known 
autoimmune disease that is characterized by autoantibodies against DNA. 
Patients with SLE develop SZ-like symptoms. This study showed that anti-DNA 
antibodies cross-react with N-methyl-D-aspartate receptor (NMDAR), which is a 
neurotransmitter receptor (Diamond et al., 2001, 2008)
Table 1.4 shows immunity related changes in the CSF of AFD and SZ patients, together with 
known autoimmune disorders SLE and MS.
Disorders CSF findings References
AFD/SZ
Elevation of IgG titer Kirsch and Wyatt, 1991
Autoantibodies Sokol et al., 2007
Elevated levels of monocytes and T 
lymphocytes Nikkila et al., 2007
Elevated levels of cytokine IL1-beta Levine et al., 1999
Impaired blood-brain barrier Kirch et al., 1992; Bauer and Kornhuber, 1987
SLE
Anti-nuclear autoantibodies Diamond et al., 2001, 2008
Elevated levels of intrathecal matrix 
metalloproteinases (MMPs) Trysberg et al., 2004
MS
Elevated B cell response Link et al., 1989, Baig et al., 1991
CSF antibodies to myelin basic 
protein (MBP), myelin-oligodendrocyte 
glycoprotein (MOG) and myelin- 
associated glycoprotein (MAG)
Gorny et al., 1983, 
Catz et al., 1986, 
Xiao et al., 1991, 
Baig et al., 1991
CSF antibodies to heterogeneous 
nuclear ribonucleoproteins (hnRNPs) Sueoka et al., 2004
Elevated levels of proinflammatory 
cytokines Matusevicius et al., 1996
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1.6 Biomarker Research and Immunoproteomics: Phage Display Strategy
1.6.1 Introduction
At the onset of any pathological disturbance, our body generates early biological 
warnings through peptides and other macromolecules. Translation of these signals 
into measurable, disease-specific markers, so-called biomarkers, ensures a better 
diagnosis and a personal medication tailored for each individual.
The immuno-proteomic survey of brain autoantigens as biomarkers originated 
from the assumption that an active immune system relays an elevated sensitivity 
towards self-proteins, in this case the CNS proteome, reflecting AFD and SZ 
pathology.
PD is the technology implemented for this quest. PD utilizes bacteriophages, 
viruses that target bacteria as a host organism. As a biological tool, phages are 
commonly used vectors to modify the E.coli genome in recombinant DNA 
engineering. A PD vector expresses the encoded segment of recombinant DNA as 
a protein or peptide besides the endogenous capsid components creating a fusion 
protein. A library with sufficient diversity of recombinant clones qualifies as a very 
powerful high-throughput selection tool. Furthermore, PD offers a similar condition 
to the interactive medium where reactions take place in solution.
PD is widely used in the ligand search for orphan receptors or vice versa, in 
signaling pathways, development of enzyme inhibitors and tags for protein 
purification. PD is favored especially in the development and epitope mapping of 
novel antibodies.
18
1.6.2 Biomarkers
Any biomolecule whose metabolic state indicates a disease condition can be 
regarded as a biomarker. Biomarkers in the proteomics field are proteins or 
peptides that have an altered expression, post-translational modification or other 
major changes that can be evaluated in conjuncture with a dysfunction or a 
disease.
The essential role of a biomarker is to define the personal risk of developing a 
disease in an objective manner and making it possible to take early measures, or 
at least, help early diagnosis before the major outbreak. Moreover, response to a 
given medical treatment or a new drug can be evaluated using a biomarker, in 
order to address people who are most likely to benefit from the treatment in 
question (Nolan, 2006).
Biomarker research has become a very popular discovery area as molecular 
biology, genomics and proteomics gain tremendous acceleration. Screenings and 
validations are faster, significantly more sensitive and precise than before, but still 
not perfect.
Blood tests are examples for commonly applied biomarker tests. For example, 
immunoglobulins against a previous infectious disease or a current epidemic are 
routinely measured from blood. Further examples are cardiovascular disease 
biomarkers like serum amyloid A protein, interleukin-6 , interleukin-8 , fibrinogen, 
and troponins, of which cardiac troponin I is elevated before a cardiac injury. The 
major cerebrospinal fluid (CSF) biomarkers in 90% of multiple sclerosis (MS) 
patients are oligoclonal bands solely in CSF, but not in serum. Similarly, 
measuring amyloid-beta peptide by ELISA is an indication for amyloid plaque 
formation in Alzheimer’s disease.
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1.6.3 Phage Display
1.6.3.1 Principle
In 1985, George P. Smith and collaborators initially described the PD concept 
(Smith, 1985; Scott and Smith, 1990; Smith and Petrenko, 1997), and soon it 
became one of the most powerful protein engineering tools. PD is a combinatorial 
technology for selecting peptides or proteins with specific binding properties as it 
provides a physical linkage between genotype and phenotype (Smith and 
Petrenko, 1997). Indeed, this shortcut made PD a unique approach for those who 
wish to study novel affinity partners in protein-protein interaction studies. Cloning 
a gene of interest as a nucleotide sequence that encodes the protein to be 
displayed into a phage genome enables expression of that protein or peptide as a 
fusion to phage coat protein. Another advantage is that it is possible to amplify a 
constructed library simply by a passage through a compatible bacterial host 
(Smith, 1985; Kay and Hoess, 1996).
An expedient phage library should be composed of diversity of coding sequences, 
potentially represented in a sufficiently large number of recombinants in the range 
of several million clones (Sidhu et al., 2000). An immobilized ligand is used to 
select the high affinity partners out of such a library in which 10 to 100 copies 
(copy number) from each recombinant clone are present.
After each biopanning, the stringency, based on the number and duration of 
washing cycles, is increased to an extent determined by the user. High affinity 
clones are eluted and amplified in a bacterial host system (enrichment). Thereby, 
a fraction of the primary recombinant collection is now represented in thousands of 
copies for the next biopanning round.
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There are basically two classes of enrichments: firstly, matrix-to-phage 
(background enrichment) and, secondly, phage-to-phage (marker enrichment). 
Enrichment is assessed by an assay called titer assay where serial dilutions of 
phage are plated over agar plates using a soft-top agar mixed with bacteria at mid­
log growth phase. As the phage infect and burst host cells, single plaques become 
visible, each representing one recombinant clone. The number of plaques 
corrected to dilution factor per milliliter gives the titer. Furthermore, the titer 
provides information about the number of viable phages (plaque forming unit or 
pfu) that are able to infect and propagate, which is a determinant for amplifying the 
selected phage for the next round (Lowman and Denise, 2004).
Theoretically, multiple rounds of iterative selection yield the highest affinity-binding 
clones. After the final round of selection, the amino acid sequence of the clone of 
interest can be obtained by sequencing the inserted DNA within the phage 
genome (Hoogenboom, 1997; Hoogenboom et al., 1998; Sparks et al., 1996).
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Figure 1.3 Panning cycles: After immobilization and incubating the PD library with the target, non­
specific phages are washed away selecting strong binders bound to the target. Infecting the 
selected clones in E.coli for propagation follows using acidic or high alkali buffer for elution of the 
bound phage. Comparing input to output phage titers can monitor enrichment. Usually, three to 
four rounds of panning are sufficient to select clones with best affinity to the target and identity of 
the clones are obtained by DNA purification and sequencing. Illustration by Sayan-Ayata, E.
1.6.3.2 Applications of phage display technology
PD is a versatile technique that can be applied in vivo, in vitro, as well as ex vivo 
(Lee et al., 2002; Whaley et al., 2000; Johns et al., 2000; Sparks et al., 1996; 
McCafferty and Johnson, 1996; Odermatt, 2001). As a high throughput assay for 
protein-protein interactions, it has major contributions to many areas of biology 
and biochemistry, such as molecular and cellular biology, oncology, immunology, 
pharmacology and protein chemistry (Smith and Petrenko, 1997; Sidhu, 2000).
PD has been successfully applied in protein-protein interaction studies (Smith and 
Petrenko, 1997; Thom et al., 2006), epitope mapping (Wang et al., 2004; Enshell- 
Seijffers et al., 2003; Tarnovitski et al., 2006; Mumey et al., 2003) and drug and 
vaccine discovery (Wang et al., 2004; Ganglberger et al., 2000).
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1.6.3.3 Types of phages used in phage display
Bacteriophages infect bacteria by inserting their genome for translation into viral 
proteins. Bacteriophages are classified as lysogenic (non-lytic) and lytic, according 
to the way they escape from the host. Non-lytic phage resides in the host with its 
DNA integrated but suppressed for expression of phage genome until a threat 
appears. It modifies host DNA polymerase and uses its DNA replication system to 
encode the viral genome. All phage proteins are produced before they assemble 
and burst out of the host cell.
M13 belongs to class of non-lytic bacteriophages, including fd and f1 phages that 
are most frequently used in PD systems. They have a circular single-stranded 
DNA genome within a tube of single major coat protein in several thousand copies 
of protein 8 (P8), and have four additional minor capsid proteins at the ends (P3- 
P6 and P7-P9) (Mullen et al., 2006; Sidhu, 2000).
Lytic phages, like lambda, T4 and T7, are ready to replicate their genomes and 
produce phage particles after they infect the host cell. When daughter phages are 
mature they erupt out of the host and spread to infect new bacterial cells. T even 
and T odd bacteriophages have linear genomes. The T7 phage head has an 
icosahedral shape and a small tail and infect gram-negative species of bacteria, 
like E.coli BL21. The T7 tail functions as an anchor between the phage and 
bacterial receptors for the transferring of the viral genome (Casjens and 
Sherwood, 1985).
Filamentous phage M13 was the first phage used in the development of PD 
(Smith, 1985). After successful implication of M13, several other E.coli targeting 
bacteriophages like lambda phage (Santini et al., 1998), T7 and T4 lytic phages
(Ren et al., 1998), and eukaryotic viruses like baculoviruses (Possee et al., 1997) 
were introduced. The non-lytic bacteriophages M13, fd, and f 1, pill, PVIII, PVI are 
often used in random peptide libraries and antibody display systems, whereas lytic 
phages are preferred in cDNA display systems.
1.6.3.4 cDNA display libraries
Complementary DNA (cDNA) is a DNA copy of the RNA template derived by the 
enzyme reverse transcriptase. A sufficiently large cDNA library reflects all the 
genes of the tissue that are being actively transcribed into mRNA at the moment of 
RNA isolation. Ideally, the degree of expression of a particular gene is directly 
related to the relative abundance of that particular mRNA (Smith and Petrenko, 
1997).
Non-lytic phage systems like M13 require all components of the phage particles to 
be exported through the bacterial inner membrane before phage assembly takes 
place. This is not an issue for extracellular domains of receptors or secreted 
proteins, as they require disulfide bond formation. However, considering a total 
cDNA library where encoded products are folding in a reducing medium, the 
limitations become apparent as only a subset of total proteins can be displayed. 
Lytic phages, on the other hand, avoid this problem because the assembly takes 
place entirely in the cytoplasm (Jespers and Fransen, 2004; Danner and Belasco, 
2001). T4 phage covalently displays the cDNA library on the C-terminus of its 
WAC tail and SOC coat proteins (Ren et al., 1996), whereas T7 uses the C- 
terminus of the major capsid protein 10A (Novagen T7 Select system).
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1.6.3.5 T7 Select system
The T7 Select phage library (Novagen) from brain tissue is constructed in the 
T7Select 10-3 vector. Recombinant phage produces gene 10 proteins that have 
the carboxyl terminus fused to the peptide encoded by the cloned insert.
C- terminal fusion is an advantage for constructing a cDNA library as it prevents 
immature termination of translation.
The product of gene 10 is the major capsid protein of T7 phage particles and there 
are 415 copies of this protein per capsid. The phage particle assembles as a 
mixture of the normal capsid protein and the fusion protein.
Phage assembly takes place in the cytoplasm of E.coli. There are two strains of 
E.coli bacteria that are compatible with the T7 system: BLT5403 and BLT 5615.
In principle, capsid is composed of a large number of 10A proteins together with 5- 
15 copies of 10 B fusion proteins per virions in a 10-3 vector system. Peptides and 
proteins up to 1200 amino acids can be displayed in such a mid-copy phage 
system. When the fusion peptides are so large that the capsid cannot assemble 
within the host cell to make infective phage particles (because of the steric 
hindrance of the carboxyl-termini interfering with each other) 415 copies cannot fit 
in the space. Regarding BLT5403, 10A capsid protein expression is driven by the 
T7 promoter with the help of an ampicillin-resistant complementing plasmid 
providing extra copies of the 10A capsid protein. In contrast, BLT5615 expression 
is driven by the lacUV5 promoter and requires IPTG to induce capsid protein 
expression.
T7Select cDNA libraries are constructed in the mid-copy T7Select10-3b vector 
using a directional random primer cloning strategy. The cDNA library was 
constructed from mRNA extracted from normal brain tissue and then converted
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into cDNA via random priming. Restriction digestion with EcoRI -  Hindlll, creates 
the reading frame of the inserted DNA with sticky ends. The vector expresses an 
inserted sequence in fusion to C-terminus of endogenous bacteriophage major 
capsid protein 10B at amino acid 348. Eventually, cDNA cloned into T7 phage 
genome is size-fractionated so that the smallest insert is 300 bp in length.
T7 is a lytic phage, meaning that the mature phages are released to the medium 
by rupturing the E.coli host. This is another advantage circumventing the 
complications of secretion through the cell membrane.
Furthermore, T7 is a rather robust bacteriophage, growing relatively fast and 
ensuring shorter durations for cloning and screening. Being still viable after 
treatments with 1% SDS, 5M NaCI, up to 4M urea, 10mM EDTA and acidic pH 
from 4 to 10, renders T7 very stable. The T7 system, therefore, offers great 
flexibility in adjusting washing and elution conditions (Table 1.5).
Table 1.5 T7 Select system.
OVERVIEW OF T7 SELECT SYSTEM
T7 bacteriophage Double stranded, linear DNA, lytic phage
Display
options
High copy
415 copies per phage, up to 50 aa
Short peptides up to 50 aa
Mid copy
5-15 copies per phage, up to 50 aa
Longer peptides up to 1200 aa
Low copy
0,1-1 copies per phage, up to 50 aa
Longer peptides up to 1200 aa 
(Maximum insert size: 3.6 kb)
Robust
5M NaCI, 4M Urea, DTT up to 100mM 
Alkali treatment up to pH: 10
Fast Lysis in 2 h (lambda phage O/N)
Plaque formation in 3 h
Pre-made normal brain cDNA library 1,67 x 107 pfu recombinant clones
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1.7 Etiology of the control diseases used in the project
Several other disease control groups like epilepsy, normal pressure 
hydrocephalus and other (non-infectious) neurological diseases (OND) were used 
in the project. Using such diseases that are classified neither as autoimmune 
based, nor affective disorders as controls provided a broader view of the selected 
clone variability and a filter for false-positives. On the other hand, control samples 
from multiple sclerosis patients provided a list of selected clones from a well 
established autoimmune disease which demonstrated outcome of a selection from 
such pathophysiology.
1.7.1 Epilepsy
Epilepsy is a chronic neurological disorder characterized by recurrent seizures and 
affects around 0.5% of the population. The incidence is higher in underdeveloped 
countries (Hirtz et al., 2007). Epilepsy is defined by two or more unprovoked 
seizures and diagnosis is based on the medical history. The syndromes are likely 
to be associated with genetic and environmental factors, although the causality is 
still elusive, and the complete range of etiologies in the population is not known. 
Mutations in several genes that encode subunits of voltage-gated and ligand- 
gated ion channels have been associated with epilepsy (Meisler and Kearney, 
2005). Anticonvulsants, surgery and ketogenic diet are methods of treatment.
1.7.2 Normal pressure hydrocephalus (NPH)
Hydrocephalus is a condition where CSF cannot be drained into the bloodstream 
when fresh CSF is produced and builds up exerting pressure on the brain. In case 
of Normal pressure hydrocephalus (NPH) draining of CSF is gradually blocked 
and excess fluid builds up over a period of time, generating pressure. NPH mostly 
becomes noticeable after 50 years of age. As a primary treatment, excess CSF
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can at times be drained by means of a lumbar puncture. Symptoms may include 
reduced cognitive function, speaking, memory, and reasoning. Other common 
symptoms are lack of leg control and urinary incontinence. Similar symptomology 
to Alzheimer’s disease, Parkinson’s disease or dementia may lead to 
misdiagnosis. Due to this, symptoms can be misperceived, and misdiagnosed or 
go undetected for many years (Thynne, 2007).
1.7.3 Multiple Sclerosis
Multiple sclerosis (MS) is an immune-mediated disease of the CNS with 
relapsing-remitting symptoms causing neurological deficits in young adults. MS 
affects approximately 1 million people worldwide, mostly in developed countries, 
and has a higher prevalence in women compared to men. The etiology of MS is 
unknown. Appearance of symptoms and the disease course are variable among 
patients, although relapsing-remitting appearance of neurological symptoms is 
common. Due to destruction of myelin sheaths that insulate nerve fibers 
(demyelination), patients suffer from impaired cognitive and visual abilities, 
uncoordinated movements and disturbances in the sensory system. MS is 
diagnosed by magnetic resonance imaging (MRI) that shows lesions in the brain 
and spinal cord and the presence of oligoclonal Igs in the CSF.
1.7.4 Other neurological diseases (non-infectious) (OND): Somatoform 
disorder, cervical rhizopathy, and shoulder-arm pain
The somatoform disorders are a group of mental disturbances placed in a 
common category on the basis of their external symptoms. However, the physical 
symptoms present cannot be fully explained by a medical disorder, substance use, 
or another mental disorder. The DSM-IV-TR (4thEd, Text Revision) has a specific
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category for somatic symptoms that includes somatization disorder, conversion 
disorder, pain disorder, hypochondriasis and body dysmorphic disorder. In order to 
meet the criteria for a somatoform disorder, the physical symptoms must be 
serious enough to interfere with the patient's daily life, and must occur unwillingly. 
Cervical rhizopathy and shoulder-arm pain are nerve root pains that may arise 
from injury, of soft tissue. Neck and shoulder disorders are prevalent among both 
men and women. Work-related factors, both of physical and psychosocial origin, 
as well as lifestyle are contributing factors.
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Chapter 2 
Objective
Affective disorders (AD) reduce patients' life quality dramatically and have a 
negative impact on the global health economy (Salokangas, 2007). BPD and SZ 
have high incidence ratios, yet the diagnostic accuracy is strikingly low (Bowden, 
2001; Birnbaum et al., 2003). So far, underdiagnosis of BPD and SZ has 
repressed the effectiveness of the therapeutic approaches (Levine et al., 1997 and 
Evans, 2000). Despite all efforts, affective disorders and SZ remain ambiguous in 
diagnosis and cure, although they are the most common psychiatric disabilities. 
Therefore, like all other prevalent diseases, affective disorders and SZ are in 
urgent need of biomarkers.
Similar patterns of disease progression, repeating periods of regression and 
recovery, young age of onset, and comparable geographical incidence rates 
suggest a mutual molecular mechanism between autoimmune diseases and 
affective disorders. Further important features shared between AFD/SZ and 
established autoimmune disorders include; existence of oligoclonal bands in the 
CSF, elevated levels of IL2R, IL-6 and increased numbers of CD5+ B-cells in the 
serum (reviewed by Knight, Menkes, Highton and Adams, 2007).
CSF is the investigational material, preferred due to its proximity to the CNS while 
exhibiting a relatively less challenging composition compared to serum. In 
addition, autoimmunity related pathological changes are detectable in the CSF of 
AFD/SZ patients, as explained in the chapter of introduction, with several 
evidences from literature.
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The CSF proteome reflects the dynamic physiological state of the central nervous 
system (CNS) making it very attractive for biomarker research on neurological and 
psychiatric disorders.
On the other hand, CSF differs from serum in the sense that the sample volumes 
are strictly limited, and procuring control CSF from healthy individuals is extremely 
challenging (Turck, 2005). Additionally, the immunoglobulin component of a 
standard CSF sample is approximately one thousandth of serum. For an 
autoantibody survey, such limitations may be intractable when taken together with 
the assumption that very few copies of a given disease-specific antibody are likely 
to be present within CSF or serum (Monaci and Cortese, 2004).
Immunoproteomics, mainly based on PD, is a convenient approach in the quest 
for brain autoantigens as it integrates high selectivity of the immune system to 
systematic monitoring of the proteome at a given physiological state (Turck et al., 
2005). PD is capable of resolving CSF-related limitations as it benefits from the 
amplification step that enriches signals from phage displaying disease-specific 
autoantigen.
In addition, the PD strategy is rather straightforward in defining partners of 
molecular interactions owing to the short cut between the phenotype expressed on 
the phage and its genome (Smith and Petrenko, 1997). Finally, PD has proven 
useful in biomarker research; for instance, in validation of novel proteins for 
therapeutic intervention, in high throughput screening in the process of developing 
agonists or antagonists, and in mapping epitopes (Sidhu, 2001).
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To further improve the overall sensitivity, the PD protocol applied in this work was 
especially modified for CSF samples with a very low immunoglobulin content that 
would render targeted autoantibody repertoire rather diluted.
Based on the given rationale, the ultimate goal of the thesis was to address the 
imperative necessity for disease-specific biomarkers for AFD and SZ.
In summary, aims of the thesis in chronological order were as follows:
1- Adaptation and optimization of phage display technology for autoantigen 
detection in the CSF of AFD and SZ patients,
2- Identification of biomarker candidates by screening AFD/SZ versus control 
CSF of EPI, OND and MS patients, using the optimized PD immuno- 
proteomics approach,
3- Evaluation, verification and further studies of the findings by alternative 
approaches like protein array, ELISA and brief functional studies.
A thorough investigation of the autoantibody repertoire of CSF by PD holds the 
potential, not only to unravel disease-specific candidate biomarkers, but also to 
contribute to a better understanding of autoimmune characteristics of AFD and 
SZ.
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Chapter 3 
Materials and Methods
3.1 MATERIALS
3.1.1 BUFFERS AND REAGENTS
a. MAIN BUFFERS
Phosphate buffered saline (1X PBS)
150mM NaCI, 9,1mM Na2HPC>4, 1,7mM NahfcPCU,
Add distilled H2O to 1 liter. Adjust pH to 7.4
Tris buffered saline (1X TBS)
150mM NaCI, 10mM Tris-HCI, pH: 7.5 Add distilled H2O to 1 liter
b. ELISA BUFFERS 
Elisa coating buffer
1x PBS or 0.05 M carbonate-bicarbonate
Elisa washing buffer
1X PBS + 0.05% TWEEN-20
Elisa blocking buffer
1X PBS-T, 1% BSA
Elisa substrate buffer
TMB (Tetra-methyl-benzidine) substrate solution (Sigma Aldrich)
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Elisa stop solution
1M H2SO4 or commercial stop solution (Sigma Aldrich)
c. VIVASPIN and MARS
Vivaspin: MW5000 cutoff
Buffer A: 25mM KH4P04) 500mM NaCI, 0.02% NaN2, pH: 7,4 
Buffer B: 2M Urea, 0.5M Glycine, pH:2.5
d. BIOMAG BEADS 
Coupling buffer: PBBS 1%
1 X PBS, 1% BSA, 1mM Na2EDTA
Washing buffer: PBBS-T 0,1%
1XPBS, 0,1% BSA, 0,1% v/v TWEEN-20
e. PANNING
Library coupling buffer: PBBS-T 0,1%
1X PBS, 0,1% BSA , 0,1% v/v TWEEN-20, sterile filtered (0.2mM) 
Washing buffer:
1X PBS (or 1X TBS), 0,1-0,2% TWEEN-20 (0.2mM)
Elution buffer:
5M NaCI, sterile filtered (0.2mM)
PEB (phage extraction buffer):
100mM NaCI, 20mM Tris-HCI, 6mM MgS04
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f. PCR ELECTROPHORESIS BUFFERS 
TAE Buffer (Tris-Acetate-EDTA) 50x
242 g Tris base 
57.1ml Acetic acid 
100ml 0.5M EDTA
Add ddH20 to 1 liter and adjust pH to 8.5
g. MEDIA and SUPPLEMENTS 
LB
10 g Bacto tryptone, 5 g yeast extract, 10 g NaCI, ddH20 up to 1 liter, 
pH: 7.5, autoclaved
TB
12g Bacto tryptone, 24g yeast extract, 4ml glycerol, ddH20 up to 1 liter, autoclaved 
LB Top agar
1g Bacto tryptone, 0,5g yeast extract, 0,5g NaCI, 0,6g Agarose, ddH20 up to 
100ml, autoclaved
20x M9 salts
20g NH4CI, 60g KH2PO4, 120g Na2HP04 .7H20, autoclaved 
M9LB
5ml 20X M9 salts, 2ml 20% glucose, 0 ,1ml 1M MgSC>4
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h. Bacterial strains 
BLT5615:
An E.coli host strain for the growth of the bacteriophage T7Select10-3. It needs 
an exogenous ampicillin-resistant plasmid for expressing the capsid protein. 
Production of 10A capsid protein is controlled by lacUV5 promoter, hence must be 
induced by the addition of isopropyl-beta-D-thiogalactopyranoside (IPTG).
BLT5403
An E.coli host strain for the growth of the bacteriophage T7Select10-3. It needs an 
exogenous ampicillin-resistant plasmid for expression of 10A capsid protein driven 
by T7 promoter. BLT5403 plaques are smaller and often accumulate deletions in 
the capsid fusion gene if the product is larger than 600 amino acids. Lysate titers 
are equivalent to BLT 5615.
3.1.2 ANTIBODIES
Table 3.1 List of antibodies used in optimization and control experiments.
Antibody Type Company Dilution Secondary- Ab conjugate
Control
peptides
Anti-alpha-
Synuclein
Monoclonal
(clone211) Sigma Aldrich
Used as test 
antibody 
at variable 
concentrations, 
In ELISA, 1:100
Anti- mouse 
HRPO 
1:50000
-
Anti-p-Actin
Monoclonal AlexisBiochemicals 1:1000
Anti- mouse 
HRPO 
1:2000
-
Anti-Caspr Polyclonal Santa Cruz Biotechnology - -
N-terminal
aa20-70
Anti-Caspr2 Polyclonal Santa Cruz Biotechnology - - N-terminal
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3.1.3 PRIMER AND PROBES
CASPR4
Fw. Primer 5’- CACCATGCACCATCACCATCACCAT-3’
Rev. primer 5’-TTATCAATCTCTTCTATTCAGCCTTGCAAA-3’
CASPR1 mouse
Fw. primer 5’- GCTGGACACCATTCTACCAAA -3’
Rev. primer 5’- GGATGTAGCGAGCCGTAAAG -3’
Probe 5’- FAM-AATGCGACCTTCTTCGGGAATGTCA-TAMRA -3’ 
Amplicon size: 111
gDNA amplicon size with primers: 493 
CASPR4 mouse
Fw. primer 5’- CTT CT GAGCT AT CCAGCAGT CA -3’
Rev. primer 5’- CCACTGGTATTTGTTGGACACA -3’
Probe 5’- FAM-ATCG AAG AGACGG AGCTGGTGGC-TAM RA -3’ 
Amplicon size: 101
DDR1 mouse
Fw. primer 5’-CAGCTCCTGGTCGGACTCT-3’
Rev. primer 5’-TCTTCTTTGGGGAACACAGG-3’
Probe 5’-FAM-AGCAGGCTGG AAAGCAGT G ATGGAGAT-T AM RA-3’ 
Amplicon size: 102
gDNA amplicon size with primers: 609 
MBP mouse
Fw. primer 5’-GACCCAAGATGAAAACCCAGT-3’
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Rev. primer 5’-GGCTGTCTCTTCCTCCCTTC-3’
Probe 5’-FAM-T CTT CAAG AACATT GT G ACACCT CG AACAC-T AM RA-3’
Amplicon size: 95
GAPDH mouse
Housekeeping gene used as internal control (purchased from ABI Biosystems)
3.1.4 CSF SAMPLES
SZ, BP, MDD, NPH and Epilepsy CSF samples were obtained from the CSF Bank 
of Max-Planck Institute of Psychiatry, Munich, Germany, according to the ethical 
rules of the CSF bank. CSF samples for MS and other neurological diseases 
(diagnosed as somatoform disorder, cervical rhizopathy, parainfectious headache 
and shoulder-arm pain) were obtained from the University of Munich clinic. In 
optimization and pilot selections, additional 2 major depression samples and 2 
normal pressure hydrocephalus control samples were used. After lumbar puncture 
was carried out by the medical staff, CSF samples were immediately stored at - 
80°C in aliquots at the clinic of the Max-Planck Institute of Psychiatry CSF bank. 
Tables 3.2-3.4 show the list of CSF samples and important patient data, while a 
more detailed version is given in appendix A2.
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Table 3.2 List of CSF samples from bipolar disorder and schizophrenia patients
Sample Gender Age Diagnosis
[igG]
pg/ml
Albumin
Quotient*
369/98 F 43 Schizophrenia (SZ) 53 7,3
454/00 F 34 SZ 22.7 3,2
464/02 F 24 SZ 45.6 9,3
244/04 F 61 SZ 23.3 4,6
076/97 M 50 SZ 24.6 5,8
166/02 M 56 SZ 28.7 6,6
071/02 F 52 Bipolar disorder (BPD) 25.4 5,9
365/04 F 48 BPD 20.3 4,5
131/05 F 64 BPD 18.9 3,1
203/05 F 46 BPD 11.9 3,1
160/98 M 21 BPD 14.7 2,5
a. Demography of SZ and BPD patients:
Females: (N= 8 -  72,7%) Mean age: 46,5 SD: ±13
Males: (N= 3 -  27,3%) Mean age: 42,33 SD: ±19
All: N=11 Mean age: 45,36 SD: +14
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Table 3.3 List of CSF samples from multiple sclerosis patients
Sample Gender Age Diagnosis
[»gG]
pg/ml
Albumin
Quotient*
70004 F 41 Multiple Sclerosis (MS) 84.2 8,7
06705 F 40 MS 52.3 6,4
14905 F 43 MS 44.7 4,6
15005 F 40 MS 108 5,7
24605 F 26 MS 54.9 6,3
24705 F 31 MS 151 8,8
31205 F 45 MS 59.4 6,5
35305 F 39 MS 51.2 6,3
b. Demography of MS patients:
Females: (N= 8 -100% ) Mean age: 38 SD: ±6,4
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Table 3.4 List of CSF samples from control disease patients
Sample Gender Age Diagnosis
[igG]
pg/ml
Albumin
Quotient*
014/00 F 25 Epilepsy (EPI) 26.6 4,3
300/04 F . 26 EPI 15.5 2,9
339/04 F 56 EPI 61 7,2
477/01 M 17 EPI 34 4,8
326/02 M 70 EPI 62.3 8,9
330/04 M 46 EPI 31.9 5,5
053/05 M 23 EPI 21.1 3,6
01805 F 39 Headache 23 5,1
19405 F 45 Somatoform disorder 34.1 8,2
25505 F 41 Cervical rhizopathy 17.3 4,3
41405 F 42 Shoulder-arm pain 26.6 7,6
c. Demography of control disease patients:
Females: (N= 7 -  63,6%) Mean age: 39 SD: ±11
Males: (N= 4 -  36,4%) Mean age: 39 SD: ±17
All: N=11 Mean age: 39 SD: ±25
* Albumin Quotient =Q(CSF/Serum)x103
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3.1.5 Animals
For each postnatal day time-point (PND1-PND7-PND14-PND21-PND28-PND35 
and PND42), 3 female and 3 male mice with C57BL/6 genetic background were 
used. Animals older than PND14 were obtained from Charles River WIGA GmbH 
(Sulzfeld, Germany). Others were inbred and maintained in the animal facilities of 
the Max Planck Institute of Psychiatry, Munich, Germany. Brain and spinal cord 
tissues were immediately frozen in liquid nitrogen after removal. They were stored 
at -80°C until cryosection or grinding for RNA extraction.
3.2 METHODS
3.2.1 cDNA Phage display assay
The T7Select normal brain cDNA library peptide library (Novagen) was panned 
against CSF immunoglobulin (IgG) using the modified PD protocol. CSF IgG is 
affinity captured onto the BioMag anti-human IgG-Fc beads. To begin each 
panning experiment, 1.7x106 PFU of T7 normal brain cDNA phage with 100 copy 
number was used. For each subsequent panning, lysate obtained by amplification 
of the previous eluate was used. As a negative control, normal human serum 
(Sigma Aldrich) was coupled to BioMag beads and selected over negative lysate 
(empty phage).
1. Preparation of the beads
BioMag-anti human IgG-Fc specific beads (Qiagen) were used to capture CSF 
IgG repertoire. The volume of BioMag beads sufficient to capture all IgG was 
calculated for each patient depending on the IgG concentration given by the 
clinical information sheet. The beads were prepared by washing with phosphate 
buffered saline, 0.1% Tween20 (PBS-T) 3 times, each time carefully removing the 
supernatant after collection of the beads in a magnetic stand (Dynal). Eventually 
the beads were re-suspended in the original volume.
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2. Negative selection of nonspecific clones
In order to clarify the library from the clones that have affinity to magnetic beads, 
T7 normal brain library was combined with BioMag anti-human IgG specific 
against Fc region, in a 1ml final volume of coupling buffer (PBBS-T, 0.1%BSA, 
0.1% Tween 20) and incubated at 4°C for O/N. Following this, the library was 
recovered from the beads for biopanning.
3. Biopanning 
Round 1
In parallel to clarifying T7 library, another set of BioMag beads (equal volume) 
were incubated with 5pg CSF IgG at 4°C, O/N. In all incubations with BioMag 
beads, a Dynal rotator or a rolling rotator (Dynal Biotech, Invitrogen) was used in 
mild rotation to avoid sticking and settling of the beads. Next, the beads, coupled 
to CSF IgG, were washed 3 times with PBS-T (0.1% Tween-20) and mixed with 
the clarified library for incubation at 4°C, O/N. The reaction was then rinsed 1 time 
5ml of washing buffer PBS-T (0.1% Tween-20) and washed 2 more times for 10 
min at room temperature (RT) in a 15ml falcon tube. After washing, bound phage 
was briefly rinsed with ddh^O while being transferring to a clean 2ml Eppendorf 
tube, and eluted by suspending CSF IgG-phage-bead complex in 200pl of elution 
buffer (5M NaCI) at room temperature for 25 min. The elution mixture was placed 
in a magnetic stand and collected in a clean tube. Determination of the titer of the 
eluate and the lysate from bacteria was performed as described in section 4.
Round 2
A second round of panning was performed using amplified phage (in the range of 
10 10-10 11 PFU) recovered from the first-round eluate. Coupling of the BioMag 
beads to CSF IgG was performed the day before adding lysate from the first 
panning. Note that in the second round panning, lysate was used directly, without 
clarification. The same volume of beads were prepared, as described above, and 
incubated O/N at 4°C in the rotator.
To reduce nonspecific binding, the stringency was turned up by increasing the 
duration of each wash to 30 min with the same buffer configuration. The titer of the 
eluate and the lysate from bacteria was determined as described in section 4.
Round 3
The third round of panning was performed using amplified phage (in the range of 
10 10-10 11 PFU) recovered from the second-round eluate. Again, lysates were 
used directly without a prior incubation with empty beads alone. The same volume 
of beads was prepared, as described above, and incubated for O/N at 4°C in the 
rotator. To reduce nonspecific binding, the stringency was increased by using 
0.2% Tween-20 for 30 min. The third round of panning was carried out using 
amplified second-round eluate (10 10-10 11 PFU). Following titer assay for the third- 
round eluate, single plaques were amplified and prepared for sequencing as 
described in sections 6 and 7.
4. Titer assay
250pl aliquots of mid-log-phase E.coli BLT5403 cells with 0.5 optical densities at 
600 nm were infected with 100pl from serial dilutions of T7phage. For eluates, 
serial dilutions were made ranging from 103 to 106 pfu/ml whereas, for lysates, 
dilutions were typically between 106 to 1010 pfu/ml. 7ml of top agar at 40 °C was
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mixed with infected bacteria and poured onto 100-mm plates of LB agar 
supplemented with ampicillin to 20pg/ml (when using agar plates that are stored at 
4°C, they should first be equilibrated to RT). Diligent and careful handling was 
essential to reduce the risk of cross-contamination. The plates were incubated at 
37°C, and it took around 3 h (O/N at RT), until the plaques were large enough for 
counting and picking. Clear plaques demonstrated the lysis of the bacterial cells. 
Well-separated plaques were counted to determine the titer and picked for 
individual amplification for the subsequent analysis when necessary. Plates were 
stored at 4°C, inverted, with parafilm wrapped until plaque picking. The titer was 
calculated by (number of plaques x dilution factor) / (volume plated, in ml).
5. Infection of E .co li cells and enrichment
Typically, a T7 phage eluate had a pfu of 103 to 105 pfu on average. To amplify 
phage for the next round of panning, 100 pi of the eluted phage was used to infect 
mid-log BLT5615 E.coli cells in M9LB (minimal medium) supplemented with 1mM 
IPTG (isopropyl-a-D-thiogalactopyranoside) and ampicillin to 20 pg/ml. 
Additionally, in-situ amplification was performed for the first and second rounds of 
panning. This modification helped rescue high affinity binder clones with slow 
dissociation times. For this purpose, the beads were transferred into the infection 
tube after the eluate was collected from them. For this, 1ml aliquot from an 
uninfected bacterial culture was added to the bead pellet to resuspend and 
transfer them back into the culture. After infection, the culture was kept on the 
bench for 10 min to ensure adequate attachment of phage on the host cells. Next, 
the Culture was placed in the shaking incubator (Innova 4230), at 37°C with 
vigorous shaking. In general, lysis took place after 2 to 3 h with clear signs of cell 
burst, such as culture becoming transparent and white strings of disrupted cell 
debris becoming visible.
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The lysates were transferred into 2ml Eppendorf tubes and centrifuged at 10000 
rpm for 10 min and the supernatant was stored as the lysate.
6. Analysis of clones:
a. DNA purification and PCR
To study single clones, randomly picked phage plaques were excised into 96 
deep-well microtiter plates with 50pl phage extraction buffer (PEB), using sterile 
pipette tips. Only well-isolated plaques were picked in a perpendicular direction to 
the plate as phage plaques diffuse horizontally. The plaques were allowed to 
dissolve in the PEB buffer for an hour at RT, keeping the tips in the well, on an 
orbital shaker with mild rotation. Tips were removed after plaques were ejected 
into and mixed with the PEB buffer. 25pl from each phage extract was transferred 
into a microtiter plate for DNA purification. The rest was covered with a sealing 
mat and stored at 4°C (master clone plate).
In order to disrupt the phages, 25pl of dissolved phage extract were mixed 1:1 with 
10 mM EDTA pH 8.0 in a microtiter plate and placed at 65°C for 10 min in a 
thermocycler. After cooling back to RT, the microtiter plate was centrifuged at top 
speed for 3 min and supernatants were collected in a clean microtiter plate, 
covered with a sealing mat and stored at 4°C (clone-PCR plate). Later, a 
conventional Polymerase Chain Reaction (PCR) was performed to amplify the 
DNA. A control reaction, without the template DNA, was always included to 
confirm the absence of contamination. PCR master mix was prepared and the 
reaction was programmed in an MJ Research P200 thermocycler as follows:
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Reaction volume 50|jl
10X Buffer, with 25mM MgCI2 . 5|jl
dNTPmix (10mM: each dNTP) 1pl
17 Select up primer * 1 pi
17 Select down primer * 1 pi
ddH20  39.75pl
Taq polymerase 0.25pl
Phage lysate 2pl
Primers (* stock: 5pmol/pl)
11 up primer (Novagen) 5’-GGA GCT GTC GTA TTC CAG TC-3’
17 down primer (Novagen) 5’-AAC CCC TCA AGA CCC GTT TA-3’
PCR Program:
80°C 5 min Initial denaturation
95 °C 30 sec Denaturation
59 °C 30 sec Annealing
72 °C 1 min Elongation
72 °C 5 min Final elongation
4°C-12°C Infinite Cooling
33-35 cycles
For clone analysis and restriction enzyme fingerprinting, 10pl PCR reactions were 
sufficient. Afterwards, selected clones were amplified in a larger volume (50pl 
PCR reaction). PCR products were stored at 4°C until purification.
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b. Restriction fingerprinting directly after PCR
PCR products can be directly digested after an amplification reaction only if the 
PCR buffer does not interfere with the restriction enzyme activity, yet there will be 
some loss in digestion efficiency. In order to circumvent this problem, it is 
recommended to dilute the PCR product minimum 3 folds.
For digesting amplified PCR products, Mval (or BstNI) restriction enzyme (Roche) 
was used.
T 
5'-C CAA G G-3' 
3'-G G TAC C-5' 
A
Figure 3.1 Restriction digest sites of Mval.
The restriction reaction was constructed by adding the reagents in the following 
order in a total volume of 25pl. The reaction was gently mixed and spun down 
before being placed in the thermocycler at 37°C for 2 h.
10X Buffer H+ 2.5pl
ddH20  39.75pl
DNA 10pl
Mval (5 units) 0.5pl
c. Clone analysis on agarose gel
1.2% Agarose gels were used to analyze 5-1 Opl of PCR products, whereas 2.5- 
3% gels were used to observe RE digestions. The image of each gel was taken 
under UV light in a BioRad Luminator using Quantity One 4.4.0 software. Clones 
from each panning were compared to others in terms of size and RE digestion 
pattern. When the size of a PCR product was equal to another clone, the RE
fingerprint was compared. Representative clones of different sizes and RE 
fingerprint patterns, together with all undigested clones, were selected for PCR 
purification and sequencing.
7. Identification of clones
a. Purification of PCR products
After selecting clones for sequencing, 50pl amplified T7 inserts were purified by 
QIAquick kit (Qiagen) for sequencing. Briefly, 5 volumes of Buffer PB were mixed 
with 1 volume of the PCR product. The sample was carefully applied on a 
QIAquick column placed in a 2ml collection tube and centrifuged at 13000 rpm for 
30-60 sec. After flow through was discarded and the column was put back into the 
collector, 750pl Buffer PE (constructed by adding 96-100% ethanol) was added to 
the column and centrifuged at 13.000 rpm for 30-60 sec. After discarding the flow 
through, the column was put back into the collector and centrifuged at 13.000 rpm 
for additional 1 min. Again flow through was discarded and the column was 
transferred into a clean 1.5ml microcentrifuge tube. 50pl Buffer EB or dd-h^O was 
dropped exactly on the center of the membrane and centrifuged at 13.000 rpm for 
1 minute. Alternatively, after adding 30pl elution buffer to the center of the 
membrane, incubation for 1 minute before centrifugation would increase the yield.
b. Sequencing
Purified PCR products were visually quantified on a 1.2% agarose gel using the 
DNA marker as standard. For PCR products smaller than 1 kb, minimum 50ng 
DNA and, for longer PCR products, 100ng DNA were sent to an external 
sequencing service (Sequiserve). Sequences were manually edited by the 
company and provided both as text file and chromogram.
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c. Blast analysis
The insert sequences were analyzed by an NCBI Blast (Balstn and Blastx) search 
against a non-redundant Homo Sapiens database. The identities of each clone 
were listed. Clones that exist in the list of background clones were omitted. In 
addition, clones that are common to control samples (epilepsy, NPH, headache, 
etc) were filtered out from the DS-Ag listing. Remaining clones were evaluated 
according to several criteria, such as frequency within a certain disease group and 
within any given patient CSF, and if it existed, the variety of epitopes (different 
epitopes from the same hit, either overlapping or not).
8. CsCI gradient purification of phage lysate
Larger volumes of phage eluates were purified further using a CsCI gradient.
7ml of BLT 5615 cells were grown in LB buffer with ampicillin O/N at 37°C, 
shaking at 200 rpm. M9LB media with 20pg/ml ampicillin was made to a final 
volume of culture 35ml with IPTG added to 1mM, approximately 10 min before 
infection. The culture was then infected with a single clone and left to stand for a 
short while on the bench before shaking at 37°C, 250 rpm. After lysis, 3.5ml of 5 M 
NaCI was added to 35ml culture for centrifugation at 7700 rpm in a Beckman JA- 
17 rotor at 4°C, for 10 min. 30ml of supernatant was put in a clean 50ml Falcon 
tube together with 5ml of 50% PEG 8000 and vortexed thoroughly. Next, PEG- 
lysate was incubated on ice for minimum half an hour or at 4°C for O/N, followed 
by centrifugation at 7700rpm in a Beckman JA-17 rotor at 4°C, 10 min. 
Supernatant was removed and the remaining fluid was drained by putting tubes 
upside down on a paper towel furnished with nylon folio underneath. CsCI gradient 
was prepared from a stock solution of 62.5% CsCI prepared by adding 25g of 
CsCI into 15ml ddH20. In order to get the gradient we mixed CsCI and TE buffer, 
starting from the least dense solution, and adding the next denser solution
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carefully over it using a pipette. When all the excess liquid had drained, 1.2ml of 
5M NaCI, 10mM Tris-HCI, pH 8.0, 1mM EDTA was mixed with vortex and followed 
by centrifugation for 10 min at 1200Qxg. The supernatant was layered onto a CsCI 
gradient and separated by ultracentrifugation for 1 hr at 35000rpm in an SW41 
rotor at RT. Subsequently, the tubes were illuminated from above when other 
lights were dim, so that the bands became visible. The turbid band above the 2:1 
layer was collected and stored at 4°C.
3.2.2 Phage ELISA
Purified phage lysate was diluted 1:20 in 1% BSA-PBS and incubated at 37°C for 
one hour. Next, stripes from the T7 capture plate were washed with 400pl 0.05% 
PBS-Tween20. Whenever necessary, CSF was diluted using 1% BSA, and 
incubated at 4°C, O/N. CSF was washed with washing buffer (400pl 0.05% PBS- 
Tween20). Subsequently, 100pl of anti-human IgG Biotin antibody cocktail (1:1000 
diluted polyclonal (Jackson Imm.) and 1:500 diluted mouse monoclonal from BD 
Biosciences) was added and incubated for 2 h at RT. After washing the stripes 
with washing buffer, streptavidin-HRPO diluted 1:2000 in 1% BSA, was added and 
incubated for 20 min at RT, in the dark and then washed. After adding 100pl TMB 
(Sigma Aldrich) at RT, the reaction was stopped by adding 100pl of stop solution 
(Sigma Aldrich) as a differential color development had occurred. The readings 
were taken at an OD 450 nm with an ELISA reader.
3.2.3 Cloning and expression of rCaspr4 peptide
Cloning, expression and purification of the Caspr4 peptide was performed in 
collaboration with Dr. Emre Sayan, Leicester University. Briefly, the first coding 
exon of CASPR4 (genebank id: GL20544135) gene was amplified by Pfx
polymerase (Invitrogen) and cloned into pET/101D-TOPO vector with an N-
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terminal 6XHis tag. Three positive clones were selected after sequencing and 
further analyzed for the expression of recombinant protein. The clone expressing 
the greatest amount of protein was used for purification. Recombinant proteins 
were expressed in E. coli (BL21) and purified under denaturing conditions using 
Ni-NTA resin. Proteins were then refolded and buffer exchanged in PBS using 
NAP buffer exchange columns (GE Amersham). Finally, proteins were 
concentrated using Centripreps (Millipore). A western blot and Coomassie staining 
were performed to check the purity, size and amount of the obtained peptide (gel 
picture is shown in appendix, A3).
3.2.4 RNA Extraction
Freshly obtained mouse brain and spinal cord tissues were frozen and embedded 
in cryomolds using OCT, and sections were cut with a Cryostat (Leica) and placed 
immediately on dry ice. For total RNA extraction, the RNeasy kit (Qiagen) was 
used according to the manufacturer’s protocol for frozen tissue sections. 600pl 
buffer RLT was added onto 10-15 10pm thick sections, and mixed by pipetting. 
The lysate was transferred to a QIAshredder column (Qiagen) and spun at 14000 
rpm for 2 min. at RT for homogenization. After this, samples can be stored at - 
80°C and should be incubated for 15min at 37°C before proceeding to the next 
step. 600pl of 70% ethanol was added to the lysate and mixed well by pipetting, 
600pl of this mixture was transferred to the RNeasy column and spun at 10000 
rpm for 20 seconds at RT. Flow through was discarded and the remaining 600pl 
was processed identically. 350ml buffer RW1 was added to the column and 
centrifuged at 10000 rpm for 20 seconds at RT. Flow through was discarded. 
DNase treatment was performed according to the manufacturer’s protocol 
(Qiagen). Next, the column was washed with 350ml buffer RW1. The collection
tube was renewed and 500ml buffer RPE was added before spinning at 10000rpm
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for 20seconds at RT. After discarding the flow through, the last step was repeated, 
but this time spinning for 2 min. The column was transferred to a new Rnase-free 
1.5ml tube to elute the RNA with 20-40pl Rnase-free water directly added onto the 
membrane and spun for 1 minute at 10000rpm at RT. Eluted RNA should be kept 
at-80°C.
3.2.5 RNA quantification
RNA concentration was determined by measuring the absorption at 260 and 280 
nm. The A280/A260 ratio was between 1.8 and 2.0 for all the samples prepared. A 
ND-1000 spectrophotometer (NanoDrop) was used for quantification of extracted 
RNA.
3.2.6 Reverse Transcription
A complimentary DNA copy was synthesized using the reverse transcriptase kit 
(MML-V, Promega). For cDNA synthesis RNase/DNase free filter tips and tubes 
were used. All solutions required for the process were prepared using molecular 
grade RNase/DNase free water.
3.2.7 Quantitative PCR (Real Time PCR)
3.2.7.1 Principle
Quantitative PCR was performed on the GeneAmp5700 (Applied Biosystems-ABI)
using the qPCR Core kit and UNG (Uracyl-N-glycosylase for carry-over
prevention, both from Eurogentec). The reaction volume was 25pl containing 5 -
50ng RNA converted to cDNA. For detection and quantification of Casprl, Caspr4,
MBP and DDR-1 genes, primers and probes were designed. GAPDH
(Glycerinaldehyd-3-phosphat-Dehydrogenase) (Applied Biosystems) was used as
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the housekeeping gene (HKG). Percent housekeeping gene values were 
calculated using the formula: %HKG = 100 x 2( ACt). Standard deviations of HKG 
and the gene of interest (GOI) were calculated using the formula based on Muller 
et al. (2002), given as SD= 100 x 2('aci) x ((In2 x SDHKg)2 + (In2 x SDGOi)2)1/2-
3.2.7.2 Primer I probe design and testing
TaqMan primers and probes were designed using Primer3 
(http://frodo.wi.mit.edu/) (Steve Rozen and Helen J. Skaletsky, 2000) and Primer 
Express v1.0 (Applied Biosystems). All primer/probe sequences were controlled 
for possible interactions with each other. Designed primers were tested with a 
conventional PCR experiment using genomic DNA as a template in order to 
confirm that it was not amplified.
3.2.8 Plaque lift assay
3.2.8.1 Introduction
Plaque lift assay (PLA) is blotting of phage plaques onto a nitrocellulose 
membrane and then probing with an antibody against the recombinant protein 
displayed on the phage colony. In this way, it is possible to detect the clones that 
display the peptide or protein of interest and it additionally helps calculate the 
enrichment factor. When selecting candidate auto-antibodies against unknown 
antigens using cDNA PD, it was not possible to perform a PLA as the displayed 
clone was only identified after sequencing. Additionally, frequently, the antibody 
against the candidate Ag was not available. Nevertheless, PLA was very useful in 
the modification of the PD technique during optimizations and pilot selections. For 
example, monoclonal anti-Synuclein antibody (Sigma, clone 211) was mixed with 
CSF at variable concentrations binding to the antigen displayed on the phage, and 
confirmed by sequencing plus PLA (chapter on optimization, section 4.3).
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3.2.8.2 Preparations of the nitrocellulose capture filters
Capture antibody was diluted to 10 mg/ml in PBS, pH 7.5. A nitrocellulose filter 
was incubated with the capture antibody for up to 3 h at RT. The filters were air 
dried for 10 min and blocked for 2 h at RT with 1% BSA in PBS. Filters were 
rinsed with PBS and air dried before applying onto the bacterial lawns infected 
with phage.
3.2.8.3 Plaque lifting
Capture antibody coated filter was applied onto the plaques (maximum 1000 
plaques per 100mM diameter plate). After double or triple lifting per plate, the 
filters were carefully removed, rinsed 4 times with 2ml PBS and blocked for 30 min 
at RT with 5% skimmed milk in 0.2% Tween20. Primary antibody, diluted in 
blocking buffer, was incubated for 1 hr at RT. Next, the filters were washed with 
0.1% PBS-Tween20, 3 times 10 min. Detection antibody was diluted in blocking 
buffer and incubated for 30 min at RT. ECL plus detection system was used 
before developing on Kodak film.
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3.2.9 Sample preparation for CSF using Vivaspin and Multiple Affinity 
Removal System (MARS) spin cartridge (optional)
3.2.9.1 Introduction
CSF samples from 11 MDD and 4 NPH patients, assigned for several different 
proteomics applications, were separated using the Multiple Affinity Removal 
System (MARS) (Agilent Technologies, USA). After depletion of 6 abundant 
proteins including IgG, CSF was processed by 2-DE gel electrophoresis and mass 
spectrometry. The IgG fraction was collected, evaluated for its IgG content and 
used in panning.
3.2.9.2 Sample (CSF) preparation for MARS spin cartridge
MARS Spin Cartridge has a cartridge capacity of 7-1 Opl human serum. 18pl serum 
corresponds to 3ml CSF. Resin bed and frits should always remain moist. MARS 
spin cartridge has the capacity to process 1.0 - 1.5ml CSF. Nevertheless, the 
actual cartridge capacity on certificate should be checked beforehand.
3.2.9.3 Vivaspin concentration and buffer exchange
Vivaspin 5kDa MWCO column (Sartorius Biolab) was washed with 2ml ddH20  
with centrifugation at 5000 rpm, RT. CSF was concentrated down to 100pl while 
flow through was collected and stored at -80 °C. Buffer was exchanged by 
washing three times with 1ml Buffer A. The flow through was collected and stored 
at -80 °C. The next step was simply to centrifugation until the final volume was 
100 -200pl and filled up to the desired volume with Buffer A. Concentrated product 
was filtered through a spin filter column (0.22pm) by centrifugation at maximum 
speed for 1 minute at RT, using a bench top centrifuge.
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3.2.9.4 CSF depletion by MARS spin cartridge
Cap and plug of the cartridge were removed. A Luer-Lock adapter was attached to 
the spin cartridge. 4ml of buffer A was drawn into the syringe (“labeled A”) to be 
attached to the L-L on the cartridge, buffer A was passed through the cartridge to 
prepare the resin, and excess buffer A was removed from the top of the spin 
cartridge using a transfer pipette. Next, the spin cartridge was placed in a 1.5ml 
Eppendorf tube and labeled as FT1 (Flowthrough 1). 200pl buffer A was added on 
top of the resin bed and the open cartridge was centrifuged at 80rcf for 1.5 min 
(the flow-rate was measured beforehand and ideally has to be ~0.2ml/min). 400pl 
Buffer A was added on top and centrifuged at 80rcf for 2.5 min. FT was collected 
into tube FT1 and the spin column was placed in a new collection tube, labeled 
FT2 (Flowthrough2). 400pl Buffer A was added and centrifuged at 80rcf for 3 min. 
The spin cartridge was removed from tube FT2 and the L-L adapter was attached 
to the top. A 5ml L-L syringe was filled with 2ml buffer B and the spin cartridge 
was attached via the L-L adapter. IgG and other high abundant proteins were 
eluted into 1.5ml eppendorf tubes and labeled as eluate by slowly pushing 2ml 
buffer B through the spin cartridge. In order to re-equilibrate, a 5ml syringe was 
filled with 4ml buffer A, and pushed slowly through the spin cartridge. For storage, 
a layer of buffer A was left on top. Both ends were recapped, and the cartridge is 
stored at 4°C.
FT2 fraction usually contains less than 10 % of the total FT. If necessary, FT1 and 
FT2 fractions can be combined and concentrated again. For my purposes, I 
checked the IgG quantity that might have leaked into FT. In order to analyze the 
eluate, one may have to perform a buffer exchange to PBS, or another buffer 
compatible with the analysis as buffer B may interfere with some protein assays.
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3.2.10 Human IgG ELISA quantification
After the Vivaspin-MARS procedure, the samples were evaluated by an IgG Elisa 
quantification kit (Bethyl Laboratories). All steps were performed at RT and all 
samples were analyzed in duplicate. Briefly, 1pl of monoclonal anti-Synuclein 
clone211 antibody (Sigma) was mixed with 100pl coating buffer and incubated for 
60 min in ELISA wells. After washing 3 times, the wells were blocked with 200pl 
blocking buffer for 30 min. 100pl volumes of standards and samples were 
prepared in the dilution buffer and incubated for 60 min. After washing 5 times, 
100pl of anti-mouse-HRP conjugated detection antibody diluted 1:50000, was 
applied to each well and incubated for 60 min. After washing, TMB substrate 
(Sigma Aldrich) was used for detection and the reaction was stopped using sigma 
stop solution before reading at 450nm by an Elisa reader.
3.2.11 Western blot
For qualitative analysis, samples were loaded directly without measuring the 
protein content, whereas for quantitative analysis, protein concentration was 
measured by BCA protein assay (Pierce).
Protein samples were dissolved in equal volumes of 2x Laemmli sample buffer 
and heated at 95°C for 5 min. Samples were spun down shortly before loading 
onto a 12-15% SDS-PAGE gel. After transferring onto a nitrocellulose membrane, 
the membrane was treated with Ponceau Red (Pierce) before blocking for 1 hour 
at RT. Primary antibody was diluted in blocking buffer and incubated at 4°C O/N. 
After washing the membranes 3 times for 10 min, secondary Ab-conjugate in 
blocking buffer was applied and incubated for 1 hour at RT. After washing, 
appropriate chemiluminescence substrates were added (ECL for HRPO 
conjugates and CDP-Star (Novagen) or for AP substrates). Signals were 
developed with a Kodak film. Alternatively chromogenic detection of alkaline
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phosphatase conjugates was developed on the membrane by a purple 
precipitation using NBT/BCIP substrate.
3.2.12 Protocol for control samples used in optimization
For initial screening of depression-related IgG repertoire, 2 unipolar depression 
(UPD) and 2 normal pressure hydrocephalus CSF samples were used. The 
secondary aim was to characterize the CSF background and to compare MARS 
depleted and non-depleted CSF samples. Samples MDD 312 and NPH 2 were 
processed by the MARS spin cartridge so that depleted IgG fraction from CSF was 
introduced into the panning. Samples Lo and NPH3 were used directly from the 
original aliquot. The new IgG concentration was measured by the Human IgG 
ELISA kit. Eventually, 5pl of IgG per panning was immobilized on Dynal tosyl- 
activated magnetic beads coupled to anti-human IgG antibody specific to the Fc 
region. During panning steps, washing was carried out by 1% TBS-T with 
increments in duration for each round. Elution was performed with 5M NaCI for 25 
min at RT. Eluates from the last panning round were plated on agar bacterial loan 
and 24 plaques were picked from each sample for clone analysis.
60
Chapter 4
cDNA Phage Display, CSF and Autoantigen Research: 
Challenges and Optimizations Addressing a Novel Approach
4.1 Introduction
Peptides and proteins can be displayed on phage particles for autoantigen 
selection from human material. Nonetheless, there are major factors that can 
greatly affect the overall success.
Most importantly, the cDNA library to be implemented within the PD selection 
system must bear a sufficient number of recombinant clones in the range of a 
minimum of several millions. Secondly, the whole system with regarding to the 
type of display (monovalent, polyvalent), type of phage (filamentous, lambda, T7) 
has to be researched and tested for suitability. Finally, stringency must be fine- 
tuned for selecting mostly the true hits with a minimum of false positives. Actually, 
co-elution of sticky and false positive clones is a constant drawback, which can be 
improved upon but never totally eliminated. Only after a series of stringent control 
steps, can there be any confidence in the success of selection as there is very 
limited sensitivity in ruling out false positives from true hits.
CSF is a valuable human material collected in rather small volumes through an 
invasive technique with almost no sampling from healthy subjects. Similar to many 
other studies, CSF was the limiting factor in this work as well.
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Psychiatric disorders, like BPD and SZ, have been studied thoroughly by 
investigators for an underlying autoimmune condition. It is still a challenging task 
to find autoantigenic targets that are not as evident or dominant as in case for 
established autoimmune disorders.
Referring to all the issues mentioned above, this thesis was based on an 
exploratory project that requires not only literature-based, but also original 
strategies that address the feasibility of our approach to unravel minute 
autoimmune activities for psychiatric disorders.
This chapter summarizes the development of our exploratory approach, elucidates 
strategically important decisions that were taken and critical parameters and 
explains the modifications made for the standard PD protocol in order to obtain 
adequate sensitivity and a relatively low false positive background, while 
surmounting the limitations of CSF. Results included herein demonstrate the 
principle and the outlook of the technique, thus providing supportive evidence of 
successful applications. Subsequently, obtained results were evaluated stringently 
and the most promising candidate autoantigen was selected for further analysis.
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4.2 Important parameters of a phage display experiment
4.2.1 Type of display
Peptide libraries are generated as in vitro synthesized, randomly expressed as N- 
terminal fusion to minor coat protein pill (monovalent display) or major coat protein 
pVIII (polyvalent display) on filamentous phage. Peptide PD libraries were used 
especially for studying the binding properties of homogenous proteins. 
Nevertheless, there are many reports about finding autoantigens from sera of 
autoimmunity disorders like rheumatoid arthritis (Dybwad et al., 1995, 1996; 
Hansen et al., 2000) multiple sclerosis (Rand et al., 1998; Cortese et al., 1998; 
and systemic lupus erythematosus (Dieker et al., 2005). Similarly, cDNA PD has 
been successfully applied in autoantibody searches in polyclonal human material 
like sera of rheumatoid arthritis (Mewar et al., 2005) and systemic lupus 
erythematosus (Kemp EH et al., 2002) patients.
Epitopes from processed antigens, presented as peptides by MHC class I and II, 
can be studied by peptide PD (Sioud, Hansen and Dybwad, 2000). Such 
applications include elucidation of target immunogenic epitopes for multiple 
sclerosis (Cortese et al., 1996; Rand et al., 1998).
In addition to processed antigens, cDNA PD also enables identification of parental 
antigens that are targets of B-cells, bearing bound or secreted immunoglobin (Ig) 
molecules that are receptors of soluble or pathogen-bound antigens (Sioud, 
Hansen and Dybwad, 2000).
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For our query on psychiatric disorders, of which the current knowledge in disease 
etiology is not based on a substantial autoimmune attack, the primal idea was to 
see whether autoantigenic molecules could be detected at all. For this initial step, 
identification of the autoantigenic target was sufficient. Accordingly, for this 
application, the cDNA PD system is more powerful than the random peptide 
display as the latter has the capacity to display only a small fraction of all possible 
sequences. In contrast, the cDNA library represents all the mRNA expression from 
a tissue at the period of extraction. Despite the existence of 3’UTR inserts and 
unknown gene products that cannot be excluded, cDNA libraries represent mostly 
the naturally expressed antigens, whereas peptide libraries include several 
unnatural epitopes (Sioud, Hansen and Dybwad, 2000). The cDNA product that is 
likely to be a candidate autoantigen is identified by sequencing, thus the 
information on the epitope mapping of the interaction is simultaneously obtained. 
As a result, the cDNA PD library strategy was chosen as it has potential to reveal 
autoantigenic targets within the CSF of the psychiatric disorders in question.
4.2.2 Quality of the library
The most important parameter of a successful PD project is the quality of the initial 
library, reflected in the diversity of the recombinant clones. Normally the range is 
between 106 and 1010 plaque forming unit (pfu) recombinant clones.
The diversity of the self-constructed or commercially obtained library should be 
tested before any application. It should always be kept in mind that all recombinant 
clones are not equally expressed within a library. For example, abundant proteins 
of a tissue are reflected as abundant transcripts within cDNA libraries. Similarly, as 
seen in peptide libraries, some sequences may be toxic, difficult to display due to 
rare residues or not compatible with the phage itself (Smith and Petrenko, 1997).
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The T7 Select library used in this study encodes cDNA obtained form normal brain 
with 1.47x107 recombinant clones. The insert size is between 0.3 and 3kb after 
PCR analysis of the amplified library.
Maintenance of the library is vital and the library should be kept in aliquots, as 
repeated freeze-thaw cycles will reduce the titer.
A further point is about the number of propagations that can be applied on the 
original library without losing its diversity. Generally, it is advisable not to 
propagate the library more than twice. In fact, the risk of losing under-represented 
clones at this very early stage is so high that it could easily jeopardize the whole 
selection from the beginning. The T7 select library was amplified in liquid culture 
only once before the whole selection was performed.
4.2.3 Stringency versus yield
During each panning round, stringency regulates the threshold for selecting better 
binders against non-specific ones. Thus, the stringency level determines the yield. 
A convenient PD library has a minimum of 106 recombinant clones with 100 copies 
from each clone.
The first round selection is of utmost importance because if none of the, for 
example, 100 copies of a given clone are able to bind to their targets due to 
excessive stringent conditions, that clone is lost and cannot be regained. 
Accordingly, yield is always favored over stringency for the first round of selection. 
Already after the first amplification step, the first round binders are represented in 
millions of copies, in other words, they are enriched against less specific binders, 
enabling re-adjustment of stringency. However, it is not advisable to practice 
extreme stringency in the following rounds, as it would dramatically reduce the 
yield. Moreover, it may push forward the non-specific but persistent clones that are
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better survivors than high affinity binders, eventually causing the sticky 
background to outnumber the true hits (Smith and Petrenko, 1997; Russel, 
Lowman, Clackson, 2004). A balanced fine-tuning between stringency and yield is 
only valid after several tests of various conditions and modifications. When 
exploring the feasibility of the T7 system, efficiency of the selection conditions 
were tested by means of pilot experiments given below (see 4.3.1 - 4.3.2). 
Subsequently, the sensitivity of selection and efficiency of elution were optimized 
(4.3.3-4.3.6).
4.2.4 Selection
In general, the target is tethered to a solid support like a microtiter plate, magnetic 
beads or porous agarose beads. Microtiter plates are practical to use and 
compatible with multi-channel pipettes but provide a limited area for the target to 
bind. By comparison, beads offer a maximum surface area and usually have better 
washing efficiency. However, due to handling mistakes, some beads may get lost 
during washing or elution, plus extensive contamination can arise. The tests 
regarding the magnetic beads used in this study seek to understand the limits of 
BioMag beads preserve CSF-IgG binding without covalent attachment (see 
4.3.2.2).
Another critical consideration is the number of rounds for selection. Enrichment is 
the key parameter to monitor if selection is working at all, and when to stop 
panning. To pursue panning after stabilization of enrichment endangers potential 
true affinity clones that are not as efficiently propagating as the others.
An option, which was applied in this work, is to run a pilot selection with a known 
target to test the typical enrichment pattern of the library, and conditions for 
selection, and to see when to stop in a relatively similar set up (section E and F).
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4.2.5 Analysis of the clones
In general, the clones selected from the last round of panning were analyzed 
individually. A single plaque on a bacterial lawn represents 106-107 phages from 
the same genomic construct. DNA purification and a subsequent sequencing 
provide the identity of the clone and the nucleotide sequence of the insert within 
the phage genome corresponding to the amino acid sequence. If necessary, the 
next step is to clone the insert into an expression vector for further analysis (Smith 
and Petrenko, 1997). In fact, one clone, identified in this study, was cloned to 
generate recombinant protein to be used in an Elisa.
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4.3 Results
4.3.1 Feasibility of the T7 system:
4.3.1.1 Standard screening conditions applied to the T7 phage display 
system yield significant enrichment after 4 rounds of panning
For evaluating the feasibility of the T7 Select system, the strong binding interaction 
between the 15 amino acids long S-tag and the 103 amino acids long S-protein, 
both derived from Rnase A, was employed (Figure 4.1). T7 Select positive phages 
bear the T7Select415-1 vector with the S-Tag insert, whereas the negative control 
vector has no insert.
S-protein and S-tag
I B  Cleavage
aa ‘i 1 5  20 124 ° f
S-peptide
I
S-protein
S15 (S -tag ): aa [1-15] necessary for interaction with S-protein
Figure 4.1 S-Tag peptide is displayed on the surface of the T7 phage as an in-frame fusion 
protein. The insert has been cloned into EcoR I/Hind III arms of T7Select415-1 vector.
S-protein was coated in the wells of microtiter plates (Corning HighBind) at 1pg/ml 
to lOpg/ml concentrations. In parallel, Dynal M-280 tosyl-activated magnetic 
beads were covalently coated with S-protein (0.7 pg/20|ul beads). A phage library 
with a ratio of positive to negative clones of 1: 106 was used for the screen (input). 
After 4 rounds of panning enrichment of the S-tag insert-carrying phage was 
assessed by counting the number of positive clones using a standard plaque lift 
assay (Figure. 4.2). When microtiter plates were used as a matrix, a maximum
6 8
1.25 x 105 enrichment of S-tag phage was found, whereas 2.8 x 104 enrichment 
was observed after the magnetic bead immobilization procedure (Table 4.1).
Figure 4.2 Plaque lift assay results (standard selection conditions). Four rounds of panning 
were performed on S-protein. Non-specific binders were washed with 0.1% TBS-Tween20 for 3 
times 10 min each. 5M NaCI was used for elution at RT for 25 min. The plaque lift assay was 
performed using S protein HRPO conjugate at 1: 5000 dilution. The film was overdeveloped to 
show the smallest plaques, yet the counting was taken when the plaques were well-separated.
Table 4.1 Comparison of enrichment. Titer assay, performed after the last round, facilitated 
evaluation of the enrichment factor.
Panning Procedure Plaque Count Enrichment
Target Matrix Total Positive
1 Non-coated Microtiter 500 0 -
2 S-protein (1 pg/ml) Microtiter 400 30 7.5x104
3 S-protein (10 pg/ml Microtiter 400 50 1.25x10b
4 BSA (1 pg/ml) Microtiter 500 3 6x104
5 S-protein (0.7 pg/ml)) DynaBead 500 14 2.8x104
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4.3.1.2 Adjusted stringent selection conditions improve signal to noise ratio 
without decreasing the yield
S-protein positive lysate was mixed with negative lysate (1:106), as well as T7 
whole human brain cDNA library composed of 1.47x107 recombinant clones, again 
with the ratio of positive clones to recombinants as 1:106. Increments in stringency 
were devised after each round with longer washing durations (three times, up to 
30 min each). Increased Tween-20 concentrations of washing buffers were tested 
and up to 0.2% PBS-Tween-20 was applied during washings during the third 
round. Background was measured by panning on non-coated wells. Positive 
clones were identified by plaque lift assay after 4 rounds of panning. Figure 4.3A 
shows the detection of S-tag insert clones with no background clones found for the 
negative control. Same strategy was repeated using whole library instead of 
negative lysate (Figure 4.3B)
Figure 4.3 Plaque lift assay results (stringent screening conditions). T7Select Brain library 
consists of 1.47 X 10? primary recombinants. All membranes were probed with S protein-HRPO 
conjugate. A. S-tag positive versus negative lysate. The left membrane shows control panning 
on non-coated microtiter wells, whereas the right membrane shows the panning carried on 
microtiter wells coated with 100 pL of 0.5 pg/ml S-protein. Enrichment was found to be 8.3 X 104 . 
B. S-tag positive versus whole library. The membrane on the left shows control panning on 
non-coated microtiter wells and the membrane on the right shows S-tag displaying plaques 
obtained from last panning round on 5 pg/ml S-protein (10 fold more target compared to panel A) 
coated wells.
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4.3.1.3 Sensitivity of T7 system is optimized and tested using anti-synuclein 
antibody as the known antibody target
Anti-synuclein mouse ascites (Syn-211; generated against amino acids 121-125 of
the protein, Sigma Aldrich) were coated with an approximate Ig concentration of 1, 
2 and 10 pig/ml in TBS on HighBind Corning microtiter strip-wells. After 4 rounds of 
panning, enrichment was assessed by titer and plaque lift assays. No background 
was observed for the negative control (panning on non-coated wells).
Figure 4.4 Plaque lift assay conducted after enrichment with anti-synuclein antibody. Left filter: 
control (no antibody); right filter: anti-synuclein ascites, dilution of anti-mouse HRPO is 1:2000.
Optimizations were based on alternative immobilization techniques. Instead of 
direct immobilization of the target on microtiter wells or Dynal beads, solution 
binding of the target and phage was tested. Binding in solution, allows phage to 
interact with the target freely in solution thus reducing avidity effects. The beads 
subsequently capture phage and target, as a complex. Magnetic beads with a 280 
mm diameter were covalently coated with recombinant protein G (Dynal) and 
prepared according to the manufacturer’s protocol. 10ng of anti-synuclein antibody 
was incubated with the brain phage library and the resulting complex was 
captured with protein G magnetic beads. PCR was carried out using the whole 
lysate, as well as individual plaques. Clones were analyzed by agarose gel 
electrophoresis and prepared for sequencing. PCR of the whole lysate from the 
last panning yielded 2 major bands that were 700 bp and 850 bp in size (data not
shown), where the insert with 700bp size was identified as alpha-synuclein, but 
the 850 bp clone was unrelated (background). Plaque lift assay was performed to 
detect synuclein displaying clones (Figure 4.5).
Figure 4.5 Synuclein positive clones. The membrane on the left depicts plaque lift assay results 
using Syn-211 antibody. After plating the lysate from the last panning, plaque lifts were performed 
using nitrocellulose membranes in disk format (3M) and blocked for 2 h. The membranes were 
incubated with anti-Syn antibody (Sigma) at 1:2000 dilution and detected by anti-mouse HRPO 
(Sigma) at 1:2000 dilution and ECL system. The spots encircled in red are anti-Syn reactive phage 
lysates. The same lysate on the right membrane, treated only with secondary antibody, did not 
yield any signal.
4.3.1.4 T7 compatible bacterial strain BLT 5615 generates less background 
compared to BLT 5403 strain
While monitoring the efficiency of the T7 system, E.coli strain BLT5403 was found 
to generate a higher background compared to BLTR5615, mainly in plaque lift 
assays. PCR analysis of the plaques showed that BLT5403 produced shorter 
inserts than expected (data not shown). In the manufacturer’s manual, strain 
BLT5403 is described to be slightly more prone to deletion mutations in the capsid 
protein if the inserts are bigger than 600 bp (Novagen). In addition, BLT 5403 
plaques looked smaller than BLT 5615 plaques when plated on LB-agar, although 
the titers were equivalent.
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In conclusion, propagation of eluted phages using BLT5403 was unsuccessful 
Instead; IPTG inducible BLT 5615 E.coli host seems to be a better option for 
amplification. PCR analysis of selected clones propagated by BLT5615 culture 
confirmed regular insert sizes that range between 300 bp-3 kb (data not shown). 
Based on these results, panning was performed from BLT 5615 lysates.
4.3.1.5 Monitoring elution efficiency
Elution must be rigorous enough to collect almost all of the selected clones. The 
clones with lower dissociation rates might not co-elute and stay on the matrix. In 
fact, those clones that bind with high affinity to the matrix are of utmost interest 
and must be efficiently recovered.
Antibody-antigen interaction is rather efficient in aqueous buffers at physiological 
pH and ionic strength. Thus, elution can be accomplished by altering the pH or the 
ionic state. Modified PD protocols were tested for elution efficiency in terms of 
alternative elution buffers (5M NaCI versus 1% SDS) and incubation times 
recommended for T7phage. The efficiency of elution was assessed by T7 phage 
ELISA that measures phage particles that are still “binding” to the matrix, and also 
by a titer assay that measures rescued phages after the elution step.
Standard tests showed efficient elution using 5M NaCI buffer at 25 min of 
incubation with small-scale tests with known targets. For comparison, a longer 
incubation for 35 min was tested. Results implicated no significant increase of the 
elution efficiency due to duration of elution and/or change of buffer. Nevertheless, 
one difference between test conditions was that the 5M NaCI eluate could be 
directly added to bacteria, whereas SDS had to be diluted to prevent bacteria from 
dying before efficiently producing the phage particles.
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4.3.2 Optimal utilization of CSF in phage display selection
4.3.2.1 Strong binder phage subtypes with low dissociation rates can be 
rescued from the beads by an in -s itu  infection step
Elution buffers and durations were quite efficient but the test results did not reveal 
on how to rescue strong binding clones with slower dissociation rates.
As the limiting factor was CSF-enriched IgG, any phage capturing CSF-IgG via its 
displayed fusion peptide is very important for the success of the selection. In order 
to make sure that almost all of the selected high affinity clones were rescued, an 
additional step was introduced to the first and second panning rounds, namely, in 
situ infection of bacteria directly on the beads.
In situ infection was initially described by Wind et al. in 1997 and was previously 
used in finding receptors for orphan ligands (Wojnar et al., 2001) and in the 
generation of antibodies (Krebs et al., 2001), as an attempt not to jeopardize high 
affinity binders.
Briefly, an aliquot of the bacterial culture at mid-log growth phase was infected 
with the phages that presumably still resided on the beads after the standard 
elution had taken place. As the phages are bound to the target by the peptide as 
fusion to capsid, the tail proteins are free to attach bacterial receptors, rendering 
them capable to infect further. After allowing a minimum 15 min for infection, 
supernatants from the beads were transferred to culture that had been infected 
previously with eluates and was propagated with good aeration and vigorous 
shaking.
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4.3.2.2 CSF IgG can be displayed as IgG-constant domain (Fc) fusion using 
BioMag beads
Another important factor is the efficiency of the beads used as the matrix to 
preserve the captured CSF-IgG throughout the incubation and washing steps. As 
an alternative to Dynal beads M-280, BioMag beads (Qiagen, Polysciences) were 
tested. BioMag beads are available covalently coated with anti-human IgG Fc 
antibodies. Different binding and washing conditions, and the ability of BioMag 
beads to keep IgG bound to the surface, were tested.
Fluorescence-labeled human IgG whole molecules (hlgG-FITC), captured on 
BioMag-Fc specific beads, were measured by Fluorescence Activated Cell Sorting 
(FACS) analysis. Counting FITC labeled-immunoglobulin molecules within the 
supernatants, collected after binding and washing steps, helped evaluation of 
unbound or released IgG particles. By the same principle, IgG in supernatants was 
quantified by ELISA.
Both results yielded a satisfactory percentage of binding at 4°C after 6hrs of 
incubation (500pil beads capturing up to 10pig IgG). Only negligible amounts of 
bound IgG were detached at adjusted washing stringency.
In this respect, BioMag beads were used to reproduce results from a panning 
performed with Dynal beads. Eventually, preparation of the BioMag beads was 
much faster compared to the Dynal beads that required 24hrs incubation for 
covalent binding of anti-human IgGs before coating with CSF-IgG. Additionally, 
BioMag beads were more economical when excess antibody, used to ascertain 
adequate coating of the Dynal beads, was taken into account. Panning performed 
by both types of beads resulted in a similar enrichment quality and yielded a
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number of common hits, implicating a comparable efficiency. As a result, BioMag- 
human IgG Fc specific beads were preferred for immobilization.
4.3.3 Feasibility of consumption of a CSF sample in multiple proteomics 
applications
A parallel objective during empirical optimizations was to investigate the likelihood 
of a better usage of CSF allowing several proteomics projects to share CSF 
samples.
The standard proteomics biomarker platform involves the depletion of the six most 
abundant proteins, including IgG, from CSF samples by an immunoaffinity 
separation system. If successful, this manipulation allows sharing of the same 
CSF sample in multiple proteomics approaches. In order to ascertain that 
immunoglobulins were not lost, and the binding affinity to their respective brain 
antigens not compromised, test antibodies mixed with CSF were initially 
processed by immunoseparation and then used as targets for the panning.
For this purpose, separation (depletion of abundant proteins from crude CSF) was 
performed by an immu noaffinity chromatography called Multiple Affinity Removal 
System (MARS) (Agilent Technologies, USA) (Figure 4.6).
The feasibility of this approach was questioned to see whether this manipulation 
would alter sample quantity and/or quality for panning.
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Multiple Affinity Removal System 
(MARS)
Crude Human
CSF
Low-Abundant Proteins
Y Y \ S
IgG fraction
Qualitative
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Figure 4.6 Principle of MARS immunoaffinity spin column. A. High abundant proteins are 
depleted from sera or CSF by immunoaffinity polyclonal antibodies. B. Crude CSF corresponding 
to a maximum of 3 mg of total serum protein may be processed by spin cartridge without clogging. 
Flow through is mainly composed of low abundant proteins. Eluate is a collection of albumin, IgG 
and IgA, transferrin, haptaglobin and antitrypsin that dissociate from the matrix after treatment with 
a buffer at pH 2.3 with 2M Urea. Illustration A was prepared by E. Sayan-Ayata, illustration B was 
modified from the manual of the MARS spin cartridge.
77
4.3.3.1 CSF IgG fraction isolated by MARS immu no-affinity spin column can 
be successfully applied as target in panning
A low pH buffer with 2M urea was used for elution of abundant proteins that were 
affinity-captured by the MARS spin cartridge system. Thus, the integrity of Igs after 
the elution step needed to be tested. First, a given amount of a known antibody 
was added to the CSF sample which had passed through the Vivaspin 
concentration/buffer exchange step and been processed by the MARS spin 
cartridge. Next, a standard biopanning experiment was performed to see if it was 
possible to capture MARS processed IgG molecules as targets. For this purpose, 
the hydrocephalus CSF sample was processed with the MARS spin cartridge. 
Control Ab was added (a-synuclein mAb, clone 211, Sigma Aldrich) in varying 
concentrations of buffer B, followed by Vivaspin buffer exchange to PBS. Later, 
the target was immobilized on Protein G beads and panned using the 50% 
a-synuclein enriched sub-library (own preparation). Table 4.2 shows experimental 
setup. After panning, the titer of the eluate was measured to investigate the 
binding affinity. Additionally, plaque lift assay was performed (Figure 4.7) and 
enrichment was measured (Table 4.3). Results showed that if the CSF sample 
was immediately neutralized after MARS separation, IgG was recovered and 
detection of the anti-synuclein antibody within the CSF IgG pool could be 
reproduced.
Table 4.2 Experimental setup for panning of MARS spin column processed samples
CSF BUFFER B PBS SYN 211 antibody
a-SYN pos/neg 
library
1 - - + 1250ng +
2 - + - 1250ng +
3 - - + - +
4 + - +
5 + < ' '' ^ ...........l i p  u p  § i  i P ' +■ - 50ng +
6 + 250ng +
7 +
- -
ti
l ■ + 1250ng +
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Figure 4.7 Results of test panning after MARS spin column. Anti-synuclein mAb is used as a 
target for panning with the T7 normal brain PD library. 1250ng a-synuclein preparation panned 
without buffer exchange (sample#2 ) had partially lost its ability for biopanning detection, although 
the same amount of antibody mixed with PBS reached 50% enrichment. Samples panned after 
buffer exchange to PBS (sample#1, #5, #6 , #7) recovered a gradual panning efficiency, as 
observed by the enrichment according to the synuclein input amount.
Table 4.3 Titer assay after the last panning of MARS spin cartridge processed samples
Controls Titer (pfu/ml) Total
Positive
clones
Enrichment
Input 2 1
Output #1 4 x 103 507 240 Saturation (-1 )
Output #2 2 x 103 444 50 0.2
Output #3 < 102 150 20 Background (13%)
Output #4 < 102 590 30 Background (5 %)
Output #5 2 x 104 578 110 0.4
Output #6 2.5 x 104 1100 630 Enhancement (1.2)
Output #7 3 x 104 1000 530 Saturation (-1 )
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4.3.3.2 Test IgG sample was at least partially deteriorated in terms of quality 
and quantity after MARS-HPLC fractionation of CSF For analytical 
grade experiments, high performance liquid chromatography (HPLC) separation is 
feasible. Hence, the MARS HPLC column was compared to the MARS spin 
cartridge system regarding applicability.
During MARS-HPLC separation, exposure to the relatively harsh elution buffer 
(low pH with 2M urea) is much longer than in the case of the spin cartridge 
system. As a result, it was uncertain whether IgGs were irreversibly affected. In 
order to minimize degeneration of IgG, the MARS HPLC protocol was modified so 
that all the steps (flow-through, elution and equilibration) were held at 4°C, plus, 
the sample was immediately manually collected into a neutralizing buffer, just 
before elution started, and until equilibration peaks were observed.
As a target, anti-synuclein antibody was processed with Vivaspin followed by 
MARS-HPLC, and subsequently quantified with ELISA before panning. Table 4.4 
shows experimental setup.
Unfortunately, a clear decline in the amount or functionality of IgG was obvious 
when results were compared to data from the spin cartridge application (Figure 
4.8A).
Furthermore, a mAb (anti p-actin) was tested on A431 cell lysates with western 
blot to check the quality of the antibody after MARS-HPLC processing. Anti p-actin 
lost its avidity almost completely, as seen in western blot (Figure 4.8B).
Eventually, despite all the efforts described above, the IgG fraction seemed to be 
affected quantitatively and qualitatively after HPLC processing.
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Table 4.4 Experimental setup for panning of MARS HPLC processed samples
CSF BUFFER B PBS SYN 211 antibody
a-SYN
pos/neg
library
1 - - + 1000ng +
2 - + - 1000ng +
3 - - + - +
4 + •f + - +
5 + + + 50ng +
6 + + + 100ng +
7 + + + 250ng +
A
B
42 kDa —►
Anti /5-actin Anti /3-actin antibody,
antibody, processed with
unprocessed MARS HPLC.
Figure 4.8 Results of test panning after MARS HPLC. Synuclein monoclonal antibody is used as 
a target. 1 pg a-Synuclein preparation panned without buffer exchange (sample#2) had lost its 
ability for biopanning detection, although the same amount of antibody mixed with PBS was 
detectable (sample#1). However, it was still not possible to detect the samples after buffer 
exchange to PBS (sample #5, #6 , #7) (A). Anti p-actin antibody was processed by MARS spin 
cartridge and used as primary antibody in western blot on A431 cell lysates. Positive signal at 42- 
kDa molecular weight was observed when original p-actin antibody was used at a dilution of 
1:1000. There was no signal with MARS-HPLC processed anti-p actin antibody used at 1:1000 
dilution after 15 min of overexposure (B). However, a very weak signal could be obtained when the 
film was left for overnight exposure (not shown).
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4.4 Strategies for filtering false positives
A constant drawback of PD is the accumulation of false positive clones over 
succeeding selection rounds. This is common to all PD systems, independent of 
the type of phage (filamentous, lambda or T7) and type of library (peptide, cDNA, 
IgG-Fc) (Kramer et al., 2003). They are not easy to distinguish and eliminate. 
Background clones and false positives may result from selection conditions, 
molecules involved in the selection, inefficient blocking or due to affinity for the 
solid support. Even at the most optimized stringency, sticky clones may get 
enriched up round after round to a level where they can completely mask specific 
clones of interaction.
The most common way to evaluate the selection is via monitoring the enrichment. 
There are two types of enrichments: the background enrichment and the marker 
enrichment. In order to monitor the marker enrichment, phage vector (phagemid) 
has to encode a selective marker like a reporter (p-galactosidase) or a drug 
resistance. For instance, eluted phages can be plated on an IPTG/Xgal plate and 
the blue/white ratio will give the specific interaction versus binding to non-coated / 
affinity matrix. Employing a negative control (empty phage) can help monitor the 
titers of the background to help compare the enrichment of the affinity selection 
(Russel, Lowman, Clackson, 2004).
One strategy, applied in this study, was to reduce the background by pre­
clarification of the cDNA phage library used in the panning. More specifically, 
normal brain cDNA library was incubated with excess BioMag anti-human IgG-Fc 
beads, so that the phages that would have affinity to the matrix (BioMag beads)
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were isolated. The recovered library was theoretically free of the BioMag reactive 
clones, thus adding straightforwardness to the protocol.
Another control, introduced in this project, was monitoring the marker enrichment 
by an alternative panning using serum in parallel to CSF. While IgG from patient 
CSF was under selection against the cDNA brain library, total human serum 
diluted to five ng/ml was immobilized on BioMag-anti human IgG-Fc beads and 
selected by a non-recombinant phage lysate (negative lysate). The enrichment 
monitored in this manner revealed an estimation of titer of the phages that would 
stick to a rich variety of IgG molecules provided by the serum. In other words, this 
type of control mimics the action of sticky clones, namely binding devoid of any 
affinity to the target, which in this case is the negative phage without fusion protein 
or peptide to display.
Enrichment factors in the range of two to ten fold, correspond to a minimum of 50 
to 90 percent of all clones with a target specificity compared to the potential false 
positive. A minimum factor of two-fold enrichment was held as threshold 
considering the strategy applied and the level of stringency. It is suggested to 
sequence a minimum of 10 clones when ten-fold enrichment is observed (Dennis 
and Lowman, 2004). Accordingly 24 to 32 clones were analyzed in this study from 
the eluates of the last panning round.
4.5 Pilot CSF panning experiment
One further strategy applied in cDNA PD was to run a pilot selection to observe 
the nature of selection, maintained by the optimizations and adjusted level of 
stringency. The protocol of selection was tested using 4 CSF samples (2 unipolar 
depression, 2 NPH controls). As a secondary goal this pilot test would help
familiarization with sticky clones and clarify the baseline for the background 
coming from non-recombinant phages, and the phages that have affinity to matrix. 
Although prior to panning, the library was pre-cleared from bead reactive clones, 
there were some sticky clones resisting in both disease samples and the negative 
control. 9 clones were obtained from screenings of depressive patients, with no 
common clone in both patients. Both depression and NPH clones had 2 clones in 
common that were classified as CSF background which are independent of the 
disease (clones are listed in Chapter 5; Results).
4.6 Further fine-tuning: Compromising the number of selection rounds 
helps sustain weakly expressed peptides from being overrun by false 
positives
Despite all efforts to monitor and clean the sticky clones, there were always 
several false positives within the selected clones. This is partially due to two major 
factors: Initially, some clones might simply be underrepresented in the original 
library and high abundant competitors may outnumber some specific binders. 
Secondly, the phages have distinct capabilities to get propagated in the host when 
they are modified with different capsid fusion proteins. It is reasonable to assume 
that some clones might be more easily expressed while others might be toxic or 
deleterious to proper functioning of the phage. In summary, the phages with 
selective advantages but no specificity against the target may even out with real 
binders, and they would be carried away through the selection process. 
Considering the uncontrollable selective bias favoring such false positives over 
true hits, the most crucial criteria after the quality of the original library is the 
number of selection rounds of panning. Passing beyond the optimal number of 
rounds (over-selection) may yield a smaller number of true hits at the expense of
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many clones getting lost, introducing false positives that have escaped the natural 
selective pressure of binding affinity and were more successful in propagating. 
Such contaminating clones actually have no affinity to the target, and they may 
display totally unexpected properties (Russel M et al., 2004).
Strategically, three rounds of selection were used. The pilot experiments 
performed with CSF verified a reasonable enrichment after panning rounds three 
to four. To end the selection after three rounds would yield a heterogeneous 
mixture of clones; namely, true hits mixed with some background, and sticky
! clones that survived the stringent selection filter as false positives. Nevertheless,
the aim of this modification was to observe the tendency of the selection pattern at 
the window of selection after round three, so that the true hits would not be lost 
even if they had a selective disadvantage compared to others.
After listing all the clones, a rigorous selection criteria was set by choosing the 
clones that repeatedly existed in the patient group and never in the control group 
list. Another criterion was finding different clones with overlapping or non­
overlapping epitopes of the same hit, which was the case for a small number of 
hits.i
i
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4.7 Conclusion:
The efficiency of the cDNA PD using T7 select system and the overall feasibility of 
this strategy in finding autoantigens from CSF were addressed by a series of 
experiments. Several literature-based examples and this work demonstrated that 
the T7 cDNA PD is efficient and practical in finding autoantigens from 
heterogeneous human material. A special focus on CSF as a human sample, with 
low IgG content and limited sample size. Such limitations demanded adaptations 
and modifications to increase the sensitivity of the standard selection protocol. 
Criteria confirmed for autoantigen selection by the T7 system with a special focus 
on limitations of CSF are:
1- Quality of the T7 Select cDNA library from normal brain
2- Sensitivity of the T7 select system
3- Ability of the matrix to maintain CSF-IgG without covalent attachment
4- Modifications on stringency in a balance that preserves the yield
5- Characterization of the background and sticky clones
There are many intrinsic limitations of PD as a technique and CSF as a sample 
which are not completely manageable. These limitations considerably decrease 
the sensitivity of PD while fostering the risk of high false positive rates. To 
overcome some of these factors, several modifications were tested to improve 
protocol and selection criteria. A critical attempt was to fractionate CSF by the 
MARS immunoaffinity separation which comprises both pros and cons. On one 
hand, the advantage of utilizing this precious human material in multiple 
applications is evident but, on the other hand, there is no way to avoid partial loss 
of CSF content and integrity. The evaluation of quantitative and qualitative
differences of MARS treated and non-treated samples was compulsory for
understanding the feasibility of this approach. Normal pressure hydrocephalus
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(NPH) CSF samples were used in testing MARS depletion. After Vivaspin 
concentration, buffer exchange and MARS spin cartridge application, the protein 
amount was re-evaluated by BCA assay. The results showed a cumulative protein 
loss (Vivaspin plus MARS spin cartridge) around 15-20% compared to non­
depleted CSF aliquot. Although spin cartridge separation was successful, 
analytical grade preparation by MARS HPLC was dissatisfactory with plaque lift 
assay results showing altered avidity. The alterations observed do not need to be 
universal for all IgG molecules in a CSF sample. But, for screening unknown 
autoantigen targets, such an alteration would introduce artifacts during sample 
preparation and greatly risk significance of the results.
Eventually, taking all the risks into account, the overall decision was to use whole 
CSF (crude sample) for selection. Even so, the MARS separation trials helped 
recognize that the MARS spin cartridge is suitable when CSF is strictly limited and 
has to be shared within several projects, provided that the results will not be 
affected by this intervention.
In summary, major contributions of the novel strategy applied in this study are:
1- Targeting optimal usage of CSF in several proteomics platforms (MARS)
2- In situ infection applied to autoantigen selection
3- Novel filtering systems for differentiating false positives from true hits, by
a- avoiding accumulation of false positives with an approach to 
undermine the loss of true hits by fixing the panning to three rounds 
of selection for all samples, and 
b- setting a threshold of confidence for differentiating false positives 
from true hits, in terms of enrichment factors that compare a real 
selection in CSF to a control selection in serum mimicking 
generation of false positives.
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Chapter 5
Results
5.1 Introduction
In order to identify disease-specific autoantigen candidates for affective disorders 
and SZ, 5 BPD and 6 SZ CSF samples were analyzed, as well as 2 major 
depression samples that were used in the primary pilot tests. In total, 21 samples 
from the non-AFD disease group were used as controls composed of multiple 
sclerosis, epilepsy, normal pressure hydrocephalus and others such as headache, 
somatoform disorder, cervical rhizopathy and shoulder-arm pain.
PD selection was optimized and tested for detection down to nanomolar range of 
autoantigen in CSF. As the limiting factor was CSF, repetition of panning and 
validation experiments, were dependent on the CSF volume available. 
Strategically 3 rounds of panning were always performed, which yielded a “snap 
shot” identification of the best fitting clones. Each selected clone from a given 
disease group was controlled in terms of absence of disease controls and sticky 
clones. The repetitive clones were evaluated for disease-specificity or sharing of 
common pathways. The best candidate clone was studied further with quantitative 
PCR and standard ELISA using recombinant autoantigen.
5.2 Enrichment of binding clones specific to CSF IgG
5 \ig IgG from AFD/SZ and disease control CSF samples were immobilized on 
BioMag magnetic beads with an affinity to the Fc region of the human IgG 
molecule. The brain library displayed on T7 phage with 1.7x106 pfu at 100-copy 
number was incubated with beads coupled to CSF IgG. Washing and elution 
conditions were tuned to the stringency level that had been tested and optimized, 
as given in the chapter on optimization. The concept based on the first panning 
round favoring yield over specificity, gradually shifted to utmost specificity in the 
following rounds. Titer assay was conducted after every panning round to monitor 
both the success of specific selection and, at the same time, the number of viable 
phage particles.
The enrichment over empty beads is the background enrichment and the 
enrichment over non-displaying phage is the marker enrichment. In this study, 
both types of enrichment were controlled at two levels. Firstly, the phage library 
was incubated with the BioMag-anti human IgG to wash out the clones that bind 
non-specifically to the matrix. After this step there was no further need for the 
assessment of the background enrichment as it was eliminated by the nature of 
the selection. Secondly, a separate set of BioMag-anti human IgG beads was 
coupled to human total serum, followed by incubation with non-displaying 
(negative) phage lysate. By conducting a titer assay, this strategy helps monitor 
the number of negative phages that stick to serum IgG non-specifically, but with a 
degree of affinity that survives the stringency of washing. Besides, serum is a 
more complex source than CSF with a huge variability of IgG subtypes, thereby 
contributing further to the likelihood of interactions yielding false positive results.
Due to the fact that a positive selection marker for autoantigen selection was not
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feasible, measuring the titer of false positive binding made it possible to set a 
threshold of confidence.
A factor of two-fold enrichment with respect to false positive selection marker was 
used as threshold of confidence. It also helped determine the number of clones to 
be analyzed, on the basis of the assumption that approximately one third of the 
final clones selected are specific to the target. Enrichment factor of an example 
selection is given below (Table 5.1). Figure 5.1 shows the selection efficiencies 
based on threshold of two-fold difference between enrichment factors of true 
selections versus false positive marker selection.
Table 5.1 Evaluation of enrichment with respect to marker for false positives. Counting well- 
separated plaques on an E.coli lawn gives the titer of the phage eluate that is conducted after each 
round of selection. The enrichment factor is calculated by dividing the ratio of titers of the samples 
(first round to last round) to the ratio of titer of the marker for the false positives.
Titer 
round1 
(pfu/ml)
Titer 
round 2 
(pfu/ml)
Titer 
round 3 
(pfu/ml)
Ratio
(pan#1/pan#3)
Enrichment 
factor 
(ratio disease 
sample /
EPI 014 8 x10s 9x10 ' 3 x108 37,5 6,3
SZ 76 5 x10s 8x10 ' 2,3 46 7,7
BP 203 3 x10s 1 x10B 2x10“ 66,7 11,1
EPI 300 1 x10' 9x10 ' 2 x10s 20 3,3
Marker 5 x105 2x10° 3 x10s 6 1,0
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Figure 5.1 Enrichment of selection. A minimum 2-fold difference between the enrichment factors 
between disease and false positive marker was considered an indicator of true selection (bold line: 
threshold). X-axis shows the identity of CSF samples. A. Enrichment chart of epilepsy patients as a 
control group to AFD and SZ disease groups. B. BPD group showing relatively low enrichment 
efficiencies compared to EPI and SZ groups. CSF sample SZ #365 was considered more prone to 
include high numbers of non-specific interactions, as it was below the threshold. C. Enrichment 
factors associated with SZ disease group.
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5.3 Identification of clones
After three rounds of panning, the plaques obtained by plating the eluate were 
picked for purification of DNA. Following a test PCR with primers flanking the 
multiple cloning site of T7Select10-3b vector, amplified insert was digested using 
Mval restriction enzyme for fingerprinting. Both undigested clones, and the clones 
digested in different patterns, were selected for identification. Selected clones 
were amplified with PCR for sequencing, purified with the Qiaquick PCR 
purification system and sent to an external sequencing facility (Sequiserve 
GmbH). After the NCBI Blast search, the identified clones were listed according to 
disease groups and patients individually. Below is the listing of all clones obtained.
Table 5.2 All clones identified from major depression disorder (MDD) group.
Patient Accessionnumber Protein ID
AAC51273 putative protein p150
AAM22955 Rho-GTPase activating protein 10
CM CAI41883 DEAH (Asp-Glu-Ala-His) box polypeptide 16T”CO AAQ91815 estrogen receptor 1
L_J
Q A0MZ66 shootin-1
NP_004732 nucleolar and coiled-body phosphoprotein 1, p130
AB040934 KIAA1501 protein
BC022348 KIAA1598 protein
AAR95501 cytochrome c oxidase subunit I
AAH07647 ADP-ribosylation factor 3
:0-J AA113669 proteasome activator subunit 4
QQ EAW68085 hydroxysteroid (17-beta) dehydrogenase 12
NP_004732 nucleolar and coiled-body phosphoprotein 1 , p130
AAA60350 proteolipid protein, myelin proteolipid protein (PLP or lipophilin)
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Table 5.3 All clones identified from normal pressure hydrocephalus (NPH) control group.
Patient Accessionnumber Protein ID
NP_000691 annexin A1
NP_112420 heterogeneous nuclear ribonucleoproteinAI isoform b
CM
x AAC51273 putative protein p1500.z NP_004759 splicing factor, arginine/serine-rich 11
CAE55174 v-myb myeloblastosis viral oncogene homologue
BAC87650 unnamed protein product
AAH07501 protein-L-isoaspartate (D-aspartate) 0- 
ethyltransferase , PCMT1
CO AAM71140 neuregulin 1 isoform GGF2
XQ_ AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
XP_531360 hypothetical protein XP_531360 [Pan troglodytes]
BAC85305 unnamed protein product
Table 5.4 All clones identified from epilepsy (EPI) control group.
Patient Accessionnumber Protein ID
oo
ABQ09374 haplotype H7 mitochondrion NADH dehydrogenase subunit 1
AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
(L
ID NP_003624 ectodermal-neural cortex (with BTB-like domain)(ENC1)
IT) 
ID iO
NP_536341
septin 4 (SEPT4), transcript variant 3/hucep-7 mRNA 
for cerebral protein-7/cell division control-related 
protein 2b (hcdcrel2b)
O AAH93730 podocalyxin (PODXL)
E § NP_001001433 syntaxin 16 (STX16), transcript variant 1
ID g  
CO AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
NP_073568 nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1)
©
|s.
NP_061054 calcium/calmodulin-dependent protein kinase II inhibitor 1 (CAMK2N1)
AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
LD NP_006279 Thy-1 cell surface antigen (THY1)
NP_001486 GDNF family receptor alpha 2 (GFRA2)
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AAI30448 protocadherin alpha 10
NP_057371 heterochromatin protein 1, binding protein 3 (HP1BP3)
CM NP_003783 endothelial differentiation-related factor 1 (EDF1)O
<3CMCO XP_001134430
protein immuno-reactive with anti-PTH polyclonal 
antibodies
El
lu
AAH15491 small EDRK-rich factor 2 (SERF2)
AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
NP_002859 RAB5B, member RAS oncogene family
NP_703157 heparan sulfate 6-O-sulfotransferase 3 (HS6ST3)
NP_570824 synaptosomal-associated protein, 25kDa (SNAP25)
NP_036269 dimethylarginine dimethylaminohydrolase 1 (DDAH1)
NP_055180 heat shock 22kDa protein 8 (HSPB8)
NP_647539
tyrosine 3-monooxygenase/tryptophan 5- 
monooxygenase activation protein, beta polypeptide 
(YWHAB)
NP_036347 meningioma expressed antigen 5 (hyaluronidase) (MGEA5)
©
o> AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1COCO AAP72185 migration-inducing protein 3
0 .
LU AAH 15491 small EDRK-rich factor 2 (SERF2)
NP_114399 microtubule-associated protein 1B (MAP1B)
ABQ09374 haplotype H7 mitochondrion NADH dehydrogenase subunit 1
NP_477512 olfactomedin 2 (OLFM2)
AAL37898 brain-specific GTP-binding protein
AAH73834 CGI-96 protein
NP_056049 G protein-coupled receptor 116
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Table 5.5 All clones identified from schizophrenia (SZ) group.
Patient Accessionnumber Protein ID
AAF27330 mitochondrial RNA-processing endoribonuclease RNA (RMRP) talin (TLN)
AAH36243 interleukin 17D (IL17D)
NP_001029197 endoplasmic reticulum protein 29 (ERP29)
AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
NP_536341
septin 4 (SEPT4), transcript variant 3/hucep-7 mRNA 
for cerebral protein-7/cell division control-related 
protein 2b (hcdcrel2b)
NP_003635 growth arrest-specific 7 (GAS7)
NP_001070958 GNAS complex locus (GNAS)
NP_207837 contactin associated protein-like 4 (CNTNAP4)
i"-o> AAI06032 ribosomal protein L17
toh-o AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
Nto NP_071746 EF-hand calcium binding protein 1 (EFCBP1)
BAD92272 myosin head domain containing 1 variant protein.
AAI32828 coiled-coil domain containing 66
NP_001393 eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)
AAH 17445 erythrocyte membrane protein band 4.9 (dematin)
AAH 15491 small EDRK-rich factor 2, (SERF2)
AAH01811 RRS1 ribosome biogenesis regulator homolog
BAD96295 TATA binding protein interacting protein 49 kDa variant/erythrocyte cytosolic protein of 54 kDa
AAM28436 Tho2
AAN01237 selectin E (endothelial adhesion molecule 1) (SELE)
AAF27330 mitochondrial RNA-processing endoribonuclease RNA(RMRP) talin (TLN)
NP_736606 proteasome (prosome, macropain) 26S subunit, non- ATPase, 10(PSMD10)o© NP_001032411 ubiquitin specific peptidase 14 (tRNA-guanine transglycosylase) (USP14)
N(0
AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
AAV97814 B-cell translocation gene 1, anti-proliferative (BTG1)
AAH 15491 small EDRK-rich factor 2 (SERF2)
CAI41507 interleukin 3 receptor, alpha (low affinity) (IL3RA)
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Patient Accessionnumber Protein ID
NP_001958 eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2)
NP_003077 MAP7 domain containing 2/small nuclear RNA activating complex, polypeptide 4, 190kDa (SNAPC4)
AAH08749 myelin basic protein (MBP)
NP_001020272 myelin basic protein (MBP)
NP_002036 growth associated protein 43 (GAP43)
AAH01883 nucleolar and coiled-body phosphoprotein 1 N0LC1
00O AAH04357 zinc finger protein 410
o><0CO NP_001607 activin A receptor, type IIA (ACVR2A)
N(0 AAH 15491 small EDRK-rich factor 2 (SERF2)
AAF59903 Intersectin 2
NP_079508 receptor accessory protein 4 (REEP4)
AAC25978 ES/130-related protein
AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
NP_003635 growth arrest-specific 7 (GAS7)
NP_003169 synapsin II (SYN2)
AAH32398 ATPase, H+ transporting, lysosomal VO subunit a1
NP_061054 calcium/calmodulin-dependent protein kinase II inhibitor 1 (CAMK2N1)
NP_004619 xeroderma pigmentosum, complementation group C (XPC)
NP_004310 astrotactin 1 (ASTN1)
CMo
AAI28578
AAC25978
ribosome binding protein 1 homolog 180kDa/ES/130- 
related protein
Tt(0 AAH15491 small EDRK-rich factor 2 (SERF2)
N(/> AA013489 peroxisome proliferative activated receptor, alpha (PPARA)
AAD30425 SH3 domain-binding protein SNP70
NP_005648 tumor protein p53 binding protein, 1 (TP53BP1)
AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
NP_207837 contactin associated protein-like 4 (CNTNAP4)
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Patient Accessionnumber Protein ID
AAI06032 ribosomal protein L17
NP_057017 coiled-coil domain containing 72 (CCDC72),
CM© AAH 15491 small EDRK-rich factor 2 (SERF2)
CO
COT" AAB69001 T-cell receptor alpha/delta
N
CO AAH01883 nucleolar and coiled-body phosphoprotein 1 N0LC1
NP_207837 contactin associated protein-like 4 (CNTNAP4)
NP_036419 centaurin, beta 2 (CENTB2)
NP_002678 pinin, desmosome associated protein (PNN)
o AAH 15491 small EDRK-rich factor 2
CM AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
N
CO AAH65700 Shwachman-Bodian-Diamond syndrome
NP_055969 mesoderm development candidate 2 (MESDC2)
Table 5.6 All clones identified from bipolar disorder (BPD) group.
Patient Accessionnumber Protein ID
NP_006470 RAD51 associated protein 1 (RAD51AP1)
NP_690608 regucalcin (senescence marker protein-30) (RGN)
AAB69001 T-cell receptor alpha/delta
m©
COo
CM
NP_002678 pinin, desmosome associated protein (PNN)
AAH 16660 heat shock 70kDa protein 8 (HSPA8)
Q
Q_ AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
00 NP_207837 contactin associated protein-like 4 (CNTNAP4)
AAH01315 small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen)
NP_000365 uroporphyrinogen decarboxylase (UROD)
AAH 15491 small EDRK-rich factor 2 (SERF2)
CM
© AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
o
Q
ABQ09374 haplotype H7 mitochondrion NADH dehydrogenase subunit 1
Q-
00 AAH15177 ubiquinol-cytochrome c reductase hinge protein
NP_477512 olfactomedin 2 (OLFM2)
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Patient Accessionnumber Protein ID
NP_116274 ATG4 autophagy related 4 homologue D (ATG4D)
NP_004136 myosin IXB (MY09B)
AAH80654 myelin basic protein
AAH21994 cytochrome c, somatic
00O)
©CO
NP 002679 
AAA20398
septin 5 (SEPT5) / glycoprotein lb beta / cell division 
control related protein (hCDCrel-1)
ABQ45201 haplotype W1 mitochondrion
O AAH15491 small EDRK-rich factor 2 (SERF2)
0.
CO NP_001633 amyloid beta (A4) precursor-like protein 2 (APLP2)
NP 00102517 
6 AAH 12889
complexin 3 (CPLX3) / amyloid beta (A4) precursor­
like protein 1
AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
AAH 10352 
ABA60896
tyrosine 3-monooxygenase/tryptophan 5- 
monooxygenaseactivation protein beta polypeptide
CAA32502 manganese superoxide dismutase (from SOD-2 gene)
NP_057371 heterochromatin protein 1, binding protein 3 (HP1BP3)
AAW65373 matrix metalloproteinase 11 (stromelysin 3) (MMP11)
©
in AAH75862 calpain 1, (mu/l) large subunitCOCO
Q
NP_009151 carbonic anhydrase VB, mitochondrial (CA5B), nuclear gene encoding mitochondrial protein
Q_
CQ CAI41507 interleukin 3 receptor, alpha (low affinity) (IL3RA)
AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
NP_003635 growth arrest-specific 7 (GAS7), transcript variant a
BAE78598 HLA-A gene for major histocompatibility complex, class I, A
AAH07647 ADP-ribosylation factor 3
NP_004168 syntaxin 3 (STX3)
NP_002678 pinin, desmosome associated protein (PNN)
10o AAT38112 RAD51-like 3 (RAD51L3)
CO AAH 15491 small EDRK-rich factor 2
a AAH01883 nucleolar and coiled-body phosphoprotein 1 NOLC1
lL
00 ABC40742 NADPH oxidase 1 (NOX1)
NP 940852 
AAB69018
apolipoprotein O-like (APOOL) / 
T-cell receptor alpha/delta
AAF25871
AAC97946
AAB52589
lens epithelium-derived growth factor p52 / 
transcriptional coactivator p75 / autoantigen DFS70
Table 5.7 All clones identified from multiple sclerosis (MS) group.
Patient Accessionnumber Protein ID
NP_009028 clathrin, light chain (CLTB)
NP_003635 growth arrest-specific 7 (GAS7)
AAH80654 myelin basic protein (MBP)
AAH70049 LanC lantibiotic synthetase component C-like 2
BAD92428 kinesin heavy chain isoform 5C variant
to
S AAH 15491 small EDRK-rich factor 2 (SERF2)
ABQ09374 haplotype H7 mitochondrion-NADH dehydrogenase subunit
AAH 15491 small EDRK-rich factor 2 (SERF2)
AAI26226 SCC-112 protein
AAH45759 MAP1LC3B protein
NP_0010701 neural cell adhesion molecule 1 (NCAM1)
NP_207837 contactin associated protein-like 4 (CNTNAP4)
NP_003635 growth arrest-specific 7 (GAS7)
CMCO
s
AAR85357 RNA-binding protein N0B1
ABQ09374 haplotype H7 mitochondrion-NADH dehydrogenase subunit
NP_733752 MAX-like protein X (MLX), transcript variant 3
NP_004519 microsomal glutathione S-transferase 3 (MGST3)
AAH 18823 splicing factor, arginine/serine-rich 5
AAD48774 3'-5' exonuclease TREX1
NP_963293 NDRG family member 2 (NDRG2)
NP_872620 G patch domain containing 4 (GPATCH4)
NP_004732 nucleolar and coiled-body phosphoprotein 1 (N0LC1)
CO(05
NP_073568 nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1)
NP_477512 olfactomedin 2 (0LFM2)
NP_057341 hippocalcin like 4 (HPCAL4)
AAI08307 ring finger protein 130
BAA82978 KIAA1026 protein
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Patient Accessionnumber Protein ID
NP_004990 myosin VI (MY06)
NP_036611 tyrosine 3-monooxygenase/tryptophan 5- monooxygenase activation protein, gamma
AAP69527 RRS1 ribosome biogenesis regulator homolog/pyruvate kinase RBC (PKLR)
NP_055180 heat shock 22kDa protein 8 (HSPB8) alpha-crystallin- type heat shock proteins
CO AAH15491 small EDRK-rich factor 2
BAD92869 PI-3-kinase-related kinase SMG-1 isoform 1 homolog protein
AAF36133 HSPC213
NP_002678 pinin, desmosome associated protein (PNN)
BAD92869 PI-3-kinase-related kinase SMG-1 isoform 1 homolog protein
NP_071746 EF-hand calcium binding protein 1 (EFCBP1)
NP_000054 complement component 2 (C2)
NP_064619 DTW domain containing 1 (DTWD1
CAA49533 mitochondrial ATP synthase c subunit (P2 form)
LOCOs
NP_006708 spindlin 1 (SPIN1)
NP_002678 pinin, desmosome associated protein (PNN)
NP_114381 eukaryotic translation initiation factor 4H (EIF4H)
NP_057672 neuritin 1 (NRN1)
CAA77750 human elongation factor 2
AAA84914 pigment epithelium-derived factor
AAH47646 zinc finger protein 85 (ZNF85)
NP_002374 MYC-associated zinc finger protein transcription factor (MAZ)
AAI06081 high-mobility group nucleosome binding domain 1
CO ABF14463 neighbour of BRCA1 gene 2CO NP_002678 pinin, desmosome associated protein (PNN)
NP_000977 ribosomal protein L24 (RPL24)
AAF43103 vanilloid receptor gene, partial sequence; CARKL and CTNS genes
AA112200 V-erb-a erythroblastic leukemia viral oncogene homologue 4 (avian) (ERBB4)
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Patient Accessionnumber Protein ID
AAH05916 pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1
AAH14512 stromal membrane-associated protein 1-like
AAH 15491 small EDRK-rich factor 2 (SERF2)
AAH01883 nucleolar and coiled-body phosphoprotein 1
EAW63602 neurofilament 3 (150kDa medium)
NP_477512 olfactomedin 2 (OLFM2)
h»CO NP_0010118 BTB (POZ) domain containing 1 (BTBD1)
NP_056335 membrane associated guanylate kinase, WW and PDZ domain containing 1 (MAGI1)
NP_002086 general transcription factor ME, polypeptide 2, beta 34kDa (GTF2E2)
NP_060914 protein phosphatase 2C, magnesium-dependent, catalytic subunit (PPM2C), nuclear gene encoding
AAI39926 thymosin, beta 4, X-linked
NP_002061 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 (GNAI2)
NP_0010117 GTP-binding protein 9 (putative) (GTPBP9)
NP_003635 growth arrest-specific 7 (GAS7)
00CO NP_000875
IMP (inosine monophosphate) dehydrogenase 2 
(IMPDH2)
NP_073568 nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1)
NP_004719 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 (DDX21)
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Table 5.8 All clones identified from non*infectious disease control group.
Patient Accessionnumber Protein ID
He
ad
ac
he
 
(O
N
D
)
NP_000025 aldolase A, fructose-bisphosphate (ALDOA)
CAC42117 NOD2 gene for LRR-containing protein, exons 1-11.
NP_004719 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 (DDX21),
BAC06146 chromosome 19 clone CTD-3064H 18/seven transmembrane helix receptor
NP_065790 cell cycle progression 1 (CCPG1)
NP 207837 contactin associated protein-like 4 (CNTNAP4)
AAH15491 small EDRK-rich factor 2 (SERF2)
NP_065778 zinc finger protein 295 (ZNF295)
BAD92869 PI-3-kinase-related kinase SMG-1 isoform 1 homologue protein
AAA84914 pigment epithelium-derived factor
NP_003608 regulator of G-protein signaling 5 (RGS5)
AAH08850 ribosomal protein L7
so
m
at
of
or
m
 
di
so
rd
er
 
(O
N
D
)
AAT45456 interleukin 12 receptor, beta 2 (IL12RB2)
AAH00373 amyloid beta (A4) precursor-like protein 2
ABQ09374 haplotype H7 mitochondrion-NADH dehydrogenase subunit
NP 002678 pinin, desmosome associated protein (PNN)
AAH 15491 small EDRK-rich factor 2
NP_892116 eukaryotic translation initiation factor 5 (EIF5) transcript variant2
AAH99907 general transcription factor II
NP_071746 EF-hand calcium binding protein 1 (EFCBP1)
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Patient Accessionnumber Protein ID
NP_057589 zinc.finger, CCHC domain containing 17 (ZCCHC17)/HSPC243
NP_002678 pinin, desmosome associated protein (PNN)
NP_064541 core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 (C1GALT1)
NP_612370 leucine rich repeat and sterile alpha motif containing 1 (LRSAM1)
Q
z NP_715624
potassium voltage-gated channel, Shaw-related 
subfamily, member 2 (KCNC2)y
NP_006097 Yes-associated protein 1, 65kDa (YAP1)
JC4->(0Q.ON
!Ek.
NP_004719 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21(DDX21)
AAC50968 KIT protein and alternatively spliced KIT protein (KIT)
AAH95420 splicing factor, arginine/serine-rich 5
wo
EVo
NP_003606 solute carrier family 4, sodium bicarbonate cotransporter, member 7 (SLC4A7)
AB178944 SEC16L (SEC16L)
NP_056982 zinc finger and BTB domain containing 7A (ZBTB7A)
ABQ09374 haplotype H7 mitochondrion-NADH dehydrogenase subunit
ABK41936 CD40 ligand (TNF superfamily, member 5, hyper-IBM syndrome) (CD40LG)
ABQ45202 haplotype W1 mitochondrion NADH dehydrogenase subunit 2
E ABK41936
CD40 ligand (TNF superfamily, member 5, hyper-IBM 
syndrome) (CD40LG)
(0
« . E S■n (0 z
ABQ45202 haplotype W1 mitochondrion NADH dehydrogenase subunit 2
Io£ NP_001767
ectonucleoside triphosphate diphosphohydrolase 1 
(ENTPD1)
(/)
AAH 15491 small EDRK-rich factor 2 (SERF2)
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5.4 Selected clones
5.4.1 Repetitive clones
The overall distribution of identified clones among different disease groups 
primarily yielded a group of clones that were repetitively selected with hit 
frequency > 2.
Secondly, there were clones from a family of proteins that were exclusively 
selected from disease groups, although each clone was not repetitive when taken 
alone. For instance, clones the products of which belong to heat shock, ribosomal, 
myosin, cytochrome c and zinc finger family proteins compromise a large portion 
of all selected clones.
Non-frequent hits were of two classes: One class involved clones that were 
detected with different transcriptional variants, either overlapping or non­
overlapping clones encoding the same protein. The other class involved few 
clones that qualify as multiple hits only when they are considered collectively with 
a one-time hit matching only one of the control samples. These clones were listed 
as repetitive clones due to the fact that the control disease samples were as 
heterogeneous as disease samples and it could not be totally excluded that a 
control subject might have a subtle autoimmune response to a candidate 
autoantigen, albeit showing no pathological phenotype. Table 5.9 represents all 
repetitive clones falling into explained categories.
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Table 5.9 Repetitive clones. The list of all repetitive clones identified after three rounds of 
panning with hit frequency >2 among different disease groups. Sticky clones are given to indicate
the uniform presence of such background interactions throughout the experiment.
Identification
Disease Groups
SZ
n=6
BP
n=5
MS
n=8
EPI
n=7
MDD
n=2
NPH
n=2
Other
n=4
Talin (TLN) 2 - - - - - -
Septin 4/Septin5 (SEPT4/SEPT5) 1 1 - 1 - - -
Growth arrest-specific 7 (GAS7) 2 1 3 - - - -
T-cell receptor alpha delta locus 1 2 - - - - -
Pinin, desmos 
protein (PNN)
some associated
1 2 4 - - - 2
Heat shock
70kDa protein8 
(HSPA8) - 1 - - - - -
22kDa protein 8 
(HSPB8) - - 1 1 - - -
Contactin associated protein-like 
4 (CASPR4/CASPR3) 3 1 1 - - - 1
Interleukin
17D (IL17D) 1 - - - - - -
3 receptor, alpha 
(low affinity) 1 1 - - - - -
Heterochromatin protein 1, 
binding protein 3 (HP1BP3) - 1 - 1 - - -
Olfactomedin 2 (OLFM2) - 1 2 1 - - -
Nuclear casein kinase and cyclin- 
dependent kinase substratel 
(NUCKS1)
- - 2 1 - - -
Calcium/calmodulin-dependent 
protein kinase II inhibitor 1 1 - - 1 - - -
Myelin basic protein (MBP) 1 1 1 - - - -
Ribosomal
protein
L17 2 - - - - - -
L24 - - 1 - - - -
Ribosome binding protein 1 
homologue 180kDa/ES/130- 2 - - - - - -
EF-hand calcium binding protein 
1 (EFCBP1) 1 - 1 - - - 1
Myosin
IXB (MY09B) 1 - - - - - -
VI (MY06) - - 1 - - - -
Coiled-coil
domain
containing
66 (CCDC66) 
72 (CCDC72)
1 - - 1 - - -
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Identification
Disease Groups
SZ
n=6
BP
n=5
MS
n=8
EPI
n=7
MDD
n=2
NPH
n=2
Other
n=4
Protease (prosome, macropain) 
26S subunit, non-ATPase, 10 
(PSMD10)
1 - - - - - -
cytochrome c
reductase 
hinge protein 
(ubiquinol)
- 1 - - - - -
somatic 1 - - - - - -
Haplotype,
mitochondrion
NADH
dehydrogenase
W1,
subunit2 1 - - - - - 1
H7,
subunitl - 1 2 2 - - 2
Splicing factor, 
arginine/serine-rich 5 - - 1 - - - 1
PI-3-kinase-relat< 
1 isoform 1homo
3d kinase SMG- 
og protein - ■ - 1 - - - 1
Zinc finger 
orotein
410 (ZNF410) 1 - - - - - -
85(ZNF85) - - 1 - - - -
Amyloid beta 
(A4) precursor­
like
protein 1 
(APLP1) - 2 - - - - 1protein 2 
(APLP2)
General transcription factor II - - 1 - - - 1
Tyrosine3 monoox 
/tryptophan 5-mon 
activation protein,
ygenase
ooxygenase
beta
- - 1 1 - - -
Lens-,(p52) or 
transrciptional 
coactivator p75
epithelium- 
derived 
growth factor
1 - - - - - -
Pigment- - - 1 - - - 1
Nucleolar and coiled-body 
phosphoprotein 1 (NOLC1) 33
Small EDRK-rich factor 2 25
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5.4.2 Major sticky clones
A number of sticky clones are uniformly present in the eluates from almost all 
samples from any type of disease or control group. Table 5.10 shows the most 
common sticky clones.
Table 5.10 Major sticky clones of T7 library. Nucleolar and coiled-body phosphoprotein p130 is 
the most prominent background clone as it was encountered in almost all samples, and in 
optimization experiments carried out using negative lysate (empty T7 phages).
Non specific clones (BG) SZ BP MS EPI MDD NPH Other
Nucleolar and coiled-body 
phosphoprotein, NOLC1, 
p130
+ + + + + +
Haplotype (H7) 
mitochondrion NADH 
dehydrogenase subunit 2
+ + + + +
Small EDRK-rich 
factor 2
+ + + + +
5.4.3 Pseudo genes, novel genes and uncharacterized proteins
The PD selection survey in Blast yielded many clones that are translated into 
unknown proteins with novel or pseudo gene identity. These clones were not 
studied in further detail except categorizations according to genomic locations 
(Table 5.11) and repeated hit frequency within disease groups (Table 5.12).
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Table 5.11 Distribution of selected pseudo/novel/unidentified genes. Below is the number of 
unknown genes selected by PD listed according to their genomic locations.
Chromosome SZ(n=6)
BP
(n=5)
MS
(n=8)
EPI
(n=7)
MDD
(n=2)
NPH
(n=2)
Other
(n=4)
1 1 - 9 1 2 - 4
2 4 2 3 2 - 6
3 2 3 2 1 1 1
4 2 1 2 1 3
5 3 - 1 4 2
6 - 2 2 2 4
7 7 1 4 1 2
8 3 1 2 3 1
9 3 1 2 3 2
10 1 - 5 - 1
11 3 2 2 1 1
12 3 4 4 1
13 2 3 1 1
14 - 5 1
15 - 1 -
16 1 1 2 2
17 2 4 - -
18 - 1 - -
19 1 2 - 2
20 - - 2 1
21 - - - -
X 1 1 - 1 4
Y - - - - 1
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Table 5.12 Distribution of repeatedly selected pseudo/novel/unidentified genes among 
disease groups. Upper left part shows AFD, SZ or MS specific clones with no hit in control 
samples. Bottom left part shows other repetitive clones that are not SZ/BPD specific.
Clone Chromosome SZ BP MS MDD EPI NPH Other
BAC RP11-241J12 5 2
BAC clone RP11- 
708P17 7 1 . 1
PAC clone RP4- 
754G14 7 2
clone RP11-131N11 10 1 1
BAC RP4-601P9 12 1 1
BACR-158A24 of 
library RPCI-11
14 2
clone CTC-471J1 19 2
BAC clone RP11- 
762E8
2 1 1
BAC RP11-321A2 3 1 1
clone RP3-422G23 6q24 1 1
PAC clone RP5- 
1102B4 7 1
1
clone RP11-134N2 8 1 1
clone RP11-354P17 9 2 2 1
genomic DNA, RP11- 
822I2 11q 1
1 1
BAC RP11-641A6 12 1 1
clone RP11-533D19 16 2
clone RP1-274L7 X 1 2
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5.4.4 Clonality
Plaque selection performed after PD assay from each patient yielded a number of 
clones. Plaques were picked randomly and clones were subsequently sorted 
according to the size of the insert and the restriction pattern after PCR 
amplification. Only undigested clones and a representative clone from each 
restriction analysis were sequenced. Clones were found to represent known genes 
as well as unknown gene products and pseudo genes. Table 5.13 shows the 
quantitative representation of clonality that represents the frequency of the same 
hit per patient. In the table, the number of clones picked, sequenced and identified 
known gene products are listed. This is followed by the frequency of highly 
enriched clones for each patient, which is obtained from the analysis of undigested 
or same size PCR products. Regarding the frequency of the identical restriction 
digestion patterns, MBP was found as the clone with the highest enrichment 
compared to other selected hits. Not included are the background and sticky 
clones, unknown gene products and pseudo genes.
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Table 5.13 Clonality in terms of quantitative evaluation of identical clones picked from each 
patient
I
Samples
Clones
A
PL
P
Cy
to
ch
ro
m
e 
C
H
S
P
70 O
CL
X
SH
3 
bi
nd
in
g 
pr
ot
ei
n 
S
N
P
70
ER
P
29
R
PL
17
Ta
lin
M
B
P
C
as
pr
4
G
as
7
TC
R
A
/D
II3
R
A
To
ta
l
nu
m
be
r
pi
ck
ed
To
ta
l
nu
m
be
r
se
qu
en
ce
d
Id
en
tif
ie
d
Number of identical sized PCR 
products
Number of identical 
restriction patterns
SZ076 48 32 2 0 2 2 1 1
SZ454 24 9 7 2 1
SZ369 48 30 16 2 3 1
SZ464 24 14 1 0 2 1
SZ166 24 17 7 1 1
SZ244 24 13 5
BPD203 24 14 9 2 1 1
BPD365 30 14 7 1 1
BPD071 30 15 5
BPD160 24 16 1 2 2 2 1
BPD131 24 18 1 0 1
Abbreviations: APLP: amyloid beta protein precursor, HS70: heat shock protein 70, XPC: 
Xeroderma pigmentosum complementation group C, ERP29: endoplasmic reticulum protein 29, 
RPL17: ribosomal protein L17, MBP: myelin basic protein, Caspr4: contactin associated protein4, 
GAS7: growth arrest specific 7, TCRA/D: T cell receptor alpha/delta, IL3RA: interleukin 3 receptor 
alpha.
I l l
5.4.5 Gene ontology profiling
AFD, BPD, MDD and MS related repetitive clones were classified. The results 
yielded a rather broad distribution of clones. Therefore, a GO classification was 
performed to see the overall distribution of selected clones. As shown in Figure 
5.2, the prominent groups were found to be structural, adhesion (17%), followed 
by immune specific and ATP-related (13%) proteins.
5%
9%
S  adhesion molecule /structural 
/cell movement
□  GTPase activity
□  cell cycle arrest/growth factor
■  chaperon
I I  immune specific
□  ribosomal
□  ATP synthesis/electron 
transport
□  signalling cascade
□  mRNA splicing 
H zinc finger
□  transcriptional regulation
■  protease
Figure 5.2 GO distributions of repetitive clones. All of the clones depicted within this scheme 
are autoantigen candidates that are categorized only according to their GO, irrespective of their hit 
frequency.
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5.5 BPD and SZ related autoantigen candidate profiles
There were 7 molecules that were classified as frequent hits among 11 samples 
(5 BPD, 6 SZ). Table 5.14 demonstrates that these six clones have the potential to 
act as candidates with high hit frequencies.
Table 5.14 Overview: The selected autoantigen profiles that have a hit frequency >2 selected from 
AFD and SZ, with co-reactivity to MS samples.
TLN IL3RA GAS7 CASPR4/CASPR3 TCRA/D MBP RPL17
SZ 454 H 1 IS® 1
SZ 076 8 J IJ J I r t « l
SZ 464
SZ 166 '}■ *'% tys. ■*'. : ;S y y ^ 7p > ; :
SZ 244
SZ 369
• ! . ;r • WJ
|,J», .,,7^.1 ,<,/ r o#,,;*,,,,
BP 203 ;/ / y  //v 
r  v f e ' - y >■ ''
BP 365 • , , r „ „  , «y<>
BP 071
BP 160 y ,," t
BP 131
MS1
MS2
MS3
MS4
MS5
MS6
MS7
MS8
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5.5.1 Clones with hit frequency 4 within the BPD/SZ disease group
Contactin associated protein or cell recognition protein 4 (CNTNAP4 or CASPR4) 
isoforml (NP_207837) was repeatedly selected from 4 patient samples, as 3 hits 
from 6 SZ patients and 1 hit from 5 BPD patients. Caspr3 was also identified by 
Blast by 85% homology to the sequence obtained from PD selection. Caspr4 and 
Caspr3 are, therefore, both considered as hits, although Caspr4 is more often 
referred to for simplicity. Caspr4/Caspr3 displaying phage was selected from one 
MS patient’s CSF and headache control.
C a s p r 4  DDCDDPLVSALPQASFSSSSELSSSHGPGFARLNRRDGAGGWSPLVSNKYQWLQIDLGER 60
C a s p r 3  -DCDSPLASALPRSSFSSSSELSSSHGPGFSRLNRRDGAGGWTPLVSNKYQWLQIDLGER 59
A A A  A  A  A  A  A  A • • ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ■ A - • A A A A A A A A A A A  • ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ■ A '
C a s p r 4  MEVTAVATQGGYGSSNWVTSYLLMFSDSGWNWKQYRQEDSIWGFSGNANADSVVYYRLQP 12 0
C a s p r 3  IEVTAVATQGGYGSSDWVTSYLLMFSDGGRNWKQYRREESIWGFPGNTNADSVVHYRLQP 1 1 9
* * * * * * * * * * * * * * * * * * * * * * * * * * *  A A A A A A A » A » A A A A A  A A » A A A A A A « A A A A A
C a s p r 4  SIKARFLRFIPLEWNPKGRIGMRIE 1 4 5
C a s p r 3  PFEARFLRFLPLAWNPRGRIGMRIE 14 4
• « A A A A A A » A A  A A A « A A A A A A A A
Figure 5.3 Caspr4 and Caspr3 amino acid sequences obtained form PD selection. The 145
amino acids long autoantigenic target sequence maps to N-terminal aa30 to aa173. Among this 
region, Caspr4 and Caspr3 have sequence identity with score 85 as determined by CLUSTAL 
2.0.5 Multiple Sequence Alignment. are the identical residues or nucleotides in that column, 
are conserved substitutions, and are semi-conserved substitutions.
5.5.2 Clones with hit frequency 3 within the BPD/SZ disease group
Growth arrest specific protein 7 (Gas7) (NP_003635), and T-cell receptor 
alpha/delta (TCRA/D) (AAB69001, AAB69001, AAB69018) were selected 
repeatedly from 3 SZ/BPD patients. Gas7 was found among MS clones 3 more 
times, while TCRA/D was restricted to the SZ/BPD disease group only.
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5.5.3 Clones with hit frequency 2 within the BPD/SZ disease group
Myelin basic protein (MBP) was selected from 1 BPD and 1 SZ patient’s CSF 
(AAH08749 and NP_001020272: SZ patient, AAH80654: BPD patient).
Additionally, 1 MS patient was responding to MBP (AAH80654).
Talin (AAF27330) was selected from 1 BPD and 1 SZ patient. The CSF of the 
same SZ patient reacted with Interleukin 3 receptor alpha (IL3RA) (CAI41507) 
and, together with another SZ patient, IL3RA was detected exclusively within the 
SZ group with a hit frequency of 2.
Ribosomal protein RPL17 was identified from 2 SZ patients. According to PD 
selection, one of the patients (SZ 076) that reacted with RPL17 was also reactive 
with Caspr4, Talin and Gas7. Similarly the other patient (SZ 166) was reactive with 
Caspr4 and TCRA/D as well.
5.6 Validation of selected clones by phage ELISA
After categorization of clones the most prominent candidate autoantigen was 
assessed for confirmation with alternative immunological methods.
After a PD selection, phage ELISA is the classical option for such a query. 
Accordingly, the primal goal was to try to reproduce findings from the PD 
selection using phage ELISA on Caspr4/Caspr3 displaying phage particles. 
Consequently, the CSF from 4 patients yielding Caspr4/Caspr3 as an 
autoantigen candidate was tested. Caspr4/Caspr3 displaying phage lysate was 
purified by CsCI gradient and incubated with anti-T7 tail coated strip well ELISA 
plates. As controls, Gap43 displaying phage and negative lysate (empty phage) 
were used. Caspr4/Caspr3 positive crude CSF samples from 4 positive patients 
were individually used as detection antibody source. CSF was pre-incubated with 
empty T7 phage before application.
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The reaction was amplified by a biotin-streptavidin step, using anti-human IgG- 
biotin and streptavidin-HRPO complex, and detected by TMB at X=450 nm.
In agreement with PD selection, Caspr4/Caspr3 positive CSF showed a more 
pronounced reaction with Caspr4/Caspr3 displaying phage compared to others 
(p<0.05, Student t-test) (Figure 5.4). On the other hand, high background noise 
was observed that came from negative control lysate Gap43, empty phages and 
blank (wells coated with anti-T7tail antibody), that compromised the signal.
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0.800
Ec
0.600OO
0.400 
0.200 
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CASPR4 GAP43 empty phage no phage
Figure.5.4 Phage ELISA testing CSF samples that yielded Caspr4/Caspr3 as autoantibody 
candidates according to the PD selection. Small scale Caspr4/Caspr3, Gap43 and empty 
phage lysates were purified by CsCI gradient and 1:20 dilution was applied on ELISA wells pre­
coated with lgG2a T7 tail fiber monoclonal antibody. CSF of Caspr4/Caspr3 positive patients, 
pre-cleared of empty T7 phage (negative lysate), was used as detection antibody source. A 
cocktail of 1:1000 diluted polyclonal (Jackson laboratories) and 1:500 diluted monoclonal (BD 
Biosciences) antihuman-lgG-biotin was applied for 2 hrs and subsequently incubated with 
streptavidin-HRPO (BD Biosciences) at 1:2000 dilutions for 25 min.
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5.7 Validation by conventional ELISA using recombinant Caspr4 peptide
A conventional ELISA, that tests the reactivity of CSF from PD positive patients 
against Caspr4 recombinant peptide, was applied. For this purpose, the 
sequence within the N-terminal epitope of caspr4 that corresponds to 61 amino 
acids from the discoidin domain was cloned. After bacterial expression and 
purification by His-Tag absorption, the recombinant peptide was concentrated 
and buffer exchanged to PBS. After confirmation by western blot using anti-his 
antibody, the peptide was coated in 1 %PBS-BSA to Corning High-Bind microtiter 
plates.
One CSF sample that was positive for rCaspr4 peptide according to the PD was 
used in comparison to a negative CSF from the epilepsy group. Regarding the 
IgG content, two concentrations were used: 1 pg/ml and 10 pg/ml. 2 (ig/ml 
rCaspr4 was used as target. Similar to phage ELISA, signal to noise 
enhancement by biotin coupled anti-human IgG and streptavidin-HRPO 
incubation was preferred (Figure 5.5).
Next, 7 ng/ml rCaspr4 was used as target to analyze PD positive SZ and BPD 
samples and a comparison at fixed IgG concentration (12 |ug/ml IgG) of CSF 
from disease and control disease groups was performed (Figure 5.6).
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Figure 5.5 2pg/ml recombinant Caspr4 peptide mapping N-terminal peptide from aa1 to 60, was 
coated on Corning High-Bind 96-well microtiter plates. CSF samples were diluted in blocking 
buffer at concentrations of 10 pg/ml and 1 pg/ml IgG. Caspr4+ CSF designates BPD patient 203, 
identified with PD selection, as positive for Caspr4 autoantigen. Caspr4+ CSF containing 1pg/ml 
IgG dilution reacted stronger with Caspr4 peptide than the EPI patient 1, with 10 pg/ml IgG 
dilution, implying that up to ten-fold reactivity is observable. The experiment was performed in 
duplicate, results representing the average values.
The results indicated that the Caspr4 recombinant peptide may act as an 
immunogenic epitope for Caspr4 reactive CSF selected by PD. Different CSF 
samples, either positive or negative for Caspr4, had a different reactivity for the 
rCaspr4 peptide. However, a trend for higher reactivity of SZ/BPD CSF than the 
control disease groups existed (t-test, p=0.14).
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Figure 5.6 CSF reactivity to recombinant Caspr4 peptide. 7 jag/ml rCaspr4 peptide was coated 
on 96-well microtiter plates. After blocking, CSF samples were added (IgG concentration adjusted 
to 12pg/ml). Anti-human IgG-Biotin (Jackson laboratories) used to detect CSF IgG bind to rCaspr4 
peptide. The results showed that, there is a trend for SZ/BPD group to yield a higher signal 
intensity compared to the disease control group, indicating an autoantigenic response (p=0.14, two 
tailed test).
5.8 Differential autoantigenic characteristics of N-terminus of Caspr 
family proteins
After validation of the reaction to the rCaspr4 peptide, we questioned whether 
other members of the Caspr family have the same autoantigenic property. For 
this purpose, two commercially available recombinant peptides, Casprl and 
caspr2 were used. The whole amino acid sequence of casprl and caspr2 has 38 
and 37 % homology to caspr4 and caspr3, respectively. rCasprl peptide maps to 
20-70 aa at the N-terminus of Casprl of human origin. rCaspr2 has 50 aa size 
and maps to the immediate N-terminus of human Caspr2.
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Caspr4 recombinant peptide has a size of 61 aa and it was cloned from human 
genomic DNA. The aa sequence homology of the N-terminal amino acids of 
recombinant Caspr4, Caspr and Caspr2 are given in Table 5.15.
Table 5.15 Homologies of Caspr family members at N-terminus compared by ClustalW2 
multiple sequence alignment.
Seq A Name
aa
sequence
Length
(aa)
Seq B Name
Length
(aa)
Score
1 Casprl
WGYYGCDEELVG
PLYARSLGASSYY
SLLTAPRFARLHGI
SGWSPRIGDPNP
51 2 Caspr2 51 23
2 Caspr2
SCLCRAWTAPSTS
QKCDEPLVSGLPH
VAFSSSSSISGSYS
PGYAKINKRGG
51 3 Caspr4 61 37
3 Caspr4
MGSVT GAVLKTLL
LLSTQNWNRVEAG
NSYDCDDPLVSAL
PQASFSSSSELSS
SHGPGFARL
61 1 Casprl 51 29
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Figure 5.7 Recombinant Caspr4, Caspr and Caspr2 peptides at 1pg/ml concentrations were 
coated on Corning HighBind 96-well microtiter plates. A. CSF samples from SZ/BPD patients that 
were identified with PD selection as positive for Caspr4 autoantigen were tested. All the 
recombinant peptides represent N-terminal discoidin domains, conserved among Caspr family 
proteins There was a significant response to Caspr4 epitope compared to signal from 
homologous recombinant peptides (p<0.05, two-tailed t-test). The experiment was performed in 
duplicate and repeated twice, results representing average values and showing SEM B. CSF 
from BPD patient 203 showed more reactivity to rCaspr4 than rCasprl and rCaspr2 and control 
wells with no CSF, indicating epitope selectivity.
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As depicted in Figure 5.7, a significant difference in reactivity against the epitope 
obtained by PD selection in comparison to homologue sequences from close 
family members was observed (p<0.05, two tailed test). This implicates that the 
N-terminal sequence of Caspr4 obtained after PD selection, may act as a highly 
specific autoantigen target.
5.9 Quantitative PCR analysis of expression pattern of myelination related 
genes
In order to understand the expression pattern of relevant myelin-related genes, 
Casprl, Caspr4, MBP and DDR1 in an integrated way, a quantitative PCR 
approach was applied. In this way it is possible to assess the differential 
expression of these genes from birth until early adulthood in mice. Three male 
and three female mice were analyzed at PND1, PND7, PND14, PND21, PND28, 
PND35 and PND42, thus allowing observation of the possible difference between 
sexes. The whole brain and spinal cord cryo-sections were used for RNA 
isolation. Expression of CASPR1, CASPR4, DDR1 and MBP was compared to 
GAPDH expression.
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In the brain, CASPR1 and MBP mRNA levels showed a similar increased pattern 
of expression during the first two postnatal weeks (Figure 5.8). In the following 
weeks, CASPR1 levels stayed constant at peak levels while MBP expression 
dropped back to initial values. DRR1 and CASPR4 had a linear expression 
pattern after the first postnatal week. Females had a higher expression of both 
genes during the first postnatal week.
CASPR48rafnCA3PR1 Braifl
DDftl Brain
PosjtnatBj day
Figure 5.8 Casprl and MBP transcripts show a similar expression pattern from birth to postnatal 
day 14, afterwards Casprl levels stayed constant while MBP expression dropped back to initial 
values. DRR1 and Caspr4 show a linear expression pattern, females have a higher expression of 
both genes during first postnatal week. Values represent percent gene expression level relative to 
housekeeping gene (HKG), error bars show standard deviation. For each data point n=3.
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In spinal cord all four genes showed a similar expression pattern from birth to 
PND42 in males and females. The only remarkable difference at the mRNA level 
was observed at PND7, where females had a higher CASPR1 and CASPR4 
expression (Figure 5.9).
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Figure 5.9 Casprl, Caspr4, DDR1 and MBP transcripts show similar expression patterns from 
birth to PND42 for males and females. The only difference at the mRNA level is observed at 
PND7, where females have a higher Casprl and Caspr4 expression. Values represent percent 
gene expression relative to housekeeping gene (HKG), error bars show standard deviation. For 
each data point n=3.
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When female and male mice were grouped together, Casprl expression in the 
brain was higher than three other genes and reached a peak value at PND28.
In spinal cord Caspr4 expression was highest at PND1 and constantly dropped 
until PND14 when Caspr 1 reached a peak. Caspr4 and DDR1 expression levels 
and patterns were very similar in the brain. Casprl and MBP had different 
expression levels in the spinal cord but the patterns of expression were similar 
with MBP having highest expression at PND7 and Casprl at PND14, before they 
were down-regulated and stabilized at PND21 (Figure 5.10).
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Figure 5.10 In this figure, results from male and female mice have been grouped together. In 
brain tissue, Caspr4, DDR1 and MBP show similar expression through out the postnatal 
developmental period. Casprl is strongly unregulated and reaches a higher level at PND14, 
continues until the end of week 4, and then starts to drop linearly (left). In spinal cord Caspl and 
Caspr4 do the opposite as seen by a constant down-regulation of Caspr 4 until PND14 in contrast 
to up-regulated Casprl. Values represent percent gene expression relative to housekeeping 
gene (HKG). For each data point n=6 .
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5.10 SUMMARY
1. Caspr4 and Caspr3 were identified as candidate autoantigens (Caspr3 as 
a homologue with an 85% identical amino acid sequence) by phage 
display selection.
2. Extracellular 145 amino acids at the N-terminus of Caspr4/Caspr3 were 
mapped as the autoantigen target in a subset of SZ/BPD patients.
3. Phage ELISA, using purified Caspr4/Caspr3 positive lysates, showed 
reactivity against phages that display Caspr4.
4. CSF from SZ/BPD patients that were selected by PD, reacted towards the 
rCaspr4 epitope with a trend that was higher than the control disease 
group (p<0.15).
5. Conventional ELISA, using recombinant Caspr4 peptide and its close 
homologues suggested a specific autoantigenic activity of the epitope 
obtained by PD selection. A significant response (p<0.05) by PD positive 
CSF samples towards rCaspr4, but not rCasprl and rCaspr2 peptides, 
was observed.
6. Caspr4 epitope resides within the discoidin (DISC) domain. Another SZ 
related protein with a discoidin domain is called DDR1 (also TrkE), which 
is encoded by a myelin gene. Myelin basic protein is also a candidate 
autoantigen selected by PD assay, albeit with a smaller hit frequency 
(n=2) than Caspr4.
7. Quantitative PCR analysis of Caspr4, MBP and DDR1 showed expression 
and gender differences, especially during the first two weeks of post-natal 
brain development in mice.
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Chapter6
RZPD Protein Array: Method and Results
6.1 Introduction
RZPD Protein Array consists of approximately 28,000 proteins printed in duplicate 
on 22cm x 22cm PVDF membranes. The human fetal brain library consists of over 
38016 clones spotted on two membranes each having a capacity of 27648 
different clones or proteins.
RZPD protein arrays are used in several studies including target protein 
identification using antibodies and sera, identification using antibodies or 
antibodies purified from serum, functional assays, e.g. phosphorylation, 
ribosylation, methylation (Lee et al., 2002), identification of DNA/RNA binding 
proteins (Buessow et al., 2004) and protein-protein interaction studies (Grelle et 
al., 2005).
Before this study, others have applied RZPD protein array in screening of 
autoantibodies using human sera (Buessow et al., 2004), but not CSF. Similar to 
designated modifications constructed for the PD assay for this study, the protein 
array protocol had to be adopted for CSF conditions. Initially, 4 samples were 
tested but first attempts yielded no signals. Subsequent optimization trials were 
successful, so that 4 SZ, 3 BPD and 3 EP CSF samples were analyzed by RZPD 
at their facilities in Heidelberg.
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6.2 RZPD Protein array flow chart
secondary antibody
primary antibody
9  protein
filter
Figure 6.1 Principle of the array (source: RZPD).
6.2.1 Quality control of macroarray
1. Incubation of macroarray with anti-His antibody
2. Incubation with anti-mouse antibody, linked to alkaline phosphatase
3. Incubation with ECF substrate
4. Scanning
6.2.2 Characterization of antibody (epitope mapping)
1. Incubation of macroarray with antibodies to be characterized (mouse 
monoclonal antibody, rabbit antiserum, rat antiserum)
2. Incubation with secondary antibody (anti-mouse, anti-rabbit, anti-rat), linked to 
alkaline phosphatase
3. Incubation with ECF substrate
4. Scanning
1 28
6.2.3 Serum screening for autoantibodies
Pre-absorption of human serum against E.coli proteins is recommended: 
Alternatively, immobilized E. coli lysate can be used (Pierce, No. 44938 or 44940).
1. Incubation of macroarray with human CSF (or plasma, serum, etc)
2. Incubation with anti-human antiserum, linked to alkaline phosphatase
3. Incubation with ECF substrate
4. Scanning
Note: Dilutions for CSF screen were adjusted individually.
6.3 CSF Samples
Table 6.1 CSF samples analyzed by RZPD protein array
Sample
IgG 
pg/m I
Albumin
mg/l
Total
protein
mg/l Gender Age
Volume
CSF
analyzed
(Pi)
SZ 454/00 22.7 147 280 F 34 600
SZ 166/02 28.7 230 420 M 56 450
SZ 464/02 45.6 424 520 F 24 350
SZ 244/04 23.3 166 278 F 61 650
SZ 369/98 53,0 348 493 F 43 Test
SZ 076/97 24,6 265 587 M 50 Test
BP 365/04 20.3 188 298 F 48 750
BP131/05 18.9 137 199 F 64 800
BP203/05 11.9 161 223 F 46 1200
BP 071/02 25,4 231 320 F 52 Test
EP 014/00 26.6 225 304 F 25 600
EP 477/01 34 205 340 M 17 450
EP 330/04 31.9 289 411 M 46 500
EP 339/04 61,0 265 428 F 56 Test
Note that, during optimization trials and screening, the samples were analyzed 
anonymously; i.e., not knowing the disease groups they belonged to. Identified 
proteins and corresponding clones are listed as annotated clone lists with 
coordinates of spots on the filters. Protein array image and sequence analyses 
with subsequent Blast searches were carried out.
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6.4 Results and Discussion
Filter images
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c^  Array: 367-55-532 Sample: 8) 365/04
Coordinates 54 60, 53 57 
R2PD Clone: MPMGp800E 14526
Coordinates 167 45,170 44 
R2PD Clone: MPMGp8C0H15530
R2PDClone: MPMGp800l07S22
Coordinates 76124,79123  
R2PD Clone: MPMGp800H09541
Coordinates 182175,185174  
R2PD Clone: MPMGp800N12603
Figure 6.1 Protein array filter. Approximately 38,000 clones were distributed on two membranes, 
each with -27,500 clones in duplicate spots (-55,000 spots in total). Each filter had an identity 
code A. Secondary antibody control of the 367-18-xyz filter series. The membrane was solely 
incubated with secondary antibody to detect coordinates of non-specific binding clones. The 
second filter did not show any reactivity to secondary Ab (data not shown). B. The same 
membrane after incubation with CSF showing reactive clones in duplicate. Coordinates of hit 1 and 
3 are different. However, the 2 hits have the same clone identity (p800F03517), making this clone 
a strong positive hit. The second membrane yielded no positive hits (data not shown). Sample 339 
is an epilepsy patient CSF sample showing autoimmune reactivity to MHC class I antigen (NCBI 
accession CAC17463). C. An example of a membrane displaying multiple responses to BPD CSF 
probe. The signal intensities were still moderate despite optimizations. All of the clones identified 
are listed in the overall list of identified RZPD clones.
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b. Identified clones
Protein array results were evaluated manually and signals with significant 
intensities sequenced by RZPD. The signals were persistently weak. The criterion 
was the identification of the same protein twice on one membrane, making it more 
likely to be a real signal. Table 6.2 lists the Blast results of significant spots from 
all repetitive (hit frequency >2) samples.
Table 6.2: All repetitive clones resulting from the RZPD protein array screen of CSF 
samples.
Clone BP(n=4)
SZ
(n=6)
EPI
(n=4)
caspase 6 isoform beta 3 2 2
Ufm1 -conjugating enzyme 1 clonel 3 2 -
clone2 4 3 3
ankyrin repeat and SAM domain-containing protein 6 1 3 1
OTU domain, ubiquitin aldehyde binding clone 1 2 1 -clone 2 3 1 -
B-cell CLL/lymphoma11A iso3 2 - 1
proline-rich acidic protein 1 3 1 -
Stathmin-like 4
clonel 1 2 1
clone2 - 2 1
clone3 - 2 1
clone4 - 2 1
similar to GluR- (N12603) delta2 philic-protein 2 4 1
myosin light polypeptide 6B 1 - 1
histone deacetylase 10 1 3 2
histone deacetylase - 2 -
MYC-associated zinc finger protein
clonel - 1 1
clone2 - 1 1
clone3 - 1 1
clone4 - 3 1
5'-nucleotidase domain containing protein 2 - 2 -
LOC387790 protein 1 1 -
hCG2031974 - 1 1
ribosomal protein S12 - 2 1
ribosomal protein S27a - 2 -
serine/threonine protein phosphatase 1 regul.subun.10 - 1 1
zinc finger protein 358 - 1 1
zinc finger protein 259 2 - -
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Clone BP(n=4)
SZ
(n=6)
EPI
(n=4)
capicua protein 2 - -
glyceraldehyde-3-phosphate dehydrogenase 3 - -
RD RNA-binding protein, Negative elongation factor E 3 - -
G1 to S phase transition 1, peptide chain release factor 3 2 - -
CUE domain containing 2, HOYS6 and HOYS7 3 - -
splicing factor, arginine/serine-rich 11 and glutamine-rich 1 1 -
sperm-associated antigen 7 2 - -
Ras-related GTP binding A and B 2 - -
PIP5K1C protein 2 - -
eukaryotic translation elongation factor 1 gamma and 2 - 2 -
ProSAAS precursor (dynamin 1 and 2) 1 2 -
leucine rich repeat containing 47 - 2 -
superoxide dismutase copper chaperone - 2 -
mitogen-activated protein kinase 11, p38B MAP kinase - 2 -
eukaryotic translation initiation factor 3 and 4a-l - 2 -
phospholipase C gamma 1 isoform a 3 1 -
neuron navigator 1 2 -
NME1-NME2 protein, non-metastatic cells 2, protein - 2 -
c. Disease-specific repetitive clones:
The set of SZ/BPD specific clones, identified from at least two patients by RZPD 
protein array is shown in Table 6.3. The list below shows that several spots that 
belong to the same clone can be obtained from one membrane or can be 
distributed to two membranes.
Table 6.3: Disease-specific repetitive clones resulting from RZPD protein array screen of
CSF samples.
Clone RZPD clone ID
G1 to S phase transition 1, peptide chain release 
factor 3, (GSPT1)
MPMGp800H 18563, 
MPMGp800M10544, 
MPMGp800P20554
RD RNA-binding protein, Negative elongation factor E 
(NELF-E)
MPMGp800F17571, 
MPMGp800A16590, 
MPMGp800D13558
splicing factor, arginine/serine-rich 11 and 
glutamine-rich nuclear protein (p54)
MPMGp800M23569, 
MPMGp800P18528
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Clone RZPD clone ID
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH)
MPMGp800B23574, 
MPMGp800P16540
CUE domain containing 2 (HOYS6, HOYS7)
MPMGp800l07557, 
MPMGp800J05545, 
MPMGp800H15591, 
MPMGp800A22590, 
MPMGp800P10578, 
MPMGp80002356, 
MPMGp800l09541, 
MPMGp800E09558
Sperm-associated antigen 7 (SPAG7)
MPMGp800002506, 
MPMGp800F05518, 
MPMGp800N12598
Ras-related GTP binding A and B (RRAGA)
MPMGp800J19525 
MPMGp800K01582 
MPMGp800A24596 
MPMGp800J24581
PIP5K1C protein, TATA box binding protein 
(TBP)-associated factor
MPMGp800J 12548, 
MPMGp800L23591
Eukaryotic translation elongation factor 1 gamma 
and 2 (EEF2)
MPMGp800002544 
MPMGp800C17586
NME1-NME2 protein, non-metastatic cells 2 protein 
(NM23B)
MPMGp800005526,
MPMGp800H16529
OTU domain ubiquitin aldehyde binding 1 (MBD3)
MPMGp800E13553, 
MPMGp800K13541
5'-nucleotidase domain containing 2 (NT5D2)
MPMGp800J09580, 
MPMGp800K16585
Capicua protein (CIC)
MPMGp800P10599, 
MPMGp800C18591
ProSAAS precursor (dynamin 1 and 2) (PCSK1)
MPMGp800P22510, 
MPMGp800H19595
leucine rich repeat containing 47 (LRC47)
MPMGp800H21569, 
MPMGp800F22533
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Clone RZPD clone ID
superoxide dismutase copper chaperone (CCS )
MPMGp800A03589,
MPMGp800L02569
mitogen-activated protein kinase 11, p38B MAP kinase
(MAPK11)
MPMGp800N 14589, 
MPMGp800C06553
histone deacetylase (HDAC) MPMGp800E12566
Eukaryotic translation initiation factor 4A (elF4A-l), 3
MPMGp800D08553,
MPMGp800l16577
neuron navigator (NAV1) MPMGp800A11507
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d. Common clones to phage display selection:
1. Eukaryotic translation initiation factor 4A isoform 1 and isoform 2:
Eukaryotic translation initiation factor 4A isoform 1 was selected from 2 SZ 
patients by protein array (PA), and isoform 2 was selected from 1 SZ patient by 
PD assay. Blast alignment of DNA sequences from PD and protein array yielded 
an 85% sequence homology. Multiple alignment by Clustal 2.0.5 revealed the 
common amino acid sequence of both initiation factors (figure 6.2).
PD MSGGSADYNREHGGPEGMDPDGVIESNWNEIVDNFDDMNLKESLLRGIYAYGFEKPSAIQ 60
PA MSASQDSRSRDNG-PDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQ 5 9
PD QRAIIPCIKGYDVIAQAQSGTGKTATFAISILQQLEIEFKETQALVLAPTRELAQQIQKV 1 2 0
PA QRAILPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKATQALVLAPTRELAQQIQKV 1 1 9
*  *  *  *  . * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . * .  . . *  * * * * * * * * * * * * * * * * * * *
PD ILALGDYMGATCHACIGGTNVRNEMQKLQAEAPHIWGTPGRVFDMLNRRYLSPKWIKMF 1 8 0
PA VMALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMF 17  9
. . * * * * * * * * . * * * * * * * * * * *  * . * * * *  * * * * * . * * * * * * * * * * * * * * * * * * * . * * * *
PD VLDEADEMLSRGFKDQIYEIFQKLNTSIQWLLSATMPTDVLEVTKKFMRDPIRILVKKE 2 4  0
PA VLDEADEMLSRGFKDQIYDIFQKLNSNTQWLLSATMPSDVLEVTKKFMRDPIRILVKKE 2 3  9
* * * * * * * * * * * * * * * * * * . * * * * * * .  * * * * * * * * * * . * * * * * * * * * * * * * * * * * * * * *
PD ELTLEGIKQFYINVEREEWKLDTLCDLYETLTITQAVIFLNTRRKVDWLTEKMHARDFTV 3 0 0
PA ELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHARDFTV 2 99
* * * * * * * . * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . * * * * * * * * * * * * * * * * * * * *
PD SALHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHR 3 60
PA SAMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHR 3 5  9
*  *  . * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
PD IGRGGRFGRKGVAINFVTEEDKRILRDIETFYNTTVEEMPMNVADLI 4 07
PA IGRGGRFGRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI 4 0 6
'k'k'k-k’k'k'k'k'k'k'k'k’k'k'k • •k'k'k'k'k'k'k'kic'k • •
Figure 6.2 Amino acid sequence similarity of eukaryotic translation initiation factor 4A isoform 2 
(PD) and isoform 1 (PA) by ClustalW2 multiple sequence alignment with a score of 89. Both factors 
were exclusively selected from the SZ disease group and were absent from the epilepsy control 
group. "*" are the identical residues or nucleotides in that column, are conserved substitutions, 
and "."are semi-conserved substitutions.
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2. Eukaryotic translation elongation factor gamma and alpha:
Eukaryotic translation elongation factor gamma was selected by PD while the 
alpha isoform was selected by protein array. Both genes encode a subunit of the 
elongation factor-1 complex. Translation elongation factor gamma contains an N- 
terminal glutathione transferase domain which may be involved in regulating the 
assembly of multi-subunit complexes containing this elongation factor and 
aminoacyl-tRNA synthetases. Eukaryotic translation elongation factor alpha has 
two isoforms. Isoform alpha 1 is expressed in brain, placenta, lung, liver, kidney 
and pancreas, and alpha 2 is expressed in brain, heart and skeletal muscle. 
Isoform 1 was identified as an autoantigen in 66% of patients with Felty syndrome 
that is defined by rheumatoid arthritis with an enlarged spleen and abnormally low 
white blood cell count (Ditzel et al., 2000). Gamma and alpha isoforms show no 
homology, but they have a common function where both isoforms carry out the 
enzymatic delivery of aminoacyl tRNAs to the ribosome.
3. Splicing factor, arginine/serine-rich 11 (SFRS11):
SFRS11 was selected once from a control disease patient in NPH group by PD, 
once in SZ and once in bipolar disease group by protein array. Blast nucleotide 
alignment of two sequences yielded a 100% match where the whole sequence 
from PD was found within the sequence obtained from protein array. Protein array 
mapped to clone NM_004768.2, within bases 1069 to 1952, whereas the clone 
from PD mapped between bases 1454 to 1746.
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4. Myosin light polypeptide 6B and myosin IXB (MY09B)
Myosin is a hexameric ATPase cellular motor protein. It is composed of two heavy 
chains, two nonphosphorylatable alkali light chains, and two phosphorylatable 
regulatory light chains. MYL6B was identified in 1 BPD and 1 control disease 
patient (EPI group) by protein array. It encodes a myosin alkali light chain 
expressed in both slow-twitch skeletal muscle and in non-muscle tissue.
MY09B (myosin IXB) was identified from a BPD patient by the PD method. 
MY09B is also a motor protein with an unconventional role in actin remodeling. It 
interacts with calmodulin (Post et al., 1998) and moves on actin filaments (Inoue et 
al., 2002). Like other CALM1-containing myosins, it exhibits maximal velocity of 
actin filaments in the absence of calcium. There is recent evidence of MY09B 
involvement in celiac disease, systemic lupus erythematosus, and rheumatoid 
arthritis and MY09B is recognized as a general risk factor for autoimmunity 
(Sanchez et al., 2007).
5. Ribosomal proteins L17, L24 and S12, S27a
Ribosomes consist of a small 40S subunit, and a large 60S subunit, that are 
composed of 4 RNA species and approximately 80 different proteins. RPL17 was 
identified by PD in 2 SZ patients exclusively. It encodes a ribosomal protein that is 
a component of the 60S subunit. RPL24 was selected from 1 MS patient. 
Similarly, RPS27 was detected by protein array from 2 SZ patients. RPS27 
encodes a component of the 40S subunit of the ribosome. RPS27 protein belongs 
to the S27E family of ribosomal proteins. It is located both in the cytoplasm as a 
ribosomal component, and also in the nucleus. RPS12 is also a component of the 
40S subunit and it was detected in 2 SZ and 1 disease control (EPI group).
138
6. Zinc finger proteins
Zinc finger proteins (ZNF) belong to transcriptional factors and have diverse 
functions including DNA recognition, RNA packaging, transcriptional activation, 
regulation of apoptosis, protein folding and assembly, and lipid binding (Laity, Lee 
and Wright, 2001). ZNF410 and ZNF85 were selected by PD assay from 1 SZ and 
1 MS patient, respectively. ZNF259 was selected from 2 BPD patients and 
ZNF358 from 1 SZ and 1 disease control (EPI group) by the protein array.
7. RNA binding proteins NOB1 and RD
NOB1 was selected from 1 MS patient by the PD assay, while RD (also-called 
negative elongation factor E) was identified exclusively in 3 BPD patients by the 
protein array. Both are RNA binding proteins although RD has not been shown to 
bind RNA. Interestingly, it is encoded by a gene that is located to the major 
histocompatibility complex (MHC) class III region.
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6.5 Summary
1. RZPD protein array yielded 20 disease-specific clones. When all clones with 
significant intensities (including non-disease-specific ones) were compared to 
PD assay results, it was found that several of them encode proteins that 
belong to the same families, including highly homologous pairs.
2. The most significant sequence homology (100% match according to Blast 
alignment) was observed in the arginine/serine-rich 11 splicing factor. It was 
selected from NPH disease control group by PD assay. However, it was 
identified in 1 SZ and 1 bipolar patient, and was classified as a disease- 
specific hit according to protein array.
3. Eukaryotic translation initiation factor 4A (isoforms 1 and 2) was identified by 
both methods as a SZ-specific autoantigen candidate clone.
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CHAPTER 7
DISCUSSION
7.1 GENERAL DISCUSSION
Several etiological theories re being discussed for psychiatric disorders like SZ 
and BPD. None of the prevailing views, however, can fully explain the different 
appearance and prognosis in individual patients. Technological advances and 
accumulating evidence that show immune dysfunction and the presence of 
autoantibodies in patient sera and CSF have highlighted the autoimmune 
hypothesis on SZ and bipolar disease.
The aim of this study was to investigate the autoimmune reactivity within CSF, 
based on preliminary western blot data from our lab showing the immune 
response against unknown targets in the CSF of depression patients (unpublished 
observation). Based on the evidence of possible autoimmune etiology, the 
research has expanded to include major psychoses like of SZ and BPD. The 
strategy applied is called immunoproteomics, where disease-specific 
autoantibodies against brain proteins were selected using PD.
This is a pioneering work based on cDNA PD selection of CSF, in order to test the 
autoimmune hypothesis for affective disorders and SZ. The complete approach 
was extensively tested and optimized to overcome limitations such as low 
immunoglobulin content, a limited volume of CSF and a high false positive ratio of 
PD selection. During selection and validation, we studied all samples individually
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rather than pooling them, as the risk of diluting subtle autoimmune response within 
the heterogeneity of the population was too strong.
The protocol optimized for this work is sensitive enough to detect possible 
autoantigenic targets at nanomolar levels. However, there were other limitations 
of the technique that were unavoidable. The foremost drawback was the 
accumulation of the false positives along with the true hits. The experimental 
configurations often offered limited possibilities of finding any positive control that 
could directly single out the background or sticky clones right after the selection, 
before sequencing. There was no way to sort out which clones were real 
candidates by just looking at their properties or amino acid sequences. Running a 
phage ELISA for all the hits to see if they were real was not practical due to the 
limited CSF amount. For this reason, several control parameters were applied that 
compared enrichment values to the background between selections. It is plausible 
to expect that any given clone with a high affinity to the target should be able to 
dominate the final eluate. However, it was often observed that several true hits 
were represented in small percentages within the eluate, and with a low frequency 
among the whole disease group. This may suggest that such high affinity clones 
do not necessarily acquire efficient bacterial expression and, furthermore, all 
clones were not represented equally among the original library reflecting their 
abundance in that tissue.
The confidence in discriminating true hits from others was based on the fact that 
the probability of obtaining the same clone, even once at different target selections 
is extremely low. A complementary argument was to select the same clone 
multiple times, thus having high hit frequency mainly within the targeted disease 
group.
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However, successful antigen identification is based on many factors like the type 
of the epitope, existence of the sequence as a known cDNA product and the 
reaction stoichiometry between target phage and the autoantibody. It is therefore, 
advised to use PD for antigen selection in conjunction with other methods (Owens 
et al., 2006). Furthermore, PD selection basically mimics natural interactions as 
the partners are in a non-reduced environment, creating a tendency to detect 
nonlinear (conformational) epitopes that are targets of the B-cell mediated immune 
response. Selection via protein arrays creates the possibility of screening exposed 
linear epitopes, which resemble antigens processed as peptides and become 
targets of T-cell mediated immune recognition. Accordingly, a protein array was 
applied in this study consisting of up to 27,648 proteins derived from expression 
verified, full-length as well as shorter cDNA clones. The protein spots were printed 
on PVDF membranes in duplicate so that they reached a total of 55,296 spots.
PD and protein array yielded different sets of candidate clones. It was observed 
that, PD selection was more efficient in identifying transmembrane proteins, while 
protein array mostly yielded soluble proteins. Interestingly, there were clones 
common to both methods but the hits were not frequent enough to qualify as 
autoantigen candidates, or they were listed as background clones in the PD 
method but appeared as hits in the protein array. Such diversities in the results 
can partially be explained by the principal differences in the methods. In addition, 
a human sample is a heterogeneous material, thus, either technique may provide 
a better outcome compared to the other. One common aspect was that, in addition 
to the known cDNA products, both methods yielded a large number of unknown 
gene products, including several 3’UTR sequences.
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For verification of the significance of the selected candidate cDNA products in 
raising an autoimmune response, phage ELISA was applied. In this method, CsCI 
purified phage particles serve as an antigenic target for CSF autoantibodies. 
When successful, this method is very practical as it bypasses cloning and allows 
direct application of purified phage as a target. We obtained differences between 
positive CSF and positive lysate, compared to control lysates, despite a constant 
substantial background noise.
As an alternative method of validation, a conventional ELISA was employed using 
recombinant peptide instead of purified phage. The most significant candidate was 
cloned in an expression vector. For this purpose, the sequence of the phage 
genome obtained from PCR amplified insert was used, which covered 61 amino 
acids from the N-terminal of the candidate autoantigen target. In addition, we 
compared the specificity of this reaction by using peptides mapping to the same N- 
terminal sequence from the other family members of the candidate protein. 
Additionally, we tested positive and negative CSF samples for their response to 
recombinant peptide, which showed a trend of higher reactivity among positive 
CSF than the negative group, even though overall signal intensities were weak 
(p<0.15, two-tailed test).
Immune responses from control peptides were neutral while the response to the 
selected epitope was significantly strong (p<0.05, two-tailed test). These results 
suggest a specific immune response against the epitope mimicking the discoidin 
domain of the candidate autoantigen, and the sequence obtained by PD was 
significantly more antigenic than its homologues.
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A complementary goal was to explore whether the obtained autoantigens could 
serve as biomarkers for affective disorders and SZ. Here the sample quality is the 
key factor, having a major impact on the success of biomarker research (Holland, 
Pfleger, Berger, Ho and Bastaki, 2005). Apparently, the population is 
heterogeneous, dynamic and affected by infinitely diverse environmental 
influences. Therefore, finding a sample for a disease group covering every 
possible phenotype is not easy (Petricoin, Belluco, Araujo and Liotta, 2006). 
Similarly, to set a clear-cut definition for “normal”, especially in the field of 
psychiatry, is rather subjective. In this study, it was important that patient and 
control demographics met the aim of selection. In addition, the epidemiological 
history and medical records were thoroughly documented and analyzed by our 
clinician partners to exclude the secondary effects of antipsychotic drugs. Finally, 
there wasn’t any direct correlation between patient history or patient data, and our 
screening results.
Studying disorders with unclear psychopathologies and poor diagnostic efficiency 
leads to limited, if not conflicting results that are often found in the literature. Most 
of the findings refer to a subgroup of patients who are distinguished from others 
with their predisposition to autoimmune disorders, genetic background or other 
proposed etiologies. In other words, the success in unraveling a disease etiology 
is dependent on good sampling, and yet the observations usually reflect only the 
group of patients studied. Accordingly, evidence on the disease etiology for SZ or 
bipolar patients cannot be reflected universally for all patients, unless the 
diagnostic criteria for the analyzed sample group were efficient and objective.
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7.2 Candidate autoantigens selected from AFD and SZ patients
7.2.1 CASPR (Contactin Associated Protein, or Cell Recognition Protein)
Autoantibodies specific for contactin associated protein 4 (Caspr4) were in the 
CSF of 4 patients (3 SZ and 1 BPD), out of 11 (6 SZ and 5 BPD). 
Inflammatory/autoimmunity related control disease samples from MS yielded 1 
Caspr4 positive patient, whereas non-inflammatory control group yielded a 
positive result from a headache patient.
Nucleotide sequences from Caspr4 inserts were mostly overlapping, only having 
different sizes. The longest insert encoded 143 amino acids (aa30-aa173) at the 
N-terminus of Caspr4. The Blast search identified the sequenced clone as both 
Caspr4 and Caspr3 as they have a high sequence homology (85%). Therefore, 
Caspr4 and Caspr3 were both considered as candidate autoantigens.
Caspr is the first and essential molecular constituent in the generation of 
paranodal junctions, identified from rats as contactin-associated protein (Einheber 
et al., 1997). As depicted in Figure 7.1, Caspr is a major transmembrane factor 
required for the integrity of septate/like junctions of the paranode.
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: Paranode
Figure 7.1 Longitudinal organization of the myelinated axon. Three distinct domains, 
internode, paranode and node of Ranvier are depicted with a focus on Caspr as a major 
transmembrane component of the septate-like junctions that protrude from axons towards the glial 
membrane at the paranodes (schematic structure showing the nodal region and location of Caspr 
is adopted from Einheber et al., 1997).
The internode, the paranodal region, and the node of Ranvier are three domains 
that form between axons and myelinating glial cells, i.e., Schwann cells in the 
peripheral nervous system and oligodendrocytes in the central nervous system 
(Peters et al., 1991; Salzer, 1997). In the vertebrate nervous system, myelination 
is required for efficient propagation of action potentials through saltatory 
conduction that depends on the distribution of voltage-gated channels among 
those three domains. The myelin sheath is attached to the axon at both sides of 
the nodes of Ranvier, forming a septate-like junction known as the axoglial or the 
paranodal junction (Rosenbluth, 1995).
Contactin Associated proteins belong to the NCP (NeurexinlV, Caspr, Paranodin) 
family (Bellen, Lu, Beckstead and Bhat, 1998) as a distinct subgroup of neurexins 
that are cell adhesion molecules at the synaptic cleft (Craig and Kang, 2007). In 
myelinated axons, Caspr is co-localized with the neural cell adhesion molecule
contactin at the paranodal junctions between axons and the terminal loops of 
oligodendrocytes in the CNS and myelinating Schwann cells in the PNS (Einheber 
et al., 1997; Menegoz et al., 1997; Rios et al., 2000). Contactin is a 
glycosylphosphatidyl inositol (GPI)-anchored member of the immunoglobulin gene 
superfamily (Ranscht et al., 1988; Gennarini et al., 1989), which promotes neurite 
outgrowth and fasciculation, and possibly synapse formation and maintenance 
(Faivre-Sarrailh and Rougon, 1997; Berglund et al., 1999). Binding of Contactin to 
an isoform of neurofascin (NF155) on glial loops (Charles et al., 2002) is inhibited 
by Caspr (Golan et al., 2003). It is expressed by neurons and oligodendrocytes but 
not Schwann cells (Einheber et al., 1997). The extracellular domain of Caspr binds 
to contactin in a cis interaction to form an adhesion complex (Peles et al., 1997). 
Caspr cannot be exported from ER to plasma membrane without this interaction 
(Faivre-Sarrailh et al., 2000), as shown by experiments on contactin null mice 
where Caspr was confined within neuronal cell bodies (Boyle et al., 2001). It is 
suggested that the interaction between Caspr and Contactin is necessary to 
anchor the whole complex on the axonal cytoskeleton, as Contactin is lost when 
Caspr is also lacking (Gollan et al., 2002). Furthermore, when both Caspr and 
Contactin are absent, the space between axon and paranodal loops gets larger 
(Boyle et al., 2001).
On the other hand, the cis interaction that takes place between Caspr and 
Contactin when they are in the same membrane does not necessitate their 
association during the myelination process. They are both diffusely expressed until 
later stages of myelination. On myelinated fibers Caspr accumulates at the 
paranodes, starting from the most mature myelin sheets, whereas Contactin is 
almost undetectable (Einheber et al., 1997).
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The Caspr-Contactin complex is found in the paranodes of the optic nerve, 
although free contactin is located adjacent to the nodes of Ranvier (Rios et al., 
2000).
Contactin is found in two glycoforms: high molecular weight (HMW) and low 
molecular weight (LMW), depending on the level of glycosylation. Caspr binds to 
LMW Contactin and acts as a chaperone that brings it to plasma membrane, 
thereby reducing the number of HMW isoform. HMW Contactin can be found in 
extracellular membrane without Caspr. Thus, Caspr was shown to have a major 
role in determining the localization of LMW Contactin glycoform (Gollan et al., 
2003). Moreover, Caspr can only be poorly extracted from neurons by non-ionic 
detergents indicating that it is a constitutive component of the axon cytoskeleton 
(Einheber et al., 1997) or its association with Contactin guides the complex to 
detergent insoluble domains (Faivre-Sarrailh et al., 2000).
Initially Na+ channels cluster adjacent to the locations where the processes extend 
from oligodendrocytes (Boiko et al., 2001) and myelinating Schwann cells 
(Wabnick et al., 1996). Caspr accumulates at paranodes, where each ring that 
Caspr associates with, represents one turn of the myelin wrap (Rios et al., 2000). 
In correlation to this function, Caspr was shown to have an abnormal distribution in 
multiple sclerosis (MS) (Wolswijk and Balesar, 2003).
In Caspr null mice, paranodal junctions cannot form properly and Contactin is 
absent at this site (Bhat et al., 2001). Additionally, Gollan et al., 2003, showed 
that, in the absence of caspr, HMW Contactin dominates and localizes at the 
nodes instead of paranodes in the CNS. This is in agreement with Bhat et al., 
2001.
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Caspr3 and Caspr4 were identified as two novel and closely related members of 
Neurexin IV/Caspr/paranodin (NCP) family proteins (Spiegel et al., 2002). There is 
only one study on Caspr3 and Caspr4, namely the original paper from Spiegel et 
al. that reports the structure, in-situ hybridization and immuno-localization of 
Caspr3 and Caspr4. Surprisingly, this study shows that Caspr2, Caspr3 and 
Caspr4 do not bind to Contactin.
Similar to Caspr and Caspr2, both Caspr3 and Caspr4 share a structural 
resemblance to neurexins, as they have a large extracellular domain, single 
transmembrane domain and a short cytoplasmic domain. Unlike Caspr, but similar 
to Caspr2 and other neurexins, both Caspr3 and Caspr4 have a binding site for 
PDZ domains at their carboxy termini. Remarkably, caspr3 and caspr4 have a 
70% complete amino acid sequence homology, which is the highest among all 
caspr proteins. The domains of all members of the Caspr family are given in 
Figure 7.2.
Caspr4
Disc LamG EGF FIB
□  D V
PGY JXT PDZ-Binding
Figure 7.2 Structure of Caspr family proteins. All Caspr proteins contain a discoidin-like domain 
(DISC), four laminin G (Lam G) domains, a region similar to fibrinogen (FIB), two EGF repeats and 
tyrosine residues. Proline glycine repeats (PGY) are found only in Caspr. Caspr3 and Caspr4 have 
a short cytoplasmic domain that contains a carboxy-terminal PDZ binding domain. Scheme 
modified from Spiegel et al., 2002.
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According to Spiegel et al., both Caspr3 and Caspr4 are predominantly expressed 
in the human brain and the spinal cord. The highest Caspr4 expression was 
shown to be in subthalamic nuclei, substantia nigra, corpus callosum and medulla, 
whereas Caspr3 was found highly expressed in temporal and frontal lobes, corpus 
callosum, medulla and hypothalamus. High expression of Caspr 3 was reported in 
oligodendrocytes in the corpus callosum and within the cortical white matter, but it 
was not detectable in Schwann cells. Reciprocally, expression of caspr4 was 
undetectable in oligodendrocytes. In situ hybridization results implicated that 
Caspr4 localizes in the cell bodies and the dendrites in the brain, whereas Caspr3 
was reported to be located along axons and in oligodendrocytes.
Both soluble and transmembrane forms of Caspr3 have been reported to have a 
role in glia-neuron interactions. In fact, Caspr3 was suggested as a candidate 
regulatory factor clustering Na+ channels during the early phase of CNS 
myelination (Spiegel et al., 2002), which is a similar function to axotactin 
production by glial cells in Drosophila (Yuan and Ganetzky, 1999). Furthermore, 
Schwann cells regulate Na+ channels in the PNS by direct contact, not via a 
soluble factor, which may explain the undetectable levels of Caspr3 in Schwann 
cells.
Interestingly, all Caspr proteins are distinguished from other neurexins by two 
distinct domains in the extracellular region, namely the discoidin domain (also- 
called blood coagulation factor FA5/8C) and the fibrinogen/like domain (Poliak et 
al., 1999, Peles et al., 1997).
151
Our results indicate that the candidate autoantigenic peptide maps to the discoidin 
domain of Caspr4/Caspr3. With respect to this, we focused on the properties and 
proteins that possess discoidin domain (DISC domain).
The discoidin domain is identified by an adhesion protein called discoidin that is 
extracted from the Dictyostelium discoideum (slime mold) cell. Identification of two 
C-terminal repeats of blood coagulation factors V and VIII (Jenny et al., 1987; 
Wood et al., 1987 respectively) being similar to N-terminal region of discoidin, 
helped define a new extracellular domain called DISC or FA5/8C. However, the N- 
terminal 40 amino acids are much less conserved in DISC domain than FA5/8C. 
Proteins with a discoidin motif include: neurophilins, which are receptors of 
semaphorins involved in axonal growth, neurexins, which mediate cell-to-cell 
contacts and blood coagulation factors V, VIII and XLRS-1 (Franco-Pons et al., 
2006). The proteins that have the discoidin domain are given in Table 7.1.
Table 7.1 Proteins that contain the DISC domain (adopted from Baumgartner et al., 1998)
Name Accession Synonym Function
Discoidin II P42530
Factor V, VIII P12259,P00451
Blood coagulation, 
phospholipid binding
Neurophilin AF018956 A5Antigen
Ca^+- dependent cell 
adhesion, cell recognition in 
the nervous system, 
receptors of semaphorins 
involved in axon growth
Discoidin domain 
receptor,
Receptor Tyrosine 
kinase
Q08345
DDR1, 
TrkE, 
RTK6, 
CAK ..
Cell-cell interaction.and 
recognition
Neurexin IV U87223 CASPR Cell adhesion, cell junction
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Our findings suggest that IgG from the CSF of some SZ and BPD patients has 
affinity towards 60 amino acids, located at the N-terminus that map within the 
discoidin domain of Caspr4/Caspr3. Three out of 6 SZ patients and only 1 BPD 
patient that were selected by PD produced positive response by ELISA, 
suggesting a more pronounced titer within the SZ disease group.
Remarkably, a very recent study reported that the discoidin domain receptorl 
(DDR1) gene is a susceptibility locus for SZ (Roig et al., 2007). In correlation with 
several lines of evidence suggesting that the myelin alterations predispose 
individuals to SZ (discussed in section 8.3), Roig et al., have identified DDR1 as a 
myelin gene in the human oligodendroglial cell line that is located within one of the 
best-supported chromosomal regions for susceptibility to SZ, namely 6p24-21 that 
contains the major histocompatibility complex I (MHC I) (Owen et al., 2004). Table
7.2 lists the putative susceptibility genes and their loci within this region.
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Table 7.2 Putative susceptibility genes for schizophrenia within locus 6p24-21.
Gene Loci Reference
Dysbindin 1 (DTNBP1) 6p22.3 Kendler et al., 2004
Myelin oligodendrocyte 
glycoprotein (MOG) 6p22.1 Liu et al., 2005
Tumor necrosis factor 
alpha (TNF-ot) 6p21.3
Saviouk et al., 2005, 
Hashimoto et al., 2004, 
Schwab et al., 2003
Notch type-4 receptor 
(NOTCH4) 6p21.3
Glatt et al., 2005; 
Prasad et al., 2004; Luo et 
al., 2004; Skol et al., 2003; 
W eietal., 2000
Tenascin B (TNXB) 6p21.3 W eietal., 2004
Discoidin domain 
receptorl (DDR1) 6p21.3 Roig et al, 2007
DDR is a novel subfamily of receptor tyrosine kinases (RTK), distinguishable from 
others due to its homology domain to discoidin. DDR family proteins possess a 
160 amino acid long DISC homology domain, a single transmembrane region 
followed by an extended juxtamembrane region and a catalytic tyrosine kinase 
domain. DDR1 can be activated by all types of collagens which are main 
components of the extracellular matrix (EM) (Vogel et al., 1997; Shrivastva et al., 
1998). DDR1 activation is similar to other RTKs in that, native collagen induces 
DDR1 dimerization and transphosphorylation. DDR1 expression is most abundant 
in the brain, but it can also be found in keratinocytes, the kidney, lung, breast, 
muscle and thyroid follicles (Laval et al., 1994; Di Marco et al., 1993; Perez et al., 
1994; Zerlin et al., 1993).
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DDR1 null mice are viable but smaller in size. In vitro studies revealed that DDR1 
is involved in cell proliferation and adhesion (Curat and Vogel, 2002), cell 
migration (Hou et al., 2001, Kamohara et al., 2001) and disintegration of EM by 
matrix metalloproteinase (MMP) activity (Hou et al., 2001). In particular, it is 
notable that the interaction of DDR1 with collagen of the extracellular matrix allows 
leukocytes to migrate through tissues during the intracellular signaling process 
(Kamohara et al. 2001).
Notably, DDR1 is expressed by a subpopulation of glial cells in the white matter in 
the adult murine brain (Zerlin et al., 1993). DDR1 mRNA localizes close to 
myelinated fibers. Additionally, the cellular pattern of DDR1 positive cells, which 
resemble oligodendrocytes, is prominent during myelination. On the other hand, 
myelination markers like myelin associated glycoprotein (MAG), or myelin basic 
protein (MBP) have not been shown to co-localize with DDR1 (Franco-Pons et al., 
2006).
7.2.2 Myelination related factors that may be involved in the pathology of SZ 
as candidate autoimmune targets in the CNS
In the light of our findings, that suggest an autoimmune activity towards 
myelination-related factors, we performed a brief functional study, in which the 
genomic expression profile of selected candidate Caspr4 and three others, 
Casprl, MBP and DDR1 (SZ susceptibility loci bearing myelin gene with discoidin 
domain), were analyzed. For this purpose, the abundance of mRNA in brain and 
spinal cord of mice, from PND1 to PND42, were evaluated by quantitative PCR, as 
the myelin maturation takes place actively within this period.
We observed a gender difference in the pattern of expression of Caspr4 and 
DDR1, where female mice were found to express significantly higher levels of
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mRNA in the brain compared to the males during the first week of life (p<0.05, t- 
test). For both sexes, Caspr4 and DDR1 were downregulated afterwards whereas 
MBP and Casprl were upregulated, reaching peak transcript concentrations on 
PND14 and PND28 respectively. In spinal cord, the only difference in expression 
pattern was at PND7, when Caspr4 was upregulated in female mice in contrast to 
males. A striking difference between brain and spinal cord became evident when 
samples from both sexes were pooled and analyzed together. Casprl and DDR1 
expression pattern in spinal cord was significantly different from the expression of 
MBP and Caspr4, which resembled the expression difference in the brain of 
females and males. Specifically, both Caspr4 and MBP expression were high 
between PND1-PND7, and then started to get downregulated until stabilization at 
PND14-PND21. The opposite was observed for Casprl and DDR1, where both 
transcripts reached maximal concentration at PND14 and later stabilized after a 
mild drop. During PND1-PND42 Casprl mRNA was found to be significantly 
abundant, reaching up to 1.2% of the number of housekeeping genes at PND28, 
whereas, in spinal cord, both Casprl and Caspr4 mRNA were more abundant 
then MBP and DDR1. This study provided new information on similar or 
contrasting patterns of expression that may suggest a possible interplay or 
partnership in the relevant neuronal maintenance mechanism.
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7.2.3 Support for the disconnectivity hypothesis for SZ and AFD
Identification of members of Caspr family proteins as candidates for autoimmune 
responses emphasizes a new aspect of the disconnectivity hypothesis that is 
based on downregulation of junction and nodal proteins like the peripheral myelin 
protein (PMP22), proteolipid protein (PLP), myelin associated glycoprotein (MAG) 
in SZ. A substantial downregulation of myelin-associated genes, as demonstrated 
in microarray studies, may be accompanied by a secondary impairment during 
white matter expansion that would distort axo-glial organization and interfere with 
myelination. As a result, abnormal oligodendrocytes among myelinated fibers may 
become the target of immune response and be engulfed by astrocytes, leading to 
loss of oligodendroglial cells. In fact, a reduced oligodendroglial density up to 22% 
(Hof et al., 2002) was shown in post mortem prefrontal cortex (PFC) in SZ, bipolar 
affective disorder, and major depression (Rajkowska-Markov et al., 1999; 
Orlovskaya et al., 2000; Torrey et al., 2000; Cotter et al., 2000). Such studies, 
showing a loss in glial cell density and quantitative reduction in white matter, 
confirm a major disintegrity in oligodendrocytes and myelin-related proteins in the 
SZ.
Our results are therefore consistent with and supportive of the suggested 
correlation between the disconnectivity hypothesis of SZ and the stability of the 
myelination by myelin protein abundance, proper functioning of oligodendrocytes 
and adhesion-junction proteins maintaining nodes of Ranvier, paranodes, 
juxtaparanodes and internodal regions.
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7.2.4 Other autoantigen candidates selected by phage display
7.2.4.1 Growth Arrest Specific Protein 7 (GAS7)
We identified Gas7 as a candidate autoantigen from 2 SZ patients and 1 BPD 
patient. Additionally, 3 MS patients, one of whom was also reactive to Caspr4, 
were positive for Gas7.
Schneider et al. first identified growth arrest specific genes by the induction of Gas 
genes after serum starvation and density-dependent inhibition of growth 
(Schneider et al., 1988). The expression of growth arrest-specific (Gas and Gadd) 
genes is associated with the GO'-arrest cycle (Hass, 1994). Expression of growth 
arrest-specific (Gas) genes is observed during growth arrest in terminally 
differentiating cells during the development of peripheral nerves. Overexpression 
of GAS7 in undifferentiated neuroblastoma cell cultures promotes neurite-like 
outgrowth. On the other hand, inhibition of GAS7 in terminally differentiating 
cultures of embryonic murine cerebellum impedes neurite outgrowth from maturing 
Purkinje cells (Ju et al., 1998). The role of Gas7 in neuronal differentiation is 
characterized by adenovirus-mediated overexpression in PC12 cells, and 
quantification of the expression of various neuronal markers in the absence and 
presence of different concentrations of nerve growth factor (NGF) (Chang et al., 
2005).
Gas7 interacts with F-actin and co-localizes with the terminal part of the actin 
microfilament in cells going through membrane outgrowth (Chao et al., 2005). 
Human GAS7 is located on chromosome 17p11.3, encoding a 48-kD protein 
structural domain which resembles transcription factor POU that is implicated in 
neuronal development, and synapsinl (SYN1) which is involved in the modulation 
of the neurotransmitter release.
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Interestingly, a recent study on Gas6, another member of the GAS family of 
genes, reports its role in increasing the survival rate of Schwann cells and neurons 
in vitro and its participation in autoimmunity in animal models. Furthermore, Gas6 
protein concentration is elevated in the CSF of patients with chronic inflammatory 
demyelinating polyneuropathy (CIDP), suggesting its involvement in myelin repair 
(Sainaghi et al., 2008).
7.2.4.2 Talin
Talin was selected exclusively from 2 SZ patients out of a total of 6, and not from 
any of the control or MS disease samples (n=23). Talin is a large dimeric protein 
acting as an adaptor molecule that couples the actin cytoskeleton to integrins. 
Integrins are heterodimeric proteins with single pass membrane domains, and 
they belong to cell adhesion molecules (CAMs) that include immunoglobulins, 
cadherin, neurexins and neuroligand protein families as well (Benson, Schnapp, 
Shapiro and Huntley, 2000). As mentioned earlier, neurexins include the Caspr 
protein family. Talins are reported to be present at the neuronal synapse where 
they interact with, and activate phosphatidylinositol-(4)-phosphate 5-kinase type I 
(P IP K Iy ) (Di Paolo et al., 2002, Ling et al., 2002). When talin—P IP K Iy  interaction at 
synapses is disturbed, synaptic vesicle recycling and actin dynamics are impaired 
(Morgan et al., 2004). Integrin and P IP K Iy  compete for talin (Barsukov et al., 
2003); thus regulatory mechanisms that control binding of P IP K Iy  to talin may be 
affected if talin is a target of autoimmunity.
159
7.2.4.3 Myelin basic protein (MBP)
Myelin basic protein (MBP) was found in 1 SZ, 1 BPD and 1 MS patient. We 
included MBP in the expression pattern analysis, together with other myelination- 
related and candidate autoantigen genes.
Myelin sheaths and the clustering of ion channels at the nodes of Ranvier facilitate 
efficient and fast action potential propagation in vertebrates. MBP is the major 
constituent of the myelin sheath of oligodendrocytes and Schwann cells in the 
nervous system. It is, however, not only a structural protein that works as an 
insulator around axons, but it also actively regulates several neuronal processes 
(Schafer et al., 2004) including ion channel expression and localization (Poliak and 
Peles, 2003; Salzer, 2003).
MBP destruction throughout the nervous system is the main pathology of multiple 
sclerosis (MS) although the etiology remains largely unknown. It is well known that 
MS patients suffer from demyelination due to autoimmunity that eliminates myelin 
proteins faster than the re-myelination, yet autoantibodies against MBP cannot be 
efficiently isolated from CSF. Interestingly, only a subset of patients (in the range 
of 59%) show detectable Ig titers against MBP (Egg et al., 2001).
It is interesting that, according to PD selection, the SZ patient, who was 
responsive to MBP, has reacted with growth associated protein 43 (GAP43) as 
well. GAP43 is highly expressed in developing neurons (Perrone-Bizzozero et al., 
1996) and remains at high levels in adult human brain at hippocampus and cortical 
regions thus hypothesized to be involved in synaptic plasticity and connectivity 
(Akers et al., 1985). Notably, in SZ brains GAP43 is found to be highly expressed 
in visual and frontal cortical regions (Perrone-Bizzozero et al., 1996). It can be
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speculated that abnormal high expression of GAP43 might trigger autoimmune 
activity in CNS. A simultaneous autoimmune response against MBP might be a 
secondary effect or mutually independent.
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7.3 Summary and Conclusion
Myelination and oligodendroglial function affects neural connectivity that facilitates 
the communication between multiple brain regions and circuits. White matter 
expansion in the prefrontal area is caused by increased myelination that is 
accompanied by gray matter reduction within a time frame of late adolescence and 
early adulthood. Abnormalities in myelination are negatively reflected on neural 
connectivity that would normally be compensated by the expansion of white matter 
during the reduction of gray matter. Several lines of evidence, most of which come 
from imaging studies, suggest that functionally disintegrated neural circuitry is the 
major abnormality in SZ as seen by a disconnection between prefrontal and 
posterior areas in the brain (Frith and Dolan, 1996).
Imaging techniques in the prefrontal cortex of SZ post mortem brain tissue showed 
myelin and oligodendroglia abnormalities (Miyakawa et al., 1972; Deicken et al., 
1994). Additionally, structural impairments, shown on biopsy and autopsy samples 
from the frontal cortex of SZ patients, included reduced compactness and 
formation of the concentric lamellar of the myelin sheath (Orlovskaya et al., 2000, 
Torrey et al., 2000, Cotter et al., 2000). In general, impaired myelination can be 
attributed to developmental disturbances, oligodendrocytic dysfunction and cell 
death, or other regulatory deficits.
The first evidence about expression changes in myelin-associated genes in SZ 
was provided by microarray studies (Hakak et al., 2001). The results were 
reproduced by other studies where the genes related to myelination, and 
oligodendrocyte function was found to be downregulated (Dracheva et al., 2006; 
Sugai et al, 2005; Katsel et al., 2004; Stewart and Davis, 2004; Aston et al., 2004;
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Tkachev et al., 2003). To sum up, the most prominent changes in protein 
expression in SZ were those that are involved in glial differentiation, myelin 
structure and adhesion proteins found in axoglial contacts (Katsel et al., 2005).
Our findings implicate that an epitope at the N-terminus of Caspr4 (also Caspr3, 
with 85% aa sequence homology), but not Casprl and Caspr2, is a possible target 
for an autoimmune response, at least in some cases of SZ.
Another notable implication is based on the importance of the identified epitope for 
autoantigen targeting, namely the DISC domain. Besides being reported as a SZ 
susceptibility gene and a myelin protein, DDR1 is a cell-surface receptor tyrosine 
kinase that gets activated by binding to fibrillar collagen through the DISC domain. 
Interestingly, it is the DISC domain that distinguishes Caspr family members from 
other neurexins. As a result, a further inquiry addressing the possibility of 
Caspr4/Caspr3 interacting with collagens is intriguing. Recent studies report that 
collagens have an important role in the formation of the node of Ranvier (Maertens 
et al;, 2007; Occhi et al., 2005). It is suggested that in myelinating peripheral 
nerves, gliomedin (a transmembrane collagen family including collagen type XIII 
and XVII) binds to axonal adhesion molecules like neurofascin and the neuron- 
glia-GAM-related cell adhesion molecule (NrCAM) to mediate sodium channel 
clustering at the nodes of Ranvier.
It is therefore noteworthy to underline the possible implication of proteins carrying 
the discoidin domain with regard to SZ. In other words, instability in a subset of 
proteins with the discoidin domain might have an adverse effect on myelination, as 
well as possible interactions with collagen, thus, eventually causing a diverse 
neuropathology.
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When SZ is compared to demyelinating disorders like multiple sclerosis and 
metachromatic leukodystrophy (MLD), many similarities become clear considering 
the psychiatric and cognitive discrepancies (Davis, 2003). In the case of MLD, a 
rare inborn disease, the accumulation of sulfatides in the CNS and PNS causes 
demyelination that begins in the periventricular white matter and corpus callosum. 
Interestingly, late adolescence and early adulthood onset type MLD displays 
mainly psychiatric symptoms including auditory hallucinations, emotional liability, 
loss of concentration, thought fragmentation and poor concentration, which begin 
after age 16 and may lead to a misdiagnosis of SZ. It is remarkable that psychosis 
symptoms are observed solely when the disease is centered in the frontal lobes, 
before it spreads to the rest of the forebrain and is replaced by disorders of 
movement, posture late dementia (Hyde et al., 1992).
Caspr4 and Caspr3 are novel proteins, which have yet to be studied. 
Nevertheless, based on the high expression of Caspr3 in oligodendrocytes and 
within the cortical white matter, it can be hypothesized that destabilization of 
caspr3, probably by a temporal autoimmune attack, might be detrimental for a 
group of susceptible people, especially during white matter expansion between 
adolescence until early adulthood. Such alterations might form the base for 
schizoaffective symptoms that surface later in life, albeit with a subtle clinical 
association with a chronic autoimmune pathology. The lack of information on 
changes in their expression patterns during onset restricts us from providing 
further insight into their possible impact on the pathogenesis of SZ.
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Our results additionally show that cDNA PD can be used in the identification of 
autoantigens in inflammatory and autoimmune diseases of the CNS. This is 
especially the case when the causal mechanism of the CNS specific IgG response 
and the nature of the target are unknown. cDNA library based-selection was the 
most applicable system, recapitulating the heterogeneity of the Ig content in the 
CSF and selecting peptides and proteins that exist in nature. Every round of 
selection generates a subpopulation of high affinity binders from the initial 
recombinant pool. The PD technology, indeed, introduced great flexibility to this 
project in adjusting stringency and other selective criteria. The manual application 
of selection by panning is somewhat time-consuming and laborious. The whole 
system could, however be scaled up as a high-throughput system if there were an 
opportunity for automation.
Consequently, our approach has proven effective for finding autoantigens as 
candidate biomarkers. We cannot, however, claim that Caspr4 or Caspr3 are 
absolute biomarkers for SZ and BPD. Furthermore, we agree that it is more 
reasonable to assume that an “array” of biomarkers spanning the profoundly 
heterogeneous population, will give a better assurance than one single biomarker 
(Gulmann, Sheehan, Kay, Liotta and Petricoin, 2006). Actual confirmation of their 
potential to act as biomarkers depends on understanding the molecular pathology 
showing what happens to latent patients under an acute attack of elevated caspr4 
and caspr3 autoantibodies. It also depends on whether this can feasibly be 
detected when the acute phase is over and the major symptoms start to appear.
This study extended our knowledge of the role of myelination with regard to 
neuropsychiatry and supports the disconnectivity hypothesis of SZ. It is intriguing 
to consider that autoimmune targeting towards Caspr3 and Caspr4 proteins could
directly or indirectly impair myelination and, thereby, trigger schizoaffective 
symptoms in some cases of SZ and BPD. Further efforts, however, have to be 
made to gain more insight from our findings. These may include developing 
mouse models that are subjected to high titers of Caspr3 and Caspr4 antibodies 
during white matter maturation to observe changes in neuro-psychiatric conditions.
Eventually, we are suggesting a concept that connects autoimmunity to myelin 
and oligodendrocyte dysfunction with respect to the neuroetiology of SZ and AFD. 
Future studies focusing on revealing other factors that render autoimmunity 
towards destabilization of myelination, would provide important new insights into 
the current understanding of affective disorders.
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APPENDICES
A1. Proposed etiologies and literature references
SZ Etiology References
Neurodegeneration Lieberman et al., 1999
Neurotransmitter
system
Garbutt et al., 1983, Seeman et al., 1987,
Dean et al., 2000;1999, Ohnuma et al., 1999, 
Tallerico et al., 2001, Tandon 1999, Taylor et al., 
1998
Viral infection Jones et al., 1998; Yolken et al., 1995, 2001, Leweke et al, 2004, Pelonero et al., 1990, Dickerson et al., 
2003
Neurodevelopmental Raine, 2006, Hornig et al., 2002, Toro and Deakin, 
2007
Genetic predisposition Mowry et al., 2001, Mueser et al., 2004, Tsuang et 
al., 2000
Autoimmunity / 
immune dysfunction
Noy et al., 1994; Fontana et al., 1980; Knight et al., 
1992; Muller et al., 2000, Nunes, 2005, Lin et al., 
1998, Altamura et al., 2003, Amital. et al., 1993; 
Jones, Mowry, Pender and Greer, 2005, Ganguli, 
Brar, Chengappa, Yang, Nimgaonkar and Rabin 
1993; Henneberg et al., 1993, 1994, Legros et al., 
1985, Ganguli, Brar and Rabin 1994; Wright et al., 
1993; Logan etal., 1970; Kirch et al., 1993, DeLisi 
et al., 1986; Sirota et al., 1990; Hornig et al., 1999, 
1996, Schwarz et al.,1998, Abramsky et al., 1978
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A2. Detailed patient data
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SZ-076/97 24,6 265 587 M 50 + + 6 n.a n.a - - / -
SZ-369/98 53 348 493 F 43 - - 1 n.a n.a - -  / -
SZ-454/00 22,7 147 280 F 34 - - 1 n.a n.a - -  / -
SZ-166/02 28,7 230 420 M 56 - - 5 n.a n.a - -  / -
SZ-464/02 45,6 424 520 F 24 - - 4 n.a n.a - -  / -
SZ-244/04 23,3 166 278 F 61 - - 1 1 0 - - / -
BPD-160/98 14,7 140 229 M 21 + - 3 n.a n.a - - / -
BPD-071/02 25,4 231 320 F 52 - - 2 n.a n.a - - / -
BPD-365/04 20,3 188 298 F 48 - - 2 1 1 - - / -
BPD-131/05 18,9 137 199 F 64 - - 1 1 0 - - / -
BPD-203/05 11,9 161 223 F 46 - - 3 1 2 - - / -
MDD-312 43,3 303 485 n.a n.a - - 3 n.a n.a - - / -
MDD-Lo n.a n.a n.a n.a n.a n a n.a n.a n.a n.a
MS-70004 84,2 403 687 M 41 + - 1 1 0 + - / -
MS-06705 52,3 306 601 F 40 + - 1 1 0 + - / -
MS-14905 44,7 213 396 F 43 + - 1 1 0 + - / -
MS-15005 108 275 554 F 40 + - 8 8 0 + - / -
MS-24605 54,9 294 507 F 26 + - 0 0 0 + -  / -
MS-24705 151 443 781 F 31 + - 22 22 0 + -  / -
MS-31205 59,4 281 591 F 45 + - 5 5 0 + -  / -
MS-35305 51,2 228 538 F 39 + - 8 8 0 + - / -
EPI-014/00 26,6 225 304 F 25 - - 1 n.a n.a - -  / -
EPI-477/01 34 205 340 M 17 - - 3 n.a n.a - - / -
EPI-326/02 62,3 371 640 M 70 + - 21 n.a n.a - - / -
EPI-300/04 15,5 132 180 F 26 - - 36 1 35 - - / -
EPI-330/04 31,9 289 411 M 46 - - 4 3 1 - - / -
EPI-339/04 61 265 428 F 56 - - 2 1 1 - - / -
EPI-053/05 21,1 172 242 M 23 - - 3 2 1 - - / -
OND-01805 23 210 411 F 39 - - 1 1 0 - - / -
ON D-19405 34,1 320 578 F 45 - - 0 0 0 - - / -
OND-25505 17,3 177 323 F 41 - - 2 2 0 - - / -
OND-41405 26,6 308 620 F 42 + - 0 0 0 - - / -
NPH-2 n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a
NPN-3 n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a
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A3. Expression of Caspr4 peptide
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